Recent articles related to MTC

    Published: May 21st, 2022 at 06:26:54 AM

    Mounjaro Approved for Blood Glucose Control in Type 2 Diabetes | Health and Fitness

    "Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid cancer and in those with multiple endocrine ..."

    Published: May 21st, 2022 at 12:27:48 AM

    Mounjaro Approved for Blood Glucose Control in Type 2 Diabetes - KOAM

    "The FDA notes that Mounjaro caused thyroid C-cell tumors in rats, ... or family history of medullary thyroid cancer and in those with multiple ..."

    Published: May 20th, 2022 at 10:33:12 PM

    Atara's is the latest setback for a troubled field | Evaluate

    "Bayer dumps Atara, Precigen prepares for a fire sale and Tmunity struggles to find direction. Should investors still be excited about cell therapy?"

    Published: May 20th, 2022 at 07:27:04 PM

    Nkarta reveals its first off-the-shelf NK cell data, showing multiple complete responses - shares soar

    "Nearly two years after pricing its IPO, Nkarta is finally reporting its first clinical data Monday. The South San Francisco biotech revealed the ..."

    Published: May 20th, 2022 at 07:21:51 PM

    Eli Lilly Kinsale gets CDSCO panel nod to import, market anticancer drug Selpercatinib

    "... given its nod to pharmaceutical major, Eli Lilly Kinsale to import and marketing of anticancer drug Selpercatinib 40 mg and 80 mg capsules."

    Published: May 20th, 2022 at 02:22:38 PM

    FDA Approves Lilly's Novel, Dual-Targeted Treatment for Type 2 Diabetes - PharmTech

    "Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether tirzepatide causes such tumors, including medullary thyroid cancer, ..."

    Published: May 20th, 2022 at 10:57:36 AM

    Medullary Thyroid Cancer Market Potential Growth, Share, Demand and Analysis of Key ...

    "Global Medullary Thyroid Cancer Market report emphasizes on the detailed understanding of some decisive factors such as size, share, sales, ..."

    Published: May 19th, 2022 at 11:34:27 PM

    Where Will Exelixis, Inc. (EXEL) Stock Go Next After It Has Fallen 10.35% in a Week?

    "Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and ..."

    Published: May 19th, 2022 at 08:00:23 PM

    FDA Approves Mounjaro, a Novel Type 2 Diabetes Medication - Verywell Health

    "... for people with personal or family history of medullary thyroid cancer, ... The drug was shown to cause thyroid C-cell tumors in rats, ..."

    Published: May 19th, 2022 at 07:54:30 PM

    Eli Lilly oncologic selpercatinib granted Orphan Drug status for solid tumors (NYSE:LLY)

    "The candidate is also in phase 3 as a first line non-small cell lung cancer and first line medullary thyroid cancer treatment."

    Published: May 19th, 2022 at 07:54:01 PM

    Eli Lilly oncologic selpercatinib granted Orphan Drug status for solid tumors (NYSE:LLY)

    "Selpercatinib is already approved under the brand name Retevmo for metastatic RET fusion-positive non-small cell lung cancer, RET-mutant medullary ..."

    Published: May 19th, 2022 at 10:39:54 AM

    Gas chromatography-mass spectrometry-based untargeted metabolomics reveals metabolic ...

    "Medullary thyroid cancer (MTC) is a rare tumor that arises from parafollicular cells within the thyroid gland. The molecular mechanism underlying ..."

    Published: May 19th, 2022 at 09:55:27 AM

    BMS' Sprycel reimbursement criteria to be broadened for pediatric Ph+ ALL - KBR

    "After obtaining the regulatory nod in March, Lilly applied for reimbursement for Retevmo's three indications -- medullary thyroid cancer, ..."

    Published: May 19th, 2022 at 08:40:21 AM

    Thyroid cancer symptoms: Warning signs to look out for including changes to your voice - The Mirror

    "Medullary cancer: Far rarer, accounting for just 4 per cent of all cases. It's more likely to be found at an early stage because it produces a hormone ..."

    Published: May 19th, 2022 at 07:44:26 AM

    Types of Thyroid Cancer: Common and Rare Forms - Verywell Health

    "Whether papillary or follicular thyroid cancer, hereditary or sporadic medullary thyroid cancer, or undifferentiated anaplastic ..."

    Published: May 17th, 2022 at 07:06:16 PM

    KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE ...

    "Dr Dun's presentation will specifically cover the combination of paxalisib with ONC201 (Chimerix, Inc). Dr Dun commented, "Thirty years ago, ..."

    Published: May 17th, 2022 at 08:36:01 AM

    Cabozantinib Market Segments, Opportunity, Growth and Forecast by End-use Industry 2022 to 2028

    "Medullary Thyroid Cancer Treatment Second Line Treatment for Renal Cell Carcinoma. The report is the best compilation of different types of ..."

    Published: May 17th, 2022 at 05:46:17 AM

    FDA Approves Mounjaro, a Novel Once-a-Week Medication to Treat Type 2 Diabetes

    "The drug carries a warning for a risk of thyroid C-cell tumors, ... used in patients with a personal or family history of medullary thyroid cancer ..."

    Published: May 17th, 2022 at 05:16:47 AM

    FDA Approves New Treatment for T2D | Consultant360

    "Tirzepatide should not be used in individuals with a history of medullary thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2."

    Published: May 17th, 2022 at 03:40:33 AM

    Chimerix Shares Slide; to Stop Investing in DSTAT Program - MarketWatch

    "Chimerix said it expects the initiation of a Phase 3 study of ONC201 in H3 K27M Mutant Glioma in 2022. Chimerix also said it agreed with Emergent ..."

    Published: May 17th, 2022 at 01:47:36 AM

    Is There Primary Medullary Thyroid Carcinoma in the Cervical Lymph Node? A Case Report

    "Fine needle aspiration (FNA) was performed, and the cytologist diagnosed metastatic medullary thyroid carcinoma (MTC). Based on PET-CT, ultrasound and ..."

    Published: May 16th, 2022 at 01:01:59 PM

    Seeking a come-from-behind win, Eli Lilly lands big approval for next-gen diabetes drug

    "... in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2."

    Published: May 15th, 2022 at 08:03:12 PM

    FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes - Sierra Sun Times

    "Mounjaro should not be used in patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia ..."

    Published: May 14th, 2022 at 12:21:20 AM

    Lilly's Mounjaro Diabetes Approval Is First Challenge To Novo's GLP-1 Franchise - Scrip

    "The drug causes thyroid C-cell tumors in rats, but it is unknown whether it causes medullary thyroid cancer and other tumors in humans."

    Published: May 13th, 2022 at 11:20:54 PM

    FDA approves tirzepatide, first dual incretin agonist for type 2 diabetes - Healio

    "The FDA noted that tirzepatide causes thyroid C-cell tumors in rats; it is unknown whether the drug causes such tumors, including medullary thyroid ..."

    Published: May 13th, 2022 at 10:56:38 PM

    FDA Approves Dual-Targeted Treatment for Type 2 Diabetes - Pharmacy Practice News

    "Tirzepatide is not indicated for treatment of type 1 diabetes, the FDA said, and should not be used in patients with a history of medullary thyroid ..."

    Published: May 13th, 2022 at 10:46:45 PM

    First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes | MedPage Today

    "Regardless, patients with a history of medullary thyroid cancer (or a family history) and those with multiple endocrine neoplasia syndrome type 2 ..."

    Published: May 13th, 2022 at 09:05:55 PM

    Tirzepatide (Mounjaro) Wins FDA Approval for Type 2 Diabetes - Endocrinology Network

    "... used in those with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2."

    Published: May 13th, 2022 at 08:50:18 PM

    FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

    "Mounjaro causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes such tumors, including medullary thyroid cancer, in humans."

    Published: May 13th, 2022 at 05:57:37 PM

    Irv Weissman's lab spins out another biotech, with help of Forty Seven co-founders, to target ...

    "At age 24, while in Irv Weissman's lab, Amira Barkal realized the CD24 protein was another "don't eat me" signal for cancers."

    Published: May 12th, 2022 at 11:24:17 PM

    WHO 2022 Classification of Thyroid Neoplasms - Consultant 360

    "The 5th edition divides thyroid tumors into new categories to provide a ... medullary thyroid carcinomas based on mitotic count, tumor necrosis, ..."

    Published: May 12th, 2022 at 08:45:34 AM

    A Case of Medullary Thyroid Carcinoma Combined with Papillary Microcarcinoma and ...

    "Background: The histologic type of thyroid carcinomas includes follicular, papillary carcinomas, and medullary carcinomas."

    Published: May 11th, 2022 at 10:47:27 PM

    Spain May Approve Workplace Menstrual Leave - WebMD

    "Medullary Thyroid Cancer (MTC). 7/11. It starts in thyroid cells that doctors call C cells. The cancerous cells can spread to your lungs ..."

    Published: May 11th, 2022 at 09:01:48 PM

    Escrow as a Service (EaaS) Market has Huge Demand Top Key Players Profiling - Redskins 101

    "Medullary Thyroid Cancer Market Potential Growth, Share, Demand and Analysis of Key Players & Forecasts to 2030. May 11, 2022 ..."

    Published: May 11th, 2022 at 02:35:24 AM

    Cabozantinib Market Revenue Expectation 2022-2028 by Key Manufacturers - Redskins 101

    "Medullary Thyroid Cancer Treatment Second Line Treatment for Renal Cell Carcinoma. The study highlights major industries experiencing significant ..."

    Published: May 10th, 2022 at 04:51:46 PM

    Hollyoaks star Abi Phillips, 28, reveals she has been diagnosed with thyroid cancer - Daily Mail

    "medullary thyroid carcinoma accounts for less than 1 in 10 cases; unlike the other types, it can run in families; anaplastic thyroid carcinoma the ..."

    Published: May 10th, 2022 at 11:45:07 AM

    Cabozantinib Market 2021-2026 analysis examined in new Industry research report

    "The application spectrum of the Cabozantinib market is split into Medullary Thyroid Cancer Treatment andSecond Line Treatment for Renal Cell ..."

    Published: May 10th, 2022 at 07:04:23 AM

    Cabozantinib Market Report 2022: COVID-19, Qualitative Analysis and Competitive Industry ...

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Product pricing based on their application reach."

    Published: May 9th, 2022 at 09:40:04 PM

    Substantial Medical Debt, Bankruptcy Linked to Thyroid Cancer - Medscape

    "Compared to other cancers, patients with thyroid cancer may face more significant financial woes, including higher rates of bankruptcy."

    Published: May 9th, 2022 at 01:26:05 PM

    Thyroid Medullary Cancer -BIO-PROTOCOL

    "Medullary thyroid cancers (MTCs) are derived from calcitonin-producing cells (C cells) of neuroendocrine...Expose and remove the thyroid tumor ..."

    Published: May 6th, 2022 at 03:03:22 AM

    CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer - MashupMD

    "Roger B. Cohen, MD, is leading a pilot study assessing the safety and feasibility of autologous chimeric T cells targeting the GFR4 protein in ..."

    Published: May 5th, 2022 at 09:36:06 PM

    Good Response With ONC201 for Rare Neuroendocrine Tumors : Oncology Times

    "A new drug, ONC201, may be a better option. It's an imipridone heterocyclic small molecule that is a dopamine-like receptor (DRD2) ..."

    Published: May 4th, 2022 at 07:32:43 PM

    Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark - Yahoo Finance

    "RHHBY reported Gavreto product sales of 5 million CHF. Blueprint Medicines' total revenues of $62.7 million comprised net product revenues from ..."

    Published: May 4th, 2022 at 02:58:09 PM

    Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma

    "Long-Term Clinical and Biochemical Follow-up in Medullary Thyroid Carcinoma: A Single Institution's Experience Over 20 Years.-article."

    Published: May 2nd, 2022 at 01:05:11 AM

    Cabozantinib Market Consumption Status and Prospects Professional Market Research Report 2026

    "The application ambit of the Cabozantinib market is classified into Medullary Thyroid Cancer Treatment andSecond Line Treatment for Renal Cell ..."

    Published: Apr 30th, 2022 at 09:16:02 PM

    SILVER LINING FOR GOA'S LLOYD AT NAT PARA-TT C'SHIP - Herald

    "Team Herald. PANJIM: Goa's Lloyd Fernandes secured a silver in the Class 3 wheelchair catergory, at the National Para-Table Tennis championship in ..."

    Published: Apr 30th, 2022 at 02:18:29 AM

    Deep submucosal invasion not strong predictor for lymph node metastasis, surgery in CRC - Healio

    "Risk Factors of lateral cervical lymph node metastases and survival analysis in patients with medullary thyroid carcinoma."

    Published: Apr 29th, 2022 at 01:46:59 PM

    The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings in

    "A high tumor-to-normal tissue ratio (T/N ratio) of GIPR was reported both in humans' and in rats' medullary thyroid cancer (MTC), suggesting a direct ..."

    Published: Apr 28th, 2022 at 12:43:27 AM

    New generation molecule for cancer care improve access and affordability for the public

    "Cabozanib is an oral medicine consumed as tablets greatly improving the efficacy of treatment for Medullary Thyroid Cancer, Renal Cell Carcinoma, ..."

    Published: Apr 27th, 2022 at 09:08:00 PM

    Love Island's Demi Jones shows off her new butterfly tattoo in Ibiza after beating cancer - The Sun

    "Thyroid cancer develops in your thyroid gland, which is located in your neck, ... medullary thyroid carcinoma, anaplastic thyroid carcinoma."

    Published: Apr 27th, 2022 at 08:14:43 PM

    Medullary thyroid carcinoma diagnosed with liquid-based cytology and immunocytochemistry

    "Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy that arises from the parafollicular cells (C cells) secreting calcitonin."

    Published: Apr 26th, 2022 at 11:34:30 PM

    Should you invest in Chimerix Inc (CMRX) stock? Here's is what you need to know - MZP News

    "ONC201 is being developed for repetitive H3 K27M-freak glioma as its lead sign. DSTAT is in Phase 3 advancement as a potential first-line treatment in ..."

    Published: Apr 26th, 2022 at 01:29:12 PM

    Liverpool woman, 22, diagnosed with inoperable brain tumour finds miracle drug | LiverpoolWorld

    "A weekly treatment with ONC201 demonstrated 'partial response or stable disease' in nearly all patients with two different types of neuroendocrine ..."

    Published: Apr 24th, 2022 at 10:23:05 AM

    Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in ...

    "Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.-article."

    Published: Apr 23rd, 2022 at 02:31:42 PM

    Decoded: The link between Obesity and thyroid cancer | APN News

    "Medullary thyroid cancer- Medullary thyroid cancer is more likely to be discovered early because it generates calcitonin, a hormone that doctors look ..."

    Published: Apr 22nd, 2022 at 06:03:11 PM

    Medullary thyroid carcinoma a relatively uncommon entity: A case report - IP Indexing

    "Abstract : Introduction: Medullary thyroid carcinoma is an uncommon primary thyroid tumour (5-10% of all thyroid malignancies) arising from ..."

    Published: Apr 22nd, 2022 at 12:49:50 PM

    Global Cabozantinib Market Survey Report, 2021-2026 - AlgosOnline

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma . The report enumerates substantial details about the ..."

    Published: Apr 21st, 2022 at 07:14:11 AM

    Goiter Market Size, Share, Drugs, Epidemiology, Therapies And Companies By Delveinsight

    "Medullary Thyroid Cancer Epidemiology. DelveInsight's Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of ..."

    Published: Apr 21st, 2022 at 02:33:11 AM

    Evaluation of multinodular goiter and primary hyperparathyroidism leads to a diagnosis of ...

    "Thyroid ultrasound showed an asymmetric goiter with three dominant ... the thyroid includes systemic amyloidosis or medullary thyroid carcinoma."

    Published: Apr 20th, 2022 at 10:05:30 AM

    Signs and Symptoms of Advanced Medullary Thyroid Cancer - betman

    "The symptoms of advanced medullary thyroid cancer, like hoarseness and trouble swallowing, often go unnoticed. Recognize these signs early."

    Published: Apr 20th, 2022 at 07:48:32 AM

    Medullary Thyroid Cancer Market: Worldwide Industry to Boost in the Period of 2021-2026

    "Medullary Thyroid Cancer Market analysis is provided for the Global market including development trends by regions, competitive analysis of ..."

    Published: Apr 20th, 2022 at 03:29:49 AM

    GFR4 May Represent a Unique Therapeutic Target in Medullary Thyroid Cancer - OncLive

    "Along with his colleagues at Penn, he is investigating a novel CAR T-cell product as a treatment for adults with medullary thyroid cancer (MTC)."

    Published: Apr 19th, 2022 at 10:09:06 AM

    Parathyroid Hormone Market Size 2022 Analysis By Top Keyplayers | Pfizer, Abbott ...

    "Merck; Natpara; Glaxosmithkline Plc; Sanofi Sa; Eli Lilly; Cell Genesys Inc; Osi Pharmaceuticals; Paladin Labs Inc; Alza Corporation. Parathyroid ..."

    Published: Apr 19th, 2022 at 09:29:46 AM

    Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine - PubMed

    "Medullary thyroid carcinoma (MTC) is a neuroendocrine malignant tumor originating from parafollicular C-cells producing calcitonin."

    Published: Apr 19th, 2022 at 12:47:54 AM

    China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride ...

    "... differentiated thyroid cancer (rair-dtc) resistant to inoperable iodine treatment. ... small cell lung cancer and medullary thyroid cancer."

    Published: Apr 18th, 2022 at 03:14:41 PM

    Takeda's rare disease drug's manufacturing and supply woes continue as FDA rejects supplement

    "Takeda acquired Natpara when it bought out Shire for $62 billion in early 2019. In 2018, the last full year of Natpara sales, the treatment brought in ..."

    Published: Apr 18th, 2022 at 02:06:09 PM

    L-Ascorbic Acid Market Outlook: Post Covid-19 Scenario by 2029 | DSM, CSPC Pharma

    "Medullary Thyroid Cancer Market Analysis for 2022 and 2027 · Quote-to-Cash Consulting Service Market to see Huge Rapid by 2029."

    Published: Apr 17th, 2022 at 09:23:19 PM

    Parathyroid Hormone Analog Market Size, Share and Trends 2022-2028, Forecast Key Players

    "Pfizer; Cell Genesys Inc; Natpara; Abbott Laboratories; Eli Lilly; Merck; Paladin Labs Inc; Sanofi SA; GlaxoSmithKline Plc; OSI Pharmaceuticals ..."

    Published: Apr 16th, 2022 at 08:05:54 AM

    Medullary thyroid cancer - An update - PubMed

    "Medullary thyroid cancer (MTC) is a rare neuroendocrine disease, encompassing about 5% of all thyroid cancers. Due to its peculiar features, ..."

    Published: Apr 16th, 2022 at 12:08:19 AM

    Parathyroid Hormone Analog Market Global Industry Research Analysis & Forecast 2022 to 2027

    "Merck; Natpara; GlaxoSmithKline Plc; Sanofi SA; Eli Lilly; Cell Genesys Inc; OSI Pharmaceuticals; Paladin Labs Inc; ALZA Corporation. The Parathyroid ..."

    Published: Apr 15th, 2022 at 11:23:43 PM

    Mum handed 2400 tax bill for cancer drugs because of post-Brexit VAT changes - The Mirror

    "Gemma started taking ONC201, a German trial drug, after doctors said she only had a year to live. She says the drug has made a "massive ..."

    Published: Apr 15th, 2022 at 11:10:13 PM

    Agenda | Focus on Medullary Thyroid Cancer: Advances in Treatment and Cutting Edge Research

    "Gary Bloom | ThyCa: Thyroid Cancer Survivors' Association, Inc. ... CAR-T Trial for Medullary Thyroid Cancer ..."

    Published: Apr 14th, 2022 at 11:36:25 PM

    According to the Latest Report : Temperature Detection Screen Market Is Expected ...

    "Medullary Thyroid Cancer Market Scope and overview, To Develop with Increased Global Emphasis on Industrialization 2029 | Sanofi, Eli Lilly and ..."

    Published: Apr 14th, 2022 at 08:04:17 PM

    Overview | Focus on Medullary Thyroid Cancer: Advances in Treatment and Cutting Edge Research

    "Identify options for managing medullary thyroid cancer; Summarize contemporary therapies for advanced MTC and novel immunotherapy for MTC. For ..."

    Published: Apr 14th, 2022 at 06:47:03 PM

    New Trials in Lung Cancer: Could Your Patients Benefit? - Medscape

    "Patients will take twice-daily capsules of selpercatinib or placebo for up to 3 years until an "event" such as disease progression/recurrence or ..."

    Published: Apr 14th, 2022 at 02:51:01 AM

    Medullary Thyroid Cancer Market Scope and overview, To Develop with Increased Global ...

    "" Get Sample Report Buy Complete Report California (United States), April 13 - The Medullary Thyroid Cancer Market research report provides all."

    Published: Apr 13th, 2022 at 08:03:43 PM

    Lilly Presents Updated Data on Retevmo in Advanced RET Fusion-Positive NSCLC

    "Selpercatinib is a selective and potent RET kinase inhibitor that is approved in multiple countries, including the United States. The indications ..."

    Published: Apr 13th, 2022 at 06:24:18 PM

    Cabozantinib Market, Global Outlook and Forecast 2022-2028 - Industrial IT

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Global Cabozantinib Market, By Region and Country, 2017-2022, ..."

    Published: Apr 13th, 2022 at 04:51:36 PM

    Treatments for medullary thyroid cancer

    "Medullary thyroid cancer can be treated with surgery, hormone therapy, radiation therapy, targeted therapy and chemotherapy."

    Published: Apr 13th, 2022 at 04:12:36 AM

    Parathyroid Hormone Analog Market Share And Size 2022 Analysis By Top Keyplayers

    "Pfizer; Abbott Laboratories; Merck; Natpara; Glaxosmithkline Plc; Sanofi Sa; Eli Lilly; Cell Genesys Inc; Osi Pharmaceuticals; Paladin Labs Inc; Alza ..."

    Published: Apr 12th, 2022 at 07:09:18 PM

    Semiconductor Grade Isopropyl Alcohol Market Forecasting Profits 2022 | Top Leaders

    "Medullary Thyroid Cancer Market Growing Impressive Business Opportunities, Industry Trends, Global Demand, Future Scope with Top Players: CCCC, ..."

    Published: Apr 12th, 2022 at 04:57:01 PM

    Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2030 - Spooool.ie

    "Medullary Thyroid Cancer Treatment Second Line Treatment for Renal Cell Carcinoma. Cabozantinib Market: Regional Analysis."

    Published: Apr 11th, 2022 at 08:18:03 PM

    Medullary Thyroid Cancer Market Growing Impressive Business Opportunities, Industry ...

    "Successive analysis of the global Medullary Thyroid Cancer market drives a thorough primary as well as secondary research encompassing the key ..."

    Published: Apr 11th, 2022 at 07:39:21 PM

    Neuroendocrine Tumors Market Outlook for Major Applications/end Users, Consumption ...

    "Types of neuroendocrine tumors are islet cell tumors, carcinoid tumors, pheochromocytomas, medullary thyroid cancer, neuroendocrine carcinoma, ..."

    Published: Apr 11th, 2022 at 07:09:37 AM

    management guidelines of the American Thyroid Association. - University of Westminster

    "Medullary thyroid cancer: management guidelines of the American Thyroid Association.-article."

    Published: Apr 8th, 2022 at 08:49:07 PM

    Parathyroid Hormone Analog Market by Top Key Players | Pfizer, Cell Genesys Inc, Natpara ...

    "Natpara. Abbott Laboratories. Eli Lilly. Merck. Paladin Labs Inc. Sanofi SA. GlaxoSmithKline Plc. OSI Pharmaceuticals. ALZA Corporation. By Type."

    Published: Apr 8th, 2022 at 08:32:27 AM

    Exelixis Inc. | INN - Investing News Network

    "Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and ..."

    Published: Apr 8th, 2022 at 03:35:21 AM

    Parathyroid Hormone Market by Top Key Players | Pfizer, Cell Genesys Inc, Natpara, Abbott ...

    "Natpara. Abbott Laboratories. Eli Lilly. Merck. Paladin Labs Inc. Sanofi SA. GlaxoSmithKline Plc. OSI Pharmaceuticals. ALZA Corporation."

    Published: Apr 8th, 2022 at 12:31:58 AM

    Here is why Eli Lilly and Company (LLY) recent weekly performance of 5.50% shouldn't ...

    "Recently in News on April 1, 2022, Lilly Presents Updated Data on Retevmo (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung ..."

    Published: Apr 7th, 2022 at 10:49:55 PM

    File:Histopathology of follicular patterned medullary thyroid carcinoma, and intrathyroidal ...

    "File:Histopathology of follicular patterned medullary thyroid carcinoma, and intrathyroidal parathyroid tissue.jpg."

    Published: Apr 7th, 2022 at 06:31:18 PM

    Here is why Eli Lilly and Company (LLY) recent weekly performance of 5.50% shouldn't ...

    "... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who ..."

    Published: Apr 7th, 2022 at 04:34:23 PM

    Eli Lilly and Company [LLY] moved up 4.56: Why It's Important | The DBT News

    "... and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer ..."

    Published: Apr 7th, 2022 at 10:35:35 AM

    Eli Lilly and Company [LLY] moved up 4.56: Why It's Important | The DBT News

    "Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib 40 mg & 80 mg capsules) ..."

    Published: Apr 7th, 2022 at 02:32:22 AM

    I've gained weight and suffered horrific mood swings since beating thyroid cancer, says ... - The Sun

    "The cells within the thyroid grow too quickly and create a lump. ... medullary thyroid carcinoma, anaplastic thyroid carcinoma."

    Published: Apr 6th, 2022 at 02:02:02 PM

    Editorial: Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Clinical and Genetic Update

    "Outstanding experts in thefield contributed to the Special Research Topic titled"Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Clinical ..."

    Published: Apr 6th, 2022 at 04:12:30 AM

    Selpercatinib Shows Promise in Advanced RET Fusion-Positive NSCLC - Oncology Nursing News

    "... RET fusionpositive nonsmall cell lung cancer (NSCLC) experienced favorable response rates following treatment with selpercatinib (Retevmo), ..."

    Published: Apr 6th, 2022 at 03:43:14 AM

    Molecular Imaging of Neuroendocrine Neoplasms - Docwire News

    "... lung, thyroid, pituitary and adrenal glands. ... with the exception of the evaluation of advanced medullary thyroid carcinoma."

    Published: Apr 5th, 2022 at 07:23:57 PM

    Selpercatinib Shows Promise in Advanced RET Fusion-Positive NSCLC - Oncology Nursing News

    "Patients with metastatic RET fusionpositive nonsmall cell lung cancer experienced encouraging responses with selpercatinib."

    Published: Apr 5th, 2022 at 07:13:30 PM

    Medullary Thyroid Cancer Market Segmentation, Analysis by Recent Trends, Development ...

    "Global " Medullary Thyroid Cancer Market" report initially gives the overview of the industry with basic outline, descriptions, classific."

    Published: Apr 5th, 2022 at 04:49:07 AM

    Global Cabozantinib Market 2022 Trend Analysis, Growth Status, Revenue Expectation to 2028

    "Furthermore, report gives information about the numerous applications available: Medullary Thyroid Cancer Treatment; Second Line Treatment for ..."

    Published: Apr 5th, 2022 at 04:18:41 AM

    Medullary Thyroid Cancer Market Analysis for 2022 and 2027 Sanofi, Eli Lilly and ...

    "" The Medullary Thyroid Cancer Market Research Report is a professional asset that provides dynamic and statistical insights into regional and ..."

    Published: Apr 2nd, 2022 at 11:12:47 AM

    Selpercatinib Continues to Provide Clinically Meaningful Benefit in Advanced RET Fusion ...

    "Selpercatinib continued to provide clinically meaningful benefit to patients with metastatic RET fusionpositive nonsmall cell lung cancer."

    Published: Apr 2nd, 2022 at 02:49:47 AM

    CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer - OncLive

    "... novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with advanced incurable medullary thyroid cancer."

    Published: Apr 2nd, 2022 at 12:02:10 AM

    Lilly reports new data from phase 1/2 trial of Retevmo in advanced lung cancer | Seeking Alpha

    "Eli Lilly (LLY) reported updated data from a phase 1/2 trial of Retevmo (selpercatinib 40 mg & 80 mg capsules) in patients with RET ..."

    Published: Apr 1st, 2022 at 11:26:36 PM

    Lilly Presents Updated Data on Retevmo in Advanced RET Fusion-Positive NSCLC at the ...

    "... with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ... or advanced or metastatic RET fusion-positive thyroid cancer who ..."

    Published: Apr 1st, 2022 at 10:10:06 PM

    Medullary Thyroid Cancer - MTC - Facebook

    "This group is for anyone affected with or by Medullary Thyroid Cancer. This is a place of comfort and friendship for those needing someone to ..."

    Published: Apr 1st, 2022 at 05:55:57 PM

    Lilly Presents Updated Data on Retevmo (selpercatinib) in Advanced RET Fusion-Positive ...

    "PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib 40 ..."

    Published: Apr 1st, 2022 at 02:13:51 PM

    Antitumor Activity Seen with Selpercatinib in RET-Mutant MTC in Chinese Patients

    "... with RET-altered thyroid cancer, according to LIBRETTO-321 results. ... during transfection (RET)-mutant medullary thyroid cancer (MTC)."

    Published: Apr 1st, 2022 at 12:09:52 PM

    Lilly Presents Updated Data on Retevmo (selpercatinib) in Advanced RET Fusion-Positive ...

    "... medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic ..."

    Published: Mar 31st, 2022 at 08:49:32 PM

    An Overview of Differentiated Thyroid Cancer - Cure Today

    "There are differentiated thyroid cancers, poorly differentiated thyroid cancer, anaplastic thyroid cancer, and then also medullary thyroid cancer."

    Published: Mar 31st, 2022 at 10:06:00 AM

    RET targeted therapies Retevmo, Gavreto to compete in Korea < Pharma < - KBR

    "As Roche's Gavreto (pralsetinib) won the regulatory nod following Lilly's Retevmo (selpercatinib) in March, the two RET (rearranged during ..."

    Published: Mar 30th, 2022 at 09:11:11 PM

    Targeting RET in Medullary Thyroid Cancer

    "Vivek Subbiah, MD, discusses what sets medullary thyroid cancer apart from other thyroid histologies."

    Published: Mar 30th, 2022 at 09:07:54 AM

    RET targeted therapies Retevmo, Gavreto to compete in Korea < Pharma < - KBR

    "As Roche's Gavreto (pralsetinib) won the regulatory nod following Lilly's Retevmo (selpercatinib) in March, the two RET (rearranged during ..."

    Published: Mar 29th, 2022 at 10:31:38 PM

    Innovent wins sole rights to commercialize two Lilly oncology drugs in $45M deal | BioWorld

    "s oncology drugs Cyramza (ramucirumab) and Retsevmo (selpercatinib) in mainland China, where it will be responsible for the pricing, importation, ..."

    Published: Mar 29th, 2022 at 07:17:54 PM

    High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma - PubMed

    "Taken together, human endogenous retrovirus-H long terminal repeat-associating protein 2 is highly expressed in medullary thyroid carcinoma ..."

    Published: Mar 29th, 2022 at 04:58:52 AM

    Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs - Scrip

    "... rights to import, market, promote, distribute and detail Cyramza (ramucirumab) and Retevmo (selpercatinib) once approved in mainland China."

    Published: Mar 29th, 2022 at 04:03:53 AM

    FDA Rejects Changes to Natpara Cartridge, Delaying Its Relaunch - Hypoparathyroidism News

    "The U.S. FDA has rejected Takeda's proposed changes to address the problem with its Natpara's cartridge, which was recalled in 2019."

    Published: Mar 29th, 2022 at 03:03:44 AM

    Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2030 - ChattTenn Sports

    "The recent report on "Medullary Thyroid Cancer Market Report 2022 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2030" ..."

    Published: Mar 28th, 2022 at 10:25:51 PM

    Innovent Biologics, Lilly Expand Strategic Commercialization Pact - Contract Pharma

    "Retsevmo (selpercatinib) is a highly selective and potent rearranged during transfection (RET) inhibitor. It was approved by FDA, under the brand ..."

    Published: Mar 28th, 2022 at 08:11:23 PM

    Innovent Gains Licensing Rights to Eli Lilly's Retsevmo, Cyramza in China

    "... giving Innovent sole rights to commercialize RET inhibitor Retsevmo (selpercatinib) and VEGFR2 inhibitor Cyramza (ramucirumab)."

    Published: Mar 28th, 2022 at 02:36:30 PM

    China's Innovent Biologics expands oncology partnership with Eli Lilly for $45M - BioSpectrum Asia

    "Retsevmo (selpercatinib) is a highly selective and potent rearranged during transfection (RET) inhibitor. With a further expanded oncology product ..."

    Published: Mar 28th, 2022 at 01:33:28 AM

    Innovent and Lilly Expand Strategic Partnership in Oncology - PR Newswire

    "It was approved by FDA, under the brand name Retevmo, as the first therapy specifically indicated for the treatment of adult patients with ..."

    Published: Mar 28th, 2022 at 01:13:21 AM

    Innovent and Lilly Expand Strategic Partnership in Oncology - PR Newswire APAC

    "Retsevmo (selpercatinib) is a highly selective and potent rearranged during transfection (RET) inhibitor. It was approved by FDA, under the brand ..."

    Published: Mar 26th, 2022 at 08:19:13 PM

    FDA Updates for the Week of March 21, 2022 - Managed Healthcare Executive

    "... prostate cancer is approved, BMS snags approval for Opdualag, the FDA misses PDUFA date for Reblozyl and issues CRLs for sintilimab and Natpara."

    Published: Mar 25th, 2022 at 10:08:07 AM

    Medicine for the Treatment of Advanced Thyroid Cancer Market Report (COVID-19 Analysis ...

    "On the basis of cancer type the market is segmented as, papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, ..."

    Published: Mar 24th, 2022 at 06:26:55 PM

    #FierceMadness: BMS' Zeposia, Gilead's Trodelvy and Lilly's Retevmo advance to Sweet 16 ...

    "Jazz Pharmaceuticals went off on a crazy solo act as its lung cancer drug Zepzelca easily beat out Amgen's rival Lumakras, getting 73% of the vote ..."

    Published: Mar 24th, 2022 at 04:07:18 PM

    A Phase I Study of TAS0953/HM06 in People with RET-Mutated Advanced Solid Tumors

    "Full Title Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Purpose ..."

    Published: Mar 24th, 2022 at 03:27:21 PM

    Thyroid Health Blog: Medullary Thyroid Cancer

    "Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor."

    Published: Mar 24th, 2022 at 02:00:42 PM

    Indian pharma, US plastic surgeon reach deal to build $50M drug plant in Africa

    "Takeda's long slog to manufacture and relaunch its hypoparathyroidism drug Natpara got a lot tougher after the pharma giant announced it received a ..."

    Published: Mar 24th, 2022 at 08:17:49 AM

    Medullary Thyroid Cancer Market 2022-2030, By Top Key Players - ChattTenn Sports

    "The Medullary Thyroid Cancer market report is a perfect foundation for people looking out for a comprehensive study and analysis of the Medullary ..."

    Published: Mar 24th, 2022 at 05:38:01 AM

    Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks | Fierce Pharma

    "The issue prompted a 2019 U.S. recall of Natpara. Takeda issued the recall on concerns that rubber from the covering of the injector cartridge could ..."

    Published: Mar 24th, 2022 at 01:29:35 AM

    Takeda's rare disease drug's manufacturing and supply woes continue as FDA rejects supplement

    "Since the Natpara recall in September 2019, no US revenue has been recorded and concerns are growing among patients that the drug may never return to ..."

    Published: Mar 23rd, 2022 at 03:34:46 AM

    Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on | Fierce Pharma

    "Takeda's long slog to manufacture and relaunch its hypoparathyroidism drug Natpara got a lot tougher after the pharma giant announced it received ..."

    Published: Mar 22nd, 2022 at 01:33:52 PM

    Sorrento ends Phase Ib pancreatic cancer trial, shot at further study drops - Clinical Trials Arena

    "Loxo's oncology asset LOXO-292 (selpercatinib) saw a rise in its PTSR after a Phase I/II cancer trial's status was changed to ongoing."

    Published: Mar 22nd, 2022 at 07:11:12 AM

    Hypothyroidism can cause hearing loss and tinnitus - Healthy Hearing

    "An underactive thyroid gland can cause hearing problems, yet many doctors ... used to treat rare medullary thyroid and anaplastic thyroid cancers, ..."

    Published: Mar 22nd, 2022 at 05:32:39 AM

    Medullary Thyroid Cancer Market 2022-2030, By Top Key Players - Spooool.ie

    "Medullary Thyroid Cancer Market 2022-2030, By Top Key Players AstraZeneca, Sanofi, Eli Lilly and Company, Millennium Pharmaceuticals, Inc. By ..."

    Published: Mar 21st, 2022 at 09:05:29 AM

    Medullary Carcinoma of the Thyroid - 8w8

    "These be make up of consistently instances of familial secluded medullary thyroid cancer, MEN-2a, and MEN-2b. occasional medullary carcinoma occurs ..."

    Published: Mar 20th, 2022 at 08:13:30 PM

    Current approaches to medullary thyroid carcinoma, sporadic and familial | Read by QxMD

    "Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25% of cases) and sporadic forms, ..."

    Published: Mar 18th, 2022 at 04:45:26 AM

    Thyroid Cancer Drugs Global Market Report 2022 - Yahoo Finance

    "The types of thyroid cancer include follicular, papillary, medullary, anaplastic and thyroid lymphoma. The main types of thyroid cancer drugs are ..."

    Published: Mar 18th, 2022 at 03:59:18 AM

    CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for ...

    "... tolerability, and efficacy of pralsetinib in patients with RET-fusion positive NSCLC, RET-mutant medullary thyroid cancer (MTC), ..."

    Published: Mar 15th, 2022 at 06:27:38 AM

    Medullary thyroid cancer: Surgical treatment and prognosis - UpToDate

    "Patients with medullary thyroid cancer (MTC) can be cured only by complete resection of the thyroid tumor and any local and regional metastases."

    Published: Mar 15th, 2022 at 05:11:31 AM

    New drug application for treatment of thyroid cancer - eTurboNews

    "... inhibitor GAVRETO (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC)."

    Published: Mar 15th, 2022 at 04:42:36 AM

    Lilly's Retevmo nodded as Korea's 1st RET kinase inhibitor < Pharma < - KBR

    "Lilly Korea said the Ministry of Food and Drug Safety approved its Retevmo 40mg and 80mg as Korea's first RET (Rearranged during Transfection) ..."

    Published: Mar 15th, 2022 at 03:43:54 AM

    Burden of Thyroid Cancer: Substantial and Increasing - Medscape

    "The global burden of thyroid cancer is substantial, and incidence rates are increasing in many developed countries including the United States, ..."

    Published: Mar 14th, 2022 at 04:27:18 AM

    Lilly's Retevmo nodded as Korea's 1st RET kinase inhibitor < Pharma < - KBR

    "In the RET-mutated medullary thyroid cancer patient group who had not previously been treated with vandetanib or caboxantinib, the ORR of Retevmo was ..."

    Published: Mar 14th, 2022 at 03:32:47 AM

    'I was told I had thyroid cancer just days after my son was born' - Independent.ie

    "Nadia Powney, who is waiting on treatment results for thyroid cancer, ... If a family member has had medullary thyroid cancer or if you have ..."

    Published: Mar 14th, 2022 at 02:01:11 AM

    CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of ...

    "GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved in China for the treatment of RET-mutant medullary ..."

    Published: Mar 14th, 2022 at 01:21:56 AM

    CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of ...

    "... (pralsetinib) for the treatment of RET-mutant medullary thyroid cancer ... medullary thyroid cancer and RET fusion-positive thyroid cancer."

    Published: Mar 6th, 2022 at 01:39:26 PM

    Cwmbran boy Olivier Roberts has DIPG treatment | Free Press Series

    "Richard and Marina Roberts held discussions about getting Olivier on to a ONC201 trial in France, where it is only available when a patient is 'on ..."

    Published: Mar 3rd, 2022 at 04:57:02 AM

    3 Ways The FDA Is Taking Action On Lack Of Diversity In Cancer Clinical Trials

    "By now, the lack of diversity in clinical trials of cancer therapies approved ... RET fusion-positive solid tumors, and medullary thyroid cancer, ..."

    Published: Mar 2nd, 2022 at 06:27:40 AM

    Clinical Trial for DIPG Offers Hope for Children with Brain Cancer - South Florida Hospital News

    "I am currently conducting a pioneer phase I clinical trial called ONC201 at the Miami Cancer Institute (MCI) testing a new targeted therapy for ..."

    Published: Feb 28th, 2022 at 04:22:43 PM

    Identifying Clinical Risk Factors of Lateral Lymph Node | IJGM - Dove Medical Press

    "Medullary thyroid carcinoma is a rare histological subtype of thyroid cancer, characterized by early lymphatic and systemic dissemination of tumor ..."

    Published: Feb 24th, 2022 at 08:03:24 PM

    Wrexham Hospice's well-being program growing in popularity | The Leader

    "Pauline Edwards, lives with Medullary thyroid cancer and for the past 10 years has managed to keep her condition stable."

    Published: Feb 24th, 2022 at 05:14:54 PM

    Hospice has helped Pauline to live well with her cancer diagnosis | Shropshire Star

    "Pauline Edwards, lives with Medullary thyroid cancer and for the past 10 years has managed to keep her condition stable, allowing her to live a ..."

    Published: Feb 23rd, 2022 at 04:08:24 AM

    Key Objectives With Selpercatinib Use in RET Fusion-Positive Thyroid Cancer - Targeted Oncology

    "... tolerability, pharmacokinetics, and preliminary anti-tumor activity of selpercatinib in patients with advanced solid tumors."

    Published: Feb 23rd, 2022 at 02:20:08 AM

    BOS172738 Demonstrates Strong Efficacy/Tolerability in RET-Altered MTC and Other Solid Tumors

    "BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and nonsmall cell lung cancer, according to a ..."

    Published: Feb 22nd, 2022 at 10:13:45 PM

    Roche gets FDA's Orphan Drug tag for pralsetinib in solid tumors (BPMC) | Seeking Alpha

    "22 covers the use of pralsetinib in metastatic RET fusion-positive solid tumors. With its orphan drug designation, the FDA aims to offer financial ..."

    Published: Feb 22nd, 2022 at 10:04:56 PM

    Key Objectives With Selpercatinib Use in RET Fusion-Positive Thyroid Cancer - Targeted Oncology

    "Participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer ..."

    Published: Feb 22nd, 2022 at 08:09:46 PM

    BOS172738 Demonstrates Strong Efficacy/Tolerability in RET-Altered MTC and Other Solid Tumors

    "BOS172738 shows promising results in the treatment of RET gene altered medullary thyroid cancer and nonsmall cell lung cancer, according to a ..."

    Published: Feb 22nd, 2022 at 06:04:35 PM

    Regulatory actions for Feb. 15-21, 2022 | BioWorld

    "... RET-fusion-positive locally advanced or metastatic non-small-cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer, ..."

    Published: Feb 19th, 2022 at 11:12:03 PM

    Hanna Discusses Efficacy Results of Different Treatments in RET-Positive Lung Cancer

    "HANNA: You want to use selpercatinib [Retevmo] or pralsetinib [Gavreto] as first-line therapy if you know the patient has a RET fusion.1 The ..."

    Published: Feb 19th, 2022 at 01:47:32 AM

    Drug affordability imperative to ensure cancer patients benefit from cutting-edge therapies ...

    "Targeted cancer therapies, like traditional chemotherapy, ... the efficacy of treatment for medullary thyroid cancer, renal cell carcinoma, ..."

    Published: Feb 19th, 2022 at 12:44:18 AM

    Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong - Yahoo Finance

    "Cabometyx is approved for advanced renal cell carcinoma (RCC) and ... capsules) for the treatment of medullary thyroid cancer generated $7.6 ..."

    Published: Feb 19th, 2022 at 12:08:44 AM

    Radiofrequency Ablation an Option for Thyroid Microcarcinoma - Medscape

    "Microcarcinoma PTC, defined as measuring 10 mm or less, is highly common, making up approximately half of papillary thyroid cancers diagnosed in ..."

    Published: Feb 18th, 2022 at 09:49:46 PM

    Ascendis rising in HPT, Natpara comparator off base? | BioWorld

    "The comparator on many investors' minds is Natpara, the PTH product from Takeda Pharmaceutical Co. Ltd., brought aboard in the $62 billion buyout ..."

    Published: Feb 17th, 2022 at 12:25:15 PM

    CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for ...

    "Discovered by CStone's partner Blueprint Medicines, pralsetinib is a potent and selective RET inhibitor. CStone has an exclusive collaboration and ..."

    Published: Feb 17th, 2022 at 07:31:52 AM

    Blueprint Medicines Reports $107M in Q4 Revenues Helped by Growing Ayvakit Sales ...

    "The FDA approved Gavreto in 2020 for advanced RET fusion-positive advanced non-small cell lung and thyroid cancer, RET-mutant medullary thyroid cancer ..."

    Published: Feb 17th, 2022 at 01:33:05 AM

    Blueprint Medicines Reports $107M in Q4 Revenues Helped by Growing Ayvakit Sales ...

    "... cell lung and thyroid cancer, RET-mutant medullary thyroid cancer. ... of the CDK2 inhibitor BLU-222 in cyclin E-CDK2-aberrant cancers in Q1."

    Published: Feb 17th, 2022 at 12:25:45 AM

    CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for ...

    "... advanced or metastatic RET-mutant medullary thyroid cancer (MTC), ... China for the treatment of NSCLC and thyroid cancers, after AYVAKYT ..."

    Published: Feb 16th, 2022 at 06:46:26 PM

    Where Will Blueprint Medicines Corp (BPMC) Stock Go Next After It Is Lower By 11.29% in a Week?

    "Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants."

    Published: Feb 16th, 2022 at 06:13:45 AM

    "Global United States Parathyroid Hormone Market Industry 2022-28 Market Players-Pfizer ...

    "Natpara GlaxoSmithKline Plc Sanofi SA Eli Lilly Cell Genesys Inc OSI Pharmaceuticals Paladin Labs Inc ALZA Corporation."

    Published: Feb 11th, 2022 at 06:52:38 PM

    Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients

    "For example, patients with RET fusion-positive advanced or metastatic medullary thyroid cancer can be treated with either Eli Lilly's Retevmo ..."

    Published: Feb 11th, 2022 at 06:27:15 PM

    Foundation Medicine to develop companion diagnostics for Lilly's Retevmo and Loxo ...

    "Foundation Medicine to develop companion diagnostics for Lilly's Retevmo and Loxo Oncology at Lilly's pipeline. February 11, 2022."

    Published: Feb 11th, 2022 at 07:33:44 AM

    Understanding Thyroid Cancer And Its Link With Obesity | Femina.in

    "Family history of thyroid cancer or thyroid disease, having inherited genetic syndromes, for example, medullary thyroid cancer, goitre; Obese and ..."

    Published: Feb 11th, 2022 at 02:21:13 AM

    How does semaglutide work, who can take it?, the medicine approved in the United ... - OI Canadian

    "... cholesterol levels), obstructive sleep apnea, and heart disease. ... carries a warning that it has been linked to medullary thyroid cancer, ..."

    Published: Feb 11th, 2022 at 02:19:27 AM

    Medullary thyroid cancer: What you should know | WKRC

    "COLUMBUS, Ohio (WKRC) - Medullary thyroid cancer is rare and can be aggressive, and Dr. Nolan Seim shares what to look for and why getting care ..."

    Published: Feb 10th, 2022 at 12:28:39 AM

    Sofa Vergara Says She Feels "Lucky And Grateful" To Have Survived Cancer When She Was 28

    "Following that, follicular thyroid cancer accounts for about 20 per cent of thyroid cancers, and less common is medullary thyroid cancer, anaplastic ..."

    Published: Feb 9th, 2022 at 05:23:01 PM

    Foundation Medicine, Eli Lilly Ink CDx Development Deal for Retevmo | Precision Oncology News

    "NEW YORK Roche's Foundation Medicine will develop tissue- and blood-based tests for use as companion diagnostics for Eli Lilly's Retevmo ..."

    Published: Feb 9th, 2022 at 05:10:00 PM

    Foundation Medicine Announces Global Collaboration With Lilly to Develop ... - Yahoo Finance

    "CAMBRIDGE, Mass., February 09, 2022--Foundation Medicine Partners With Lilly to Develop Its Tests as Companion Diagnostics for RETEVMO and Loxo ..."

    Published: Feb 8th, 2022 at 07:57:15 PM

    Celebrity Factor: Raising Awareness for Thyroid Cancer - Medscape

    "South Korean actress Park So-dam announced publicly her thyroid cancer diagnosis, Dr Stephanie Smooke Praw discusses whether this draws attention ..."

    Published: Feb 8th, 2022 at 02:23:52 AM

    Tmunity CEO Usman Azam departing to lead 'stealth' NYC biotech firm - The Business Journals

    "Tmunity, which is based in Philadelphia, has its own manufacturing operations in East Norriton. Tmunity's founders include June and fellow Penn cell ..."

    Published: Feb 7th, 2022 at 11:37:15 PM

    UPDATED: Months after Tmunity ground to a halt on clinical hold, cell therapy pioneer Oz ...

    "Eight months after execs at Tmunity told us in an exclusive report that the FDA had slapped a clinical hold on their pipeline programs after an ..."

    Published: Feb 4th, 2022 at 10:49:52 PM

    Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial ... - Investors | Eli Lilly and Company

    "Retevmo (selpercatinib, Lilly ) Synjardy (empagliflozin/metformin, Boehringer Ingelheim ) Taltz (ixekizumab, Lilly )"

    Published: Feb 3rd, 2022 at 10:15:07 PM

    Novel Treatment Advances in Differentiated Thyroid Cancer - OncLive

    "Many of you have at your sites randomizing patients to either RET inhibitors upfront versus standard of care or for medullary thyroid cancer, ..."

    Published: Feb 3rd, 2022 at 07:58:22 PM

    Football boss on wife's heartbreaking brain tumour diagnosis and drug trial hope - honestcolumnist

    "The couple believe than ONC201 has worked, with Gemma's most recent scans showing the brain tumour as 'stable', which means the cancer has not gotten ..."

    Published: Feb 3rd, 2022 at 01:10:09 PM

    Second-Line Treatment Approaches for DTC - OncLive

    "... considering a second-line therapy for differentiated thyroid cancer. ... A lot of the patients with medullary thyroid cancer had looked like ..."

    Published: Feb 3rd, 2022 at 09:42:00 AM

    Medullary thyroid cancer: Symptoms, causes, and treatment - Medical News Today

    "Medullary thyroid cancer (MTC) is a rare type of cancer that forms in the thyroid. It differs from other forms of thyroid cancer, as it originates ..."

    Published: Feb 1st, 2022 at 11:08:45 PM

    5 Early Signs Of Thyroid Cancer - MissMalini

    "Besides these, there are certain inherited genetic syndromes (familial), for example, Medullary Thyroid Cancer may run in some families or if ..."

    Published: Jan 28th, 2022 at 12:25:28 PM

    RET and NTRK Inhibitors for Differentiated Thyroid Cancer - OncLive

    "Selpercatinib is an approved drug for RET fusion differentiated thyroid cancer [DTC], also for RET mutated medullary thyroid cancer and lung cancer."

    Published: Jan 26th, 2022 at 05:22:20 PM

    Consumer Health: Understanding thyroid cancer risk - Medical Xpress

    "Certain inherited genetic syndromes: Genetic syndromes that increase the risk of thyroid cancer include familial medullary thyroid cancer, ..."

    Published: Jan 25th, 2022 at 03:56:41 AM

    Efficacy/Safety Evaluation of Selpercatinib in RET-Driven MTC Ongoing in LIBRETTO-531

    "Selpercatinib (LOXO-292), a selective and potent RET inhibitor, is now under evaluation for the treatment of RET-mutant medullary thyroid cancer ..."

    Published: Jan 25th, 2022 at 12:40:00 AM

    Applied Pharmaceutical Science RET Inhibitor IND Gets FDA Clearance | Precision Oncology News

    "... cell lung cancer patients, as well as for certain advanced medullary thyroid cancer patients with RET mutations and advanced thyroid cancer ..."

    Published: Jan 24th, 2022 at 09:55:06 PM

    Efficacy/Safety Evaluation of Selpercatinib in RET-Driven MTC Ongoing in LIBRETTO-531

    "Selpercatinib (LOXO-292), a selective and potent RET inhibitor, is now under evaluation for the treatment of RET-mutant medullary thyroid cancer ..."

    Published: Jan 24th, 2022 at 08:19:06 PM

    Of Benign Thyroidectomies, 9% Carry Papillary Thyroid Microcarcinomas - Medscape

    "The prevalence of papillary thyroid microcarcinoma (PTMc) was 9.3% in 1802 patients who underwent total thyroidectomy for benign disease at a ..."

    Published: Jan 24th, 2022 at 03:55:02 PM

    Efficacy/Safety Evaluation of Selpercatinib in RET-Driven MTC Ongoing in LIBRETTO-531

    "Selpercatinib (LOXO-292), a selective and potent RET inhibitor, is now under evaluation for the treatment of RET-mutant medullary thyroid cancer ..."

    Published: Jan 24th, 2022 at 01:19:10 AM

    Medullary Thyroid Cancer Market 2022-2030, By Top Key Company Profiles - Industrial IT

    "The Medullary Thyroid Cancer market report will provide forecasts based on real figures and factual data to help you decide on your marketing plans."

    Published: Jan 22nd, 2022 at 07:28:20 AM

    Local Retired Teacher With Cancer Ready To Take the Next Step - PtboCanada

    "After being diagnosed with medullary thyroid cancer and 30 years of teaching, local teacher Andrew Astrom is going from the classroom to the real ..."

    Published: Jan 20th, 2022 at 05:56:25 PM

    A Phase III Study of Selpercatinib after Surgery or Radiation Therapy for RET Fusion ...

    "Full Title LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional ..."

    Published: Jan 19th, 2022 at 02:14:08 AM

    Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in ... - Yahoo Finance

    ""Given ONC201's demonstrated biological activity with DRD2, we took a deliberate approach to explore its potential utility in neuroendocrine tumors," ..."

    Published: Jan 19th, 2022 at 12:45:42 AM

    Chimerix announces publication of study data for the cancer candidate - Seeking Alpha

    "The peer-reviewed article is titled "Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and ..."

    Published: Jan 14th, 2022 at 07:09:55 PM

    Parathyroid Hormone Market Insights, Regional and Country Forecasts, Deep Analysis of ...

    "Pfizer; Cell Genesys Inc; Natpara; Abbott Laboratories; Eli Lilly; Merck; Paladin Labs Inc; Sanofi SA; GlaxoSmithKline Plc; OSI Pharmaceuticals ..."

    Published: Jan 10th, 2022 at 04:53:16 PM

    Postsurgical Hypoparathyroidism Treatment and Lower Quality of Life - Endocrinology Advisor

    "Natpara Earns FDA Approval for Hypoparathyroidism The study was conducted in 2 endocrinologic centers in Germany and enrolled 49 patients with ..."

    Published: Jan 6th, 2022 at 06:09:40 PM

    Parathyroid Hormone Analog Market Trend 2021 Forecast by Top Key Players - Industrial IT

    "Pfizer; Abbott Laboratories; Merck; Natpara; Glaxosmithkline Plc; Sanofi Sa; Eli Lilly; Cell Genesys Inc; Osi Pharmaceuticals; Paladin Labs Inc ..."

    Published: Jan 5th, 2022 at 11:20:36 PM

    Quinine Sulfate (CAS 804-63-7) Market 2022 by Types, Applications & Top Key Players - Industrial IT

    "... Abbott Laboratories, Paladin Labs Inc, Eli Lilly, Natpara, OSI Pharmaceuticals, ALZA Corporation, Sanofi SA, Cell Genesys Inc, Pfizer, Merck)."

    Published: Jan 5th, 2022 at 11:35:38 AM

    Neuroendocrine Tumor Treatment Market size Register Substantial Expansion size 2030 ...

    "Different types of neuroendocrine tumors include carcinoid tumors, islet cell tumors, medullary thyroid cancer, pheochromocytomas, neuroendocrine ..."

    Published: Jan 4th, 2022 at 07:42:36 PM

    Medullary Thyroid Cancer Market 2022 by Types, Applications & Top Key Players - Industrial IT

    "The report also provides a complete overview of Medullary Thyroid Cancer markets; including Top Players or vendors, application, Type, Share, and ..."

    Published: Jan 2nd, 2022 at 08:03:11 AM

    Medullary Thyroid Cancer Market Analysis, Research Study With Sanofi, Eli Lilly and ... - Industrial IT

    "Medullary Thyroid Cancer Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information."

    Published: Dec 30th, 2021 at 10:15:46 PM

    Parathyroid Hormone Market Size 2021 Analysis by Top Companies, And Forecast to 2028

    "Pfizer; Abbott Laboratories; Merck; Natpara; Glaxosmithkline Plc; Sanofi Sa; Eli Lilly; Cell Genesys Inc; Osi Pharmaceuticals; Paladin Labs Inc; Alza ..."

    Published: Dec 29th, 2021 at 06:59:52 PM

    What is Papillary Carcinoma? - Asap Land

    "In some cases, papillary carcinomas may be found alongside other forms of thyroid cancer such as follicular carcinomas and medullary carcinomas. These ..."

    Published: Dec 29th, 2021 at 02:07:30 PM

    Insights on Parathyroid Hormone Market: Facts, Figures and Trends 2020-2026 by Pfizer ...

    "Natpara; GlaxoSmithKline Plc; Sanofi SA; Eli Lilly; Cell Genesys Inc; OSI Pharmaceuticals; Paladin Labs Inc; ALZA Corporation. The report provides an ..."

    Published: Dec 20th, 2021 at 02:45:19 PM

    What is the Market's View on Exelixis, Inc. (EXEL) Stock's Price and Volume Trends Monday?

    "Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced ..."

    Published: Dec 17th, 2021 at 12:44:29 PM

    Diagnostic Criteria Used in Differentiated Thyroid Cancer - OncLive

    "But even in patients who have distant metastatic disease with differentiated medullary thyroid cancer, they're often completely unaware that they ..."

    Published: Dec 17th, 2021 at 12:12:50 PM

    Thyroid Cancer Risk Factors - OncLive

    "Some epidemiological studies suggest chromosomes 19 and 1 are involved, but it tends not to be a hereditary disease. Medullary thyroid cancer 20% of ..."

    Published: Dec 16th, 2021 at 08:17:06 PM

    Quinine Sulfate (CAS 804-63-7) Market 2021 by Types, Applications & Top Key Players

    "... Abbott Laboratories, Sanofi SA, Natpara. Overview for Quinine Sulfate (CAS 804-63-7) Market Helps in providing scope and definitions, ..."

    Published: Dec 16th, 2021 at 03:12:01 AM

    Cabozantinib Market Size, Share & Trends Analysis Report By Technology, By Product, By ...

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Cabozantinib Market Segmentation by Application:."

    Published: Dec 15th, 2021 at 09:39:34 AM

    Effective combination cancer treatment | Mirage News

    "This method is particularly suitable for treating medullary thyroid cancer (MTC) and is currently the subject of clinical trials conducted in ..."

    Published: Dec 14th, 2021 at 08:27:10 PM

    Thyroid Cancer Symptoms Explained As Park So-dam of 'Parasite' Diagnosed With Disease

    "The prognosis for other thyroid cancers is less positive with the rarer types, Hurthle cell cancer and medullary thyroid cancer, being the hardest ..."

    Published: Dec 13th, 2021 at 07:13:57 AM

    'Parasite' actress Park So-dam diagnosed with cancer; undergoes surgery - Manila Bulletin

    "Having certain genetic conditions such as familial medullary thyroid cancer (FMTC), multiple endocrine neoplasia type 2A syndrome (MEN2A), ..."

    Published: Dec 10th, 2021 at 09:56:22 PM

    Avistone raises $200M, acquires Pearl Biotech | 2021-12-10 | BioWorld

    "The second one was Exelixis Inc.'s Cometriq (cabozantinib), FDA-approved in 2012 for the treatment of medullary thyroid cancer."

    Published: Dec 8th, 2021 at 06:53:57 PM

    Global Non-Small Cell Lung Cancer Market Insights, Forecast and Report 2030 - The Japan Herald

    "... Telisotuzumab Vedotin, JNJ-61186372/JNJ-6372, Ensartinib/X-396, SAR408701, Selpercatinib (LY3527723/LOXO-292), and many others."

    Published: Dec 8th, 2021 at 01:39:29 AM

    China Anlotinib Hydrochloride Market Research Report 2021: A Novel Small Molecule Multi ...

    "... cell lung cancer (4) advanced or metastatic medullary thyroid cancer. ... of thyroid cancer in China in 2020, among which medullary thyroid ..."

    Published: Dec 3rd, 2021 at 11:58:29 PM

    Cancer-Related Thyroidectomy Linked to Increased Diabetes Risk - Medscape

    "Compared with nonthyroid cancer patients, those receiving thyroidectomy for thyroid cancer show up to a 40% greater risk for diabetes."

    Published: Dec 2nd, 2021 at 09:17:47 PM

    Pharmacist Medication Insights: Parathyroid Hormone (Natpara) for Hypocalcemia - Pharmacy Times

    "The FDA approved Natpara in January 2015 as an adjunct to calcium and vitamin D therapy. The bioengineered replica of human parathyroid hormone is ..."

    Published: Dec 2nd, 2021 at 12:15:13 AM

    Lincoln City fans plan minute's applause in tribute to Jack Nottingham - Lincolnshire Live

    "... his beloved Imps at Wembley back in 2018, died on Monday after being diagnosed with medullary thyroid cancer in November 2015 when he was 13."

    Published: Dec 1st, 2021 at 09:15:07 AM

    Tribute planned at Lincoln City home match for young fan who died - The Lincolnite

    "... who tragically died six years after his first cancer diagnosis. ... November 29 after a six-year battle with medullary thyroid cancer, ..."

    Published: Nov 30th, 2021 at 12:08:34 AM

    Imps community in mourning as young fan dies after six-year cancer battle - The Lincolnite

    "Jack Nottingham, otherwise known as Jack Notty, was a lifelong Lincoln fan diagnosed with medullary thyroid cancer in November 2015, at the age of ..."

    Published: Nov 29th, 2021 at 08:51:56 PM

    Blueprint Medicines (BPMC) Acquiring Lengo Therapeutics for $250 Million Plus Additional ...

    "Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants."

    Published: Nov 29th, 2021 at 06:14:10 PM

    NICE Recommends Eli Lilly's Retsevmo for RET-Altered NSCLC Through Cancer Drugs Fund

    "NEW YORK The UK's National Institute for Health and Care Excellence last week recommended that the Cancer Drugs Fund (CDF) make selpercatinib ..."

    Published: Nov 29th, 2021 at 01:51:34 PM

    ONC201 Shows Clinical Efficacy in H3 K27M-Mutated Diffuse Midline Glioma - Cancer ...

    "ONC201, a first-in-class, orally administered DRD2/3 antagonist and ClpP agonist, has been shown in preclinical research to have an anticancer ..."

    Published: Nov 29th, 2021 at 09:32:34 AM

    Lincoln City and Danny Cowley lead tributes after death of young Imps fan Jack Nottingham ...

    "Jack was diagnosed with medullary thyroid cancer in November 2015 when he was 13, resulting in having to have an emergency tracheostomy at ..."

    Published: Nov 25th, 2021 at 03:45:18 PM

    NICE backs Lilly's Retsevmo for RET fusion-positive NSCLC - The Pharma Letter

    "Selpercatinib, trade named Retevmo in the USA, is recommended for use within the Cancer Drugs Fund as an option for treating RET fusion-positive ..."

    Published: Nov 25th, 2021 at 01:31:07 PM

    Targeted drug recommended to treat some advanced lung cancer patients

    "Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England."

    Published: Nov 25th, 2021 at 09:47:03 AM

    After Scotland says no, NICE backs Lilly's Retsevmo for lung cancer - - Pharmaphorum

    "In the previously treated RET-mutant medullary thyroid cancer patients, ... gave conditional backing to NHS funding in thyroid cancers in ..."

    Published: Nov 23rd, 2021 at 08:21:16 AM

    Lung cancer, from the EU ok to therapy by form that affects young non-smokers - The Koztimes

    "Green light for Roche's pralsetinib, a precision drug that makes "even more important complete genomic profiling at diagnosis"."

    Published: Nov 22nd, 2021 at 04:29:13 PM

    Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU | Nasdaq

    "Roche RHHBY recently announced that the European Commission has granted conditional marketing authorization to Gavreto (pralsetinib)."

    Published: Nov 22nd, 2021 at 02:16:15 PM

    Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU - November 22, 2021 - Zacks.com

    "Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC."

    Published: Nov 21st, 2021 at 10:47:19 PM

    European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults ...

    "Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC ..."

    Published: Nov 20th, 2021 at 04:12:24 PM

    EC green lights Gavreto for RET fusion-positive advanced NSCLC - The Pharma Letter

    "The European Commission (EC) has granted conditional marketing authorization for Gavreto (pralsetinib) as a monotherapy for the treatment of ..."

    Published: Nov 20th, 2021 at 03:43:07 AM

    Gavreto wins conditional EU approval to treat form of lung cancer -Roche | WTVB | 1590 AM ...

    "Gavreto, known generically as pralsetinib, is the first and only precision medicine approved in the EU for first-line treatment of people with RET ..."

    Published: Nov 20th, 2021 at 01:03:19 AM

    Pralsetinib Approved in Europe for RET Fusion+ Advanced NSCLC - OncLive

    "The European Commission has granted a conditional marketing authorization to pralsetinib for use as a single agent in adult patient with RET ..."

    Published: Nov 20th, 2021 at 12:30:24 AM

    Gavreto wins conditional EU approval to treat form of lung cancer -Roche | Financial Post

    "ZURICH - Roche's Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, ..."

    Published: Nov 19th, 2021 at 11:31:01 PM

    Gavreto wins conditional EU approval to treat form of lung cancer -Roche | WTVB | 1590 AM ...

    "ZURICH (Reuters) -Roche's Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, ..."

    Published: Nov 19th, 2021 at 11:12:59 PM

    Gavreto wins conditional EU approval to treat form of lung cancer -Roche | Reuters

    "Roche's Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, ..."

    Published: Nov 19th, 2021 at 09:13:54 PM

    European Commission approves Roche's Gavreto for RET fusion-positive advanced NSCLC ...

    "Roche (RHHBY) announces that the European Commission ((EC)) has granted conditional marketing authorization for Gavreto (pralsetinib) as a ..."

    Published: Nov 19th, 2021 at 08:23:39 PM

    Roche's Gavreto wins conditional EU approval in a form of lung cancer - KFGO

    "ZURICH (Reuters) - Roche's Gavreto has won conditional European Commission approval for treating adults with a form of non-small cell lung cancer, ..."

    Published: Nov 19th, 2021 at 05:45:33 PM

    Chimerix announces positive ONC201 data in brain cancer | Seeking Alpha

    "Chimerix (CMRX) announces positive data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant diffuse ..."

    Published: Nov 19th, 2021 at 05:14:16 PM

    Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline ...

    "ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of ..."

    Published: Nov 19th, 2021 at 03:45:53 PM

    European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC ...

    "NEW YORK The European Commission on Friday granted conditional approval to Roche's pralsetinib (Gavreto) for advanced RET fusion-positive ..."

    Published: Nov 19th, 2021 at 03:26:45 PM

    Roche, Blueprint's RET cancer drug Gavreto cleared in EU - - Pharmaphorum

    "Gavreto (pralsetinib) has been cleared as a first-line treatment of people with RET fusion-positive advanced non-small cell lung cancer (NSCLC), ..."

    Published: Nov 17th, 2021 at 10:34:29 PM

    Ectopic Cushing's May Occur in Patients With Advanced Thyroid Cancer

    "Severely low levels of potassium in the blood, muscle weakness, and/or diabetes in medullary thyroid cancer patients are signs of ectopic Cushing's."

    Published: Nov 17th, 2021 at 01:53:54 PM

    Cabozantinib Sales Market 2021 includes Top Countries Figures, Growth, Market Size ...

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. The key regions covered in the Cabozantinib Sales market report ..."

    Published: Nov 12th, 2021 at 11:21:56 PM

    Global Cabozantinib Market 2021 Industry Research, Review, Growth, Segmentation, Key ...

    "Application spectrum: Medullary Thyroid Cancer Treatment and Second Line Treatment for Renal Cell Carcinoma. Sales netted and revenue volume ..."

    Published: Nov 11th, 2021 at 09:32:18 PM

    What A Former Baker Has To Say About Finding Joy While Managing Type 2 Diabetes

    "It is not known if RYBELSUS will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."

    Published: Nov 11th, 2021 at 05:14:39 PM

    Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual ...

    "Title: Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients. Abstract Number: LTBK-05"

    Published: Nov 10th, 2021 at 12:20:53 PM

    CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief ...

    "Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the ..."

    Published: Nov 6th, 2021 at 01:54:53 AM

    Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer - OncLive

    "Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer."

    Published: Nov 6th, 2021 at 12:45:27 AM

    Wegovy demonstrated significant and sustained weight loss in two-year study in adults with obesity

    "It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."

    Published: Nov 5th, 2021 at 07:55:51 PM

    Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer - OncLive

    "... discusses the phase 3 LIBRETTO-531 trial (NCT04211337) of selpercatinib (Retevmo) in patients with RET-mutant medullary thyroid cancer."

    Published: Nov 4th, 2021 at 05:46:22 PM

    Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update ...

    "Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma . U.S. Food and Drug Administration (FDA) Published Article ..."

    Published: Nov 4th, 2021 at 05:23:43 PM

    Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma

    "Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria Compelling ..."

    Published: Nov 4th, 2021 at 02:03:53 AM

    Should You Buy Exelixis, Inc. (EXEL) Stock After it Is Down 6.10% in a Week? - InvestorsObserver

    "Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced ..."

    Published: Nov 1st, 2021 at 06:18:49 PM

    Hall Breaks Down Treatment Sequencing for Patients With Medullary Thyroid Cancer

    "... central neck dissection and later declining systemic therapy, a 58-year-old man with medullary thyroid cancer was no longer asymptomatic."

    Published: Nov 1st, 2021 at 04:14:26 PM

    Parathyroid Hormone Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth

    "Natpara; GlaxoSmithKline Plc; Sanofi SA; Eli Lilly; Cell Genesys Inc; OSI Pharmaceuticals; Paladin Labs Inc; ALZA Corporation. Company Profiles This ..."

    Published: Nov 1st, 2021 at 02:12:45 PM

    Clinical Management of RET+ Advanced NSCLC - OncLive

    "Selpercatinib first, followed by pralsetinib shortly thereafter. These are both highly selective RET inhibitors. They do have some activity ..."

    Published: Nov 1st, 2021 at 10:45:08 AM

    Building a CAR-T Toolbox for More Comprehensive Assessment of Cell Therapies

    "Daniel Hui, PhD, Associate Director of Analytical Development at Tmunity Therapeutics, addresses these challenges and highlights the company's ..."

    Published: Oct 29th, 2021 at 09:33:00 PM

    Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions - Docwire News

    "In this review, we summarize the mechanism of action, pharmaceutical properties and clinical data of selpercatinib, and share some of our ..."

    Published: Oct 28th, 2021 at 11:09:25 PM

    Blueprint Medicines Reports Third Quarter 2021 Financial Results - Yahoo Finance

    "GAVRETO (pralsetinib): RET-altered cancers ... As previously reported by Roche, net end user product revenues for GAVRETO were $5.5 million."

    Published: Oct 28th, 2021 at 11:06:55 PM

    Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational ...

    "ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and the results from an efficacy analysis by blinded ..."

    Published: Oct 28th, 2021 at 07:11:31 PM

    Blueprint Medicines Reports $24.2M in Q3 Revenues Driven by Ayvakit Sales | Precision ...

    "In Q3, Blueprint's collaboration revenue was $6.9 million, driven by commercial supply shipments of pralsetinib to Roche and CStone Pharmaceuticals, ..."

    Published: Oct 27th, 2021 at 09:30:13 AM

    Procalcitonin promising as calcitonin replacement for managing thyroid cancer: Study

    "... procalcitonin (ProCT) has the potential to replace calcitonin as a new standard of care in the therapy of medullary thyroid cancer (MTC)."

    Published: Oct 25th, 2021 at 11:55:48 AM

    Fast Five Quiz: Weight Loss - Medscape Reference

    "Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma. The starting dose of subcutaneous ..."

    Published: Oct 25th, 2021 at 12:04:58 AM

    Thyroid nodules: what they are and when to remove them - Emergency Live

    "Thyroid nodules: what they are and when to remove them. Emergency Live | Pulmonary and thyroid carcinoma: FDA approves the treatment with Retevmo ..."

    Published: Oct 24th, 2021 at 08:02:09 PM

    RET Inhibitors Show Promise for Chinese Patients With RET FusionPositive NSCLC

    "RET inhibitors pralsetinib Gavreto) and selpercatinib (Retevmo) have already demonstrated significant efficacy in treating a broad patient ..."

    Published: Oct 21st, 2021 at 09:07:22 PM

    Year in review: Five studies changing thyroidology practice - Healio

    "Selpercatinib for medullary thyroid cancer. As Healio reported, researchers reported in August 2020 that selpercatinib (Retevmo, Eli Lilly), ..."

    Published: Oct 21st, 2021 at 11:00:00 AM

    The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors

    "Usman 'Oz' Azam, M.D. President and Chief Executive Officer, Tmunity Therapeutics (Vice Chairman) Amy Butler, Ph.D. President, Biosciences, ..."

    Published: Oct 11th, 2021 at 08:48:45 AM

    Effect of triptolide on thyroid cancer | DDDT - Dove Medical Press

    "Triptolide is a Promising Therapeutic Approach in Treating Thyroid Cancer Based ... papillary thyroid cancer, follicular thyroid cancer, medullary thyroid ..."

    Published: Oct 7th, 2021 at 10:07:30 PM

    AI Finds Potential Treatment for Incurable Pediatric Brain Cancer | Psychology Today

    "... Vandetanib is a drug that is already approved by the U.S. Food and Drug Administration (FDA) to treat medullary thyroid cancer that is locally advanced ..."

    Published: Oct 7th, 2021 at 08:48:45 PM

    Higher Dose Cabozantinib Demonstrates Superior Efficacy Over Lower Dose in MTC

    "Cabozantinib (Cabometyx) 60 mg tablets and cabozantinib 140 mg tablets show similar clinical efficacy in metastatic medullary thyroid cancer (MTC), ..."

    Published: Oct 7th, 2021 at 12:56:15 PM

    Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a ...

    "... a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer ... papillary and medullary thyroid cancers, and several other tumor types."

    Published: Oct 6th, 2021 at 04:07:30 AM

    Deputy Police Chief To Run Boston Marathon For Charity | Wrentham, MA Patch

    "... the worse and he was placed on the then-experimental drug Retevmo (selpercatinib, formerly known as LOXO-292), and immediately started feeling better."

    Published: Oct 6th, 2021 at 12:56:15 AM

    Josh Stanton's legacy is one of continuing help | Magnet | Eden, NSW

    ""Josh had medullary thyroid cancer; it was a relatively rare form," he explained. "Every case is different in how the tumour responses and how the patient is ..."

    Published: Oct 5th, 2021 at 08:48:45 PM

    Pralsetinib: MOA and ARROW Trial Data - Targeted Oncology

    "There were cohorts of patients with nonsmall cell lung cancer, as well as previously treated RET-mutant medullary thyroid cancer, RET-mutant MTC without prior ..."

    Published: Oct 5th, 2021 at 08:26:15 PM

    Selpercatinib: Clinical Practice Implications - Targeted Oncology

    "Lori Wirth, MD: Great, a new standard of care for people with MTC [medullary thyroid cancer]. Are there any important implications from the LIBRETTO data on ..."

    Published: Oct 5th, 2021 at 08:03:45 PM

    Case 2: RET Mutations and Disease Management - Targeted Oncology

    "We see the point mutations mostly in medullary thyroid cancer, and we see the RET fusions primarily in differentiated or follicular-derived thyroid cancers."

    Published: Oct 5th, 2021 at 07:41:15 PM

    Case 2: RET+ Metastatic Medullary Thyroid Cancer - Targeted Oncology

    "An ultrasound-guided fine needle aspiration was done, showing medullary thyroid cancer [MTC]. Calcitonin and CEA [carcinoembryonic antigen] levels were ..."

    Published: Oct 4th, 2021 at 04:07:30 PM

    Cabozantinib Market 2021 Industry Segmentation, CAGR Status, Leading Trends, Forecast to 2027

    "... growth rate of the market in each application and can be divided into Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma."

    Published: Oct 2nd, 2021 at 12:33:45 AM

    CStone presents ARROW study data for GAVRETO (pralsetinib) in Chinese patients with ...

    "CStone presents ARROW study data for GAVRETO (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late ..."

    Published: Oct 1st, 2021 at 03:10:00 PM

    UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer ...

    "Among one cohort of RET fusion-positive, previously treated medullary thyroid cancer patients, the objective response rate was 69 percent, and among another ..."

    Published: Oct 1st, 2021 at 02:48:45 PM

    Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review ...

    "Online ahead of print. ABSTRACT. Refractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and ..."

    Published: Oct 1st, 2021 at 09:10:05 AM

    New drug available for rare thyroid cancer on NHS in England

    "And almost 7 in 10 people with previously treated medullary thyroid cancer responded to treatment, but with data still be collected, it's too early to ..."

    Published: Sep 30th, 2021 at 11:15:00 PM

    UK to offer Retsevmo for people with RET fusion-positive thyroid cancer - The Pharma Letter

    "The targeted therapy has been recommended for use through the Cancer Drugs Fund ... with advanced RET-mutant medullary thyroid cancer, after cabozantinib or ..."

    Published: Sep 30th, 2021 at 08:56:29 PM

    A contemporary review of rearranged during transfection-selective inhibitors - Docwire News

    "... cell lung cancer and 10-30% of patients with papillary thyroid cancer. ... lung cancer, rearranged during transfection-mutant medullary thyroid cancer, ..."

    Published: Sep 30th, 2021 at 02:37:30 PM

    Pralsetinib receives nod from EMA for use in RET-positive NSCLC | medwirenews.com

    "Pralsetinib will be available as 100 mg hard capsules. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. 2021 Springer ..."

    Published: Sep 30th, 2021 at 06:22:30 AM

    BDR Pharma brings advanced cancer treatment drug to India at affordable rates, Health ...

    "Using Cabozanib to Treat Medullary Thyroid Cancer The treatment process for this type of cancer depends on the stage of the disease and the physical fitness ..."

    Published: Sep 29th, 2021 at 02:03:45 PM

    Wrexham: Brave little Aria's DIPG tumour shrinks in size | The Leader

    "However, her family quickly set about finding alternative forms of treatment - and heard about the new ONC201 drug. It is thought to kill certain cancerous ..."

    Published: Sep 28th, 2021 at 12:56:15 PM

    Life-changing Medicines Arcalyst and Gavreto Now Available at AllianceRx Walgreens Prime

    "Gavreto (pralsetinib) is a once-daily oral prescription medicine used to treat certain cancers caused by abnormal RET-positive (rearranged during ..."

    Published: Sep 27th, 2021 at 11:37:30 AM

    Parathyroid Hormone Global Market Report 2021: COVID-19 Growth And Change To 2030

    "It also adds the rights of parathyroid hormone natpara. Shire Plc is a USA based pharmaceutical company focusing on innovative and rare disease drugs. The rise ..."

    Published: Sep 27th, 2021 at 10:52:30 AM

    Multiple Trials Examined for RET-Targeted Therapies in MTC

    "... the case of a 58-year-old patients with RET-mutant medullary thyroid cancer. ... with MTC and papillary thyroid cancer [PTC] and treatment options?"

    Published: Sep 27th, 2021 at 06:03:37 AM

    Drugs for incurable brain tumour in children identified through AI - Hospital Healthcare Europe

    "... vandetanib and which is already approved for symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease."

    Published: Sep 25th, 2021 at 02:26:15 PM

    Pralsetinib for the treatment of non-small cell lung cancer - Docwire News

    "Recently, a novel and specific RET inhibitor, pralsetinib (BLU-667), has been reported to have excellent efficacy and low off-target toxicity in RET cancer ..."

    Published: Sep 23rd, 2021 at 02:03:45 PM

    The Importance of Patient-Reported Outcomes in The LIBRETTO-001 Trial - Targeted Oncology

    "... (PROs) from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer (MTC) or advanced thyroid cancer."

    Published: Sep 23rd, 2021 at 01:41:15 PM

    While Battling Thyroid Cancer, He's Planning a Ride to Raise Awareness - Bicycling

    "But my world changed in September 2020 when I was diagnosed with stage 4C medullary thyroid cancer at 49 years old. Initially, my symptoms weren't very ..."

    Published: Sep 22nd, 2021 at 07:30:00 PM

    FDA Approves Cabozantinib for Differentiated Thyroid Cancer - Medscape

    "In the United States, cabozantinib is currently approved for the treatment of medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma."

    Published: Sep 20th, 2021 at 06:23:11 PM

    Procalcitonin Studied in the Diagnosis and Monitoring of Thyroid Cancer - Endocrinology Advisor

    "Procalcitonin (ProCT) possesses a high level of accuracy for the diagnosis and monitoring of medullary thyroid carcinoma (MTC), suggesting ProCT could ..."

    Published: Sep 20th, 2021 at 03:56:15 PM

    Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion | Nasdaq

    "Gavreto is a once-daily, oral targeted treatment designed to selectively target rearranged during transfection (RET) alterations, including fusions and ..."

    Published: Sep 20th, 2021 at 03:11:15 PM

    Wrexham man's finish half marathon for Aria's brain tumour battle | The Leader

    "However, the treatment, the ONC201 drug, isn't available on the NHS and could eventually cost Aria's family over 1000 euros a week to import from Germany."

    Published: Sep 20th, 2021 at 02:15:00 PM

    Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers | Nasdaq

    "The selpercatinib, previously known as LOXO-292, was granted orphan drug designation by the MHLW in 2020. Thermo Fisher was granted a $192.5-million ..."

    Published: Sep 20th, 2021 at 10:07:30 AM

    Ongoing Medication Recall Ignites Formation of a New NonProfit: HypoPara ... - Pro News Report

    "Natpara was used to treat those who were the least stable or who could not adequately absorb oral calcium, which made its recall all the more painful for this ..."

    Published: Sep 17th, 2021 at 12:03:46 PM

    Roche Announces Positive CHMP Opinion For Gavreto In RET Fusion-positive Advanced NSCLC

    "(RTTNews) - Roche (RHHBY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Gavreto ..."

    Published: Sep 4th, 2021 at 04:52:30 AM

    Medullary Thyroid Cancer Market 2021 In-Depth Analysis Including Top Key ... - Clark County Blog

    "The recent report on "Medullary Thyroid Cancer Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2027" offered by ..."

    Published: Sep 3rd, 2021 at 04:52:30 PM

    Cabozantinib Market Size 2021 by Product Sales, Revenue, Price, Market Share, Growth ...

    "Cabozantinib Market , By Application:Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma. The report remembers a total ..."

    Published: Sep 2nd, 2021 at 10:28:26 AM

    Parathyroid Hormone Analog Market Outlook 2021: Big Things are Happening - Clark County Blog

    "Pfizer, Cell Genesys Inc, Natpara, Abbott Laboratories, Eli Lilly, Merck, Paladin Labs Inc, Sanofi SA, GlaxoSmithKline Plc, OSI Pharmaceuticals, ..."

    Published: Sep 2nd, 2021 at 05:20:54 AM

    Brexucabtagene Autoleucel Market: Strong Sales Outlook Ahead | Kite Pharma Inc. , Gilead ...

    "Autolus., TrakCel Tmunity Therapeutics , Bellicum Pharmaceuticals Inc. , Sorrento Therapeutics , Bluebird Inc. , etc. September 2, 2021. 5 Min Read."

    Published: Sep 1st, 2021 at 10:52:30 PM

    Huml's memory at forefront of 'Postnuptial Agreement' reprise - Yahoo News

    "Huml, a beloved educator, basketball coach and entrepreneur who conceptualized the story, died in 2020 after a five-year battle with medullary thyroid cancer."

    Published: Aug 31st, 2021 at 06:16:37 PM

    Fast Five Quiz: Medullary Thyroid Cancer and RET Mutation - Medscape Reference

    "Medullary thyroid carcinoma (MTC) arises from the parafollicular C cells of the thyroid and accounts for 3%-5% of thyroid cancers."

    Published: Aug 26th, 2021 at 01:50:49 PM

    Medullary Thyroid Cancer Market Size 2021-2027 By Key Players - The Market Tabloid

    "A new informative report titled as "Global Medullary Thyroid Cancer Market" has recently published by Credible Markets to its humongous database which helps ..."

    Published: Aug 26th, 2021 at 01:07:30 PM

    The Future of Selpercatinib in the RET-Altered Thyroid Cancer Population - Targeted Oncology

    "Selpercatinib was studied in this patient population in the phase 1/2 LIBRETTO-001 study (NCT03157128) in patients with RET-altered medullary thyroid cancer ..."

    Published: Aug 25th, 2021 at 02:03:45 PM

    Outcomes for Older MTC Patients are Poor, Limited Treatment Options Exist - Targeted Oncology

    "In medullary thyroid cancer (MTC), older patients are more likely to have more aggressive disease and disease specific mortality, according to research ..."

    Published: Aug 25th, 2021 at 06:20:40 AM

    Global Parathyroid Hormone Market Review and also Projection (2019-2028) Pfizer, Cell ...

    "Global Parathyroid Hormone Market Review and also Projection (2019-2028) Pfizer, Cell Genesys Inc, Natpara, Abbott Laboratories Exclusive Report by Contrive ..."

    Published: Aug 24th, 2021 at 10:18:45 AM

    Neuroendocrine Tumor Treatment Market Revenue, Driving Factors, Key Players, Strategies ...

    "Different types of neuroendocrine tumors include carcinoid tumors, islet cell tumors, medullary thyroid cancer, pheochromocytomas, neuroendocrine carcinomas ..."

    Published: Aug 23rd, 2021 at 11:26:15 AM

    Thyroid cancer signs and symptoms: Sofia Vergara reveals doctor found lump in her neck

    "- medullary thyroid carcinoma accounts for less than one in 10 cases; unlike the other types, it can run in families. - anaplastic thyroid carcinoma the ..."

    Published: Aug 22nd, 2021 at 08:48:45 AM

    Medullary Thyroid Cancer Market 2021-2027 By Top Key Players - Daily Research Sheets -

    "In this report a comprehensive analysis of current global Medullary Thyroid Cancer market in terms of demand and supply environment is provided, ..."

    Published: Aug 20th, 2021 at 02:48:45 PM

    The Pharmacology of Cutting-Edge Non-Small Cell Lung Cancer Therapies in 2021

    "For patients treated with selpercatinib, acid-reducing agents should be avoided, Harvey noted. However, if, for example, a proton pump inhibitor is unavoidable, ..."

    Published: Aug 20th, 2021 at 05:08:01 AM

    Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem

    "Medullary Thyroid Cancer Treatment Second Line Treatment for Renal Cell Carcinoma. Regions and Countries. The Middle East and Africa (GCC Countries and ..."

    Published: Aug 19th, 2021 at 10:06:18 PM

    Could a Burnsville man's ride change a life? That's his hope | Star Tribune

    "Thomas Drayton, who has Stage 4C medullary thyroid cancer, has decided to do a benefit ride of one (himself) from the Canadian border to Iowa to raise money for ..."

    Published: Aug 18th, 2021 at 08:13:18 PM

    Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer - Docwire News

    "Selpercatinib a highly selective RET inhibitor, was recently approved by the FDA for the treatment of RET fusion-positive lung and thyroid cancers."

    Published: Aug 18th, 2021 at 02:03:45 PM

    Konduri Discusses Treating Patients With RET-Mutated NSCLC - Targeted Oncology

    "In other words, the preferred medicines are selpercatinib and pralsetinib followed by chemotherapy after progression. What data support the use of selpercatinib ..."

    Published: Aug 17th, 2021 at 02:48:45 PM

    Neuroendocrine Tumors Market Size will Grow Profitably in the Near Future -

    "Neuroendocrine tumor arises from cells that produce hormones; thus, ... pheochromocytomas, medullary thyroid cancer, neuroendocrine carcinoma, ..."

    Published: Aug 16th, 2021 at 01:17:07 PM

    Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib ...

    "... which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

    Published: Aug 12th, 2021 at 12:09:29 AM

    Parathyroid Hormone Market 2021 Outlook, Demand, Regional Analysis, Industry Value Chain ...

    "... Analysis, Industry Value Chain | Operating Vendors: Pfizer, Cell Genesys Inc, Natpara, Abbott Laboratories, Eli Lilly, Merck, Paladin Labs "

    Published: Aug 11th, 2021 at 08:13:32 PM

    FDA Approval Decision Pending on Cabozantinib as a New Treatment Option for RR-DTC

    "The agent is FDA approved for the treatment of multiple advanced solid tumors including for the treatment of metastatic medullary thyroid cancer."

    Published: Aug 8th, 2021 at 02:01:28 PM

    Roundtable Discussion: Perez Explores Therapeutic Options in RET-Mutated NSCLC

    "Selpercatinib [Retevmo] seems to have more preference, pralsetinib [Gavreto] came second, and then vandetanib [Caprelsa] was third. How do you ..."

    Published: Aug 8th, 2021 at 08:23:19 AM

    Family spends 4000 a month to keep daughter, 3, alive after brain cancer diagnosis

    "Aria's most expensive treatment is ONC201 - a new cancer drug from Germany, which she has been on for five weeks. "It was invented for adults with ..."

    Published: Aug 7th, 2021 at 07:07:30 PM

    Selpercatinib Shows Promise as Valuable Treatment Option for Patients With RET-Mutated Thyroid ...

    "Ultimately, the FDA approved pralsetinib for RET-altered thyroid cancer, and it happened in December. There is some tumor lysis that has been ..."

    Published: Aug 6th, 2021 at 04:41:15 PM

    Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $8.6 million in net product revenues. Exelixis earned $24.9 ..."

    Published: Aug 6th, 2021 at 10:41:15 AM

    Thyroid Cancer Drugs Global Markets Report 2021: Ipilimumab, Cabozantinib-S-Malate, Caprelsa ...

    "For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC)."

    Published: Aug 6th, 2021 at 09:56:15 AM

    What Causes Hot Flashes Other Than Menopause?

    "An overactive thyroid gland (hyperthyroidism) is when your body produces too ... Other tumors, such as pancreatic tumors, medullary thyroid cancer, ..."

    Published: Aug 5th, 2021 at 10:07:30 PM

    Harper Analyzes Data for Therapies in RET-Mutated NSCLC

    "[They also enrolled] patients with nonmedullary thyroid cancer as well as medullary thyroid cancer. We'll discuss the primary end point of response ..."

    Published: Aug 5th, 2021 at 12:10:35 PM

    Exelixis Announces US FDA Accepts for Priority Review the Supplemental New Drug Application ...

    "While cancerous thyroid tumors include differentiated, medullary and anaplastic forms, differentiated thyroid tumors make up about 90 percent of cases.1 ..."

    Published: Aug 5th, 2021 at 10:52:30 AM

    Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update

    "Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in Recurrent H3 K27M-mutant Glioma Expected in Fourth Quarter 2021 ."

    Published: Aug 5th, 2021 at 09:33:45 AM

    A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors

    "... neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and ..."

    Published: Aug 3rd, 2021 at 12:11:15 AM

    CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese ...

    "It is a rapidly progressing disease with a high incidence in the elderly. ... with metastatic RET-mutant medullary thyroid cancer and RET fusion-positive ..."

    Published: Aug 1st, 2021 at 02:03:45 PM

    Rabinowits Discusses Treatment Options in Medullary Thyroid Cancer

    "... Medical Oncology at Miami Cancer Institute, Baptist Health South Florida, discussed the case of a 58-year-old patient with medullary thyroid cancer."

    Published: Aug 1st, 2021 at 01:41:15 PM

    Thyroid cancer: Signs and symptoms to look out for, treatment methods

    "The common types of thyroid cancer include anaplastic thyroid carcinoma, follicular carcinoma, papillary carcinoma, and medullary thyroid carcinoma."

    Published: Jul 30th, 2021 at 05:25:35 PM

    New Strategies for RET Inhibition May Expand Their Role in NSCLC

    "The trial is comparing selpercatinib (Retevmo) with standard of care platinum-based chemotherapy and pembrolizumab (Keytruda). The primary end ..."

    Published: Jul 30th, 2021 at 04:41:15 PM

    Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

    "In September 2020, the FDA approved Gavreto for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer ("NSCLC")."

    Published: Jul 30th, 2021 at 09:45:00 AM

    What to know about thyroid cancer

    "There are two types of medullary thyroid cancer: sporadic and familial. Most cases occur in younger people and are sporadic, where the cancer does not ..."

    Published: Jul 29th, 2021 at 06:33:45 PM

    Collaboration Plus Chemo, Surgery and CyberKnife Help Ag Teacher Beat Cancer

    "... she was referred to hematologist-oncologist Michael Moffett at the Cancer Institute, who diagnosed her with metastatic medullary thyroid cancer and ..."

    Published: Jul 29th, 2021 at 05:10:45 PM

    Blueprint Medicines Q2 Revenues Increase More Than 200 Percent

    "Blueprint's RET inhibitor pralsetinib (Gavreto), a drug for RET-altered, metastatic non-small cell lung and thyroid cancers, recorded $2.9 million in ..."

    Published: Jul 28th, 2021 at 12:56:15 PM

    Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer

    "Vandetanib and cabozantinib are "effective treatment options" in most patients with medullary thyroid cancer (MTC), according to researchers who ..."

    Published: Jul 27th, 2021 at 04:41:15 PM

    PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

    "... two unrelated families affected by non-syndromic forms of familial, non-medullary thyroid cancer (FNMTC), identifying two loss-of-function mutations ..."

    Published: Jul 27th, 2021 at 03:22:30 PM

    Feasibility of lateral sentinel lymph node biopsy in medullary thyroid cancer: A surrogate tool for ...

    "Feasibility of lateral sentinel lymph node biopsy in medullary thyroid cancer: A surrogate tool for determining prophylactic lateral neck dissection-A ..."

    Published: Jul 25th, 2021 at 03:00:00 PM

    Roundtable Discussion: Gadgeel Leads a Discussion on the Timing for RET-Targeted Therapy in ...

    "RET mutations have also been observed [in NSCLC]. As we use what I call first-generation RET-specific drugs [pralsetinib (Gavreto) and selpercatinib ( ..."

    Published: Jul 25th, 2021 at 12:11:15 PM

    RET Mutations in Medullary Thyroid Are Cancer Viable for Multiple Targeted Agents

    "... Oncology & Therapeutics Research at City of Hope, discussed the case of a 58-year-old man with RET-mutant medullary thyroid cancer (MTC)."

    Published: Jul 24th, 2021 at 02:03:45 PM

    Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLC

    "... impact the treatment of patients with RET fusionpositive nonsmall cell lung cancer who are potential candidates for treatment with pralsetinib."

    Published: Jul 21st, 2021 at 03:56:15 PM

    Becoming Informed About Comprehensive Genomic Profiling

    "There are ATA [American Thyroid Association] guidelines for medullary thyroid cancer that I've highlighted and read a million times, as Dr [Lori] Wirth ..."

    Published: Jul 20th, 2021 at 11:26:15 PM

    DC Circ. Won't Add To Novo Nordisk Whistleblower's Payout

    "The drug has been linked to a rare cancer called medullary thyroid carcinoma, according to the federal government. Kennedy's suit asserted claims ..."

    Published: Jul 18th, 2021 at 06:07:26 PM

    Cabozantinib Appears to be a Promising New Treatment Option in Radioiodine-Refractory ...

    "... COSMIC-311 trial indicated that cabozantinib elicited a promising survival benefit in patients with radioiodine-refractory differentiated thyroid cancer."

    Published: Jul 17th, 2021 at 01:52:30 PM

    Eric J. Sherman, MD, on Agents for Treating RET FusionPositive Thyroid Cancer

    "Although only a subset of patients with papillary thyroid cancer have disease that is driven by RET fusions, over half of all patients with medullary ..."

    Published: Jul 15th, 2021 at 07:07:30 AM

    State institute cautions some patients against using Saxenda

    "... patients with medullary thyroid cancer or a family history of such cancer, ... In addition, people with thyroid disease, mild or moderate hepatic ..."

    Published: Jul 15th, 2021 at 01:18:45 AM

    MedWatch Today: CyberKnife Stereotactic Radiosurgery Treats Rare Cancer

    "Mindy was referred to hematologist-oncologist Michael Moffett at Community Cancer Institute,and diagnosed with metastatic medullary thyroid cancer."

    Published: Jul 14th, 2021 at 02:03:45 PM

    George Labonte: Concerns Upon a Diagnosis of Medullary Thyroid Cancer

    "I went into the appointment expecting him to say that I have papillary thyroid cancer. He said there are four types of thyroid cancer, and I had medullary ..."

    Published: Jul 14th, 2021 at 03:22:30 AM

    Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis ...

    "doi: 10.3389/fendo.2021.653401. eCollection 2021. ABSTRACT. Familial non-medullary thyroid cancer (FNMTC) is a form of endocrine malignancy ..."

    Published: Jul 13th, 2021 at 02:37:30 PM

    Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive ...

    "Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ..."

    Published: Jul 12th, 2021 at 05:08:54 PM

    Avanos Medical appoints general counsel

    "Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at ..."

    Published: Jul 12th, 2021 at 03:56:15 PM

    RET Fusion Inhibitor Proves Safe, Effective in NSCLC

    "Consistent efficacy was seen with selpercatinib (Retevmo) in patients with RET fusion-positive non-small cell lung cancer (NSCLC), regardless of prior ..."

    Published: Jul 9th, 2021 at 10:52:30 PM

    EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress ...

    "We hypothesized ONC201 sensitivity and tumor apoptosis may increase by reducing H3K27-methylation with EZH2i or HDACi as mimics of H3K27M- ..."

    Published: Jul 7th, 2021 at 06:22:30 PM

    Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease

    "Severe diarrhoea is a very rare symptom sometimes found in people with advanced medullary thyroid cancer. The tumour produces high levels of ..."

    Published: Jul 6th, 2021 at 03:00:00 PM

    Roundtable Discussion: Brose Explores Selpercatinib and Pralsetinib in MTC

    "Both selpercatinib (Retevmo) and pralsetinib (Gavreto) are FDA-approved therapies for RET-altered medullary thyroid cancer. The research ..."

    Published: Jul 2nd, 2021 at 01:16:33 PM

    Bauman Reviews Data for Patients With RET-Mutated NSCLC

    "There is a label warning for tumor lysis syndrome with pralsetinib [in medullary thyroid cancer], which was not seen in the lung cancer cohort."

    Published: Jul 1st, 2021 at 06:56:15 PM

    Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

    "... the data supporting the regulatory approvals of selpercatinib (Retevmo) and pralsetinib (Gavreto), and future research directions with RET inhibitors ..."

    Published: Jul 1st, 2021 at 12:22:30 AM

    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

    "GLP-1 receptor agonists are contraindicated in those with a history of medullary thyroid cancer and used with caution in patients with a history of ..."

    Published: Jun 30th, 2021 at 03:36:56 PM

    Educating Patients on Germline and Somatic Testing

    "Lori Wirth, MD: This question is really relevant for people with medullary thyroid cancer [MTC], where about 25% of medullary thyroid cancers occur in ..."

    Published: Jun 28th, 2021 at 12:00:00 AM

    CStone announces positive registrational study of GAVRETO (pralsetinib) in Chinese patients ...

    "Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary ..."

    Published: Jun 27th, 2021 at 12:11:15 PM

    New Recommendations Streamline Guidelines in Thyroid Cancer

    "New Recommendations Streamline Guidelines in Thyroid Cancer ... Rarely, however, in patients with differentiated thyroid cancer (DTC) and ATC, ... thyroid and lung cancer, as well as for patients with RET-mutated medullary thyroid ..."

    Published: Jun 25th, 2021 at 03:12:30 PM

    In Brief This Week: Eli Lilly, Mirati Therapeutics, Legend Biotech, Personal Genome Diagnostics ...

    "... metastatic or unresectable medullary thyroid cancer patients who are at least 12 years old; and for RET fusion-positive, metastatic thyroid cancer in ..."

    Published: Jun 25th, 2021 at 12:11:15 PM

    Overview and Diagnosis of Differentiated Thyroid Cancer

    "All these subtypes are referred to as differentiated thyroid cancer to distinguish them from anaplastic thyroid cancer or medullary thyroid cancer."

    Published: Jun 24th, 2021 at 03:09:13 PM

    Multiple Agents Prove Useful in RET-Mutated Thyroid Cancer

    "The preferred regimens are the multikinase inhibitors vandetanib [Caprelsa] and cabozantinib [Cabometyx]2 and the [RET] inhibitors selpercatinib ..."

    Published: Jun 24th, 2021 at 12:00:00 AM

    CStone announces positive GAVRETO (pralsetinib) registrational study data for first-line ...

    "GAVRETO is a potent and selective RET inhibitor discovered by CStone's partner Blueprint Medicines. "Platinum-based chemotherapy is recommended ..."

    Published: Jun 22nd, 2021 at 12:00:00 PM

    Stephen Liu, MD, on How Targeted Therapy Results in Significant Efficacy for RET-Altered Tumors

    "... Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered nonsmall cell lung cancer."

    Published: Jun 21st, 2021 at 12:16:58 PM

    Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

    "Approved for metastatic RET fusion-positive non-small cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer and advanced ..."

    Published: Jun 21st, 2021 at 12:11:15 PM

    Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

    "RET-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease,."

    Published: Jun 21st, 2021 at 12:00:00 PM

    Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in ...

    "Retevmo is indicated as monotherapy for the treatment of: metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients,; RET- ..."

    Published: Jun 21st, 2021 at 05:09:57 AM

    CStone announces first prescriptions of precision therapy GAVRETO (pralsetinib) issued across ...

    "With this milestone, GAVRETO, as the first approved selective RET inhibitor in China, can benefit Chinese patients. Currently, lung cancer is ranked the ..."

    Published: Jun 19th, 2021 at 04:14:44 PM

    Intracranial Efficacy of Selpercatinib in RET Fusion-Positive NonSmall Cell Lung Cancers on the ...

    "Intracranial Efficacy of Selpercatinib in RET Fusion-Positive NonSmall Cell Lung Cancers on the LIBRETTO-001 Trial. Vivek Subbiah, Justin F."

    Published: Jun 19th, 2021 at 04:14:41 PM

    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET ...

    "FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions. Janice Kim, Diana Bradford, ..."

    Published: Jun 19th, 2021 at 02:03:45 PM

    For a bicyclist, a long overdue checkup uncovered the unexpected - The Washington Post

    "MTC arises from the medulla inside the thyroid gland, which contains C ... making the malignancy difficult to detect - one reason medullary cancer ..."

    Published: Jun 18th, 2021 at 03:56:15 AM

    UPMC expert: Is cancer in your future?

    "A rare cancer - such as male breast cancer, adrenal gland cancer, retinoblastoma, medullary thyroid cancer, or pheochromocytoma. A cancer that ..."

    Published: Jun 17th, 2021 at 12:33:45 AM

    Klotho Inhibits Proliferation in a RET Fusion Model of Papillary Thyroid Cancer by Regulating the ...

    "... subtypes of thyroid cancer: papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are the most common subtypes, and medullary thyroid ..."

    Published: Jun 16th, 2021 at 08:48:45 PM

    Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival

    "Results of a phase I/II trial of the RET inhibitor pralsetinib (Gavreto) showed response rates of 60% to 90% in RET fusion-positive non-small cell lung ..."

    Published: Jun 16th, 2021 at 12:22:30 PM

    UPMC Expert: Is Your Future Cancer? | Life

    "Rare cancers - male breast cancer, adrenal cancer, retinoblastoma, medullary thyroid cancer, pheochromocytoma, etc. Cancers that are likely to be ..."

    Published: Jun 15th, 2021 at 09:26:49 PM

    A study confirms the usefulness of a new drug for thyroid cancer

    "Radiation therapy treatments to the head and neck increase the risk of thyroid gland cancer Certain inherited genetic syndromes. Familial medullary ..."

    Published: Jun 11th, 2021 at 09:33:45 PM

    Doctors Discuss the 'Game-Changing' Diet Drug Semaglutide

    "Semaglutide carries a warning noting that it has been linked to medullary thyroid cancer, but this adverse effect has been reported only in studies on ..."

    Published: Jun 11th, 2021 at 12:11:15 PM

    LUNG CANCER

    "In this multi-cohort, open-label, phase 1/2 study (ARROW), researchers tested pralsetinib (a highly potent, oral, selective RET inhibitor) for its safety, ..."

    Published: Jun 10th, 2021 at 02:52:57 AM

    Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US ...

    "Thyroid cancer cases during follow-up were identified via a validated ... medullary thyroid carcinoma (MTC), the subtype that originates from C cells, ..."

    Published: Jun 10th, 2021 at 01:27:34 AM

    Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations

    "The ORR was 71% in patients with treatment-nave RET-mutant medullary thyroid cancer, 60% in patients previously treated with cabozantinib and/or ..."

    Published: Jun 9th, 2021 at 11:16:06 PM

    Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label ...

    "Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC. Funding. Blueprint ..."

    Published: Jun 9th, 2021 at 10:30:00 PM

    Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations

    "RET alterations are caused by a mutation in the DNA sequence and are oncogenic drivers in a variety of tumor types, most commonly in medullary ..."

    Published: Jun 9th, 2021 at 02:37:30 PM

    Comprehensive Genomic Profiling in Lung and Thyroid Cancer

    "Another complicating layer consists of the germline mutations that are present in a subset of patients with medullary thyroid cancer vs the tumor ..."

    Published: Jun 9th, 2021 at 01:29:08 PM

    Thyroid cancer risk higher for menopausal women with longer reproductive years

    "Of the cases, 90% were papillary thyroid cancer, 8% follicular and 2% medullary. Risk for thyroid cancer was more than double for women who had 41 ..."

    Published: Jun 8th, 2021 at 03:00:00 PM

    Novel Targeted Therapies Present Opportunities in Multiple Cancer Types

    "Selpercatinib and pralsetinib are among the new options for RET fusion-positive non-small cell lung cancer (NSCLC), according to the presentation."

    Published: Jun 8th, 2021 at 02:01:26 PM

    Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer

    "Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, ..."

    Published: Jun 8th, 2021 at 01:52:30 PM

    Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer

    "Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, ..."

    Published: Jun 7th, 2021 at 02:03:45 PM

    Pediatric Patients With RET-Altered Tumors Experience Tumor Responses With Selpercatinib

    "... Oncology (ASCO) Annual Meeting demonstrated antitumor activity of selpercatinib (Retevmo) in pediatric patients with RET-altered solid tumors.1."

    Published: Jun 6th, 2021 at 09:56:15 PM

    Selpercatinib Improves Responses Regardless of Prior Treatment in RET-Mutant Medullary ...

    "Selpercatinib (Retevmo) improved overall response rates (ORRs) in most patients with RET-mutatedmedullary thyroid cancer (MTC) irrespective of ..."

    Published: Jun 6th, 2021 at 07:07:30 PM

    Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

    "The objective response rate with Retevmo was 57% which was "markedly higher," the researchers wrote, than responses for prior treatment at 16%. A ..."

    Published: Jun 6th, 2021 at 07:00:43 PM

    Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

    "Retevmo (selpercatinib) demonstrated response improvements in previously treated patients with RET fusion-positive non-small cell lung cancer ..."

    Published: Jun 6th, 2021 at 06:44:49 PM

    Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant ...

    "Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy. figure ..."

    Published: Jun 6th, 2021 at 01:30:00 PM

    Better Responses Observed With Selpercatinib Versus Prior Systemic Therapies for RET+ NSCLC

    "Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with nonsmall cell lung ..."

    Published: Jun 6th, 2021 at 12:11:15 PM

    Pralsetinib Shows Durable Anti-Tumor Activity in Study Update for RET+ Solid Tumors

    "... medullary thyroid cancer or RET fusionpositive thyroid cancer.2 This trial is still enrolling patients with other RET fusionpositive solid tumors.1."

    Published: Jun 5th, 2021 at 06:33:45 PM

    Selpercatinib May be an Effective NSCLC Treatment

    "Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments. Consistent ..."

    Published: Jun 5th, 2021 at 06:22:30 PM

    Selpercatinib Effective in Treating NSCLC

    "Treatment with selpercatinib (Retevmo) demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer (NSCLC), ..."

    Published: Jun 5th, 2021 at 06:02:05 PM

    Gavreto 'Very Well Tolerated' in RET Fusion-Positive Non-Small Cell Lung Cancer

    "Currently, Gavreto is approved in the U.S. for treatment of RET fusion-positive NSCLC and advanced or metastatic RET- altered thyroid cancers. The ..."

    Published: Jun 5th, 2021 at 05:15:00 PM

    ARROW Update Shows Pralsetinib Has Durable Anti-Tumor Activity in RET+ Solid Tumors

    "... or more, with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusionpositive thyroid cancer.2 This trial is still enrolling patients ..."

    Published: Jun 5th, 2021 at 05:06:37 PM

    Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors

    "Pralsetinib (Gavreto) demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with ..."

    Published: Jun 5th, 2021 at 02:24:15 PM

    US FDA approves obesity drug Wegovy which helped people cut weight by 15%. All you need to ...

    "FDA has warned against its use in patients with a personal or family history of medullary thyroid carcinoma or in patients with a rare condition called ..."

    Published: Jun 5th, 2021 at 04:22:37 AM

    Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

    ""Patients with thyroid cancer usually have normal thyroid function blood tests," cautioned Dr Jeannon. Thus, people need to be aware of the physical ..."

    Published: Jun 5th, 2021 at 03:00:00 AM

    Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

    ""Patients with thyroid cancer usually have normal thyroid function blood tests," cautioned Dr Jeannon. Thus ... Medullary Thyroid Cancer (MTC)."

    Published: Jun 4th, 2021 at 05:37:30 PM

    ARROW Trial Update Continues to Support Pralsetinib Use, Biomarker Testing in RET Fusion+ ...

    "Durable responses coupled with a tolerable safety profile of pralsetinib (Gavreto) in patients with RET fusionpositive nonsmall cell lung cancer ..."

    Published: Jun 4th, 2021 at 04:52:30 PM

    Pralsetinib Tolerable, Durable in RET Fusion-Positive Non-Small Cell Lung Cancer

    "Pralsetinib (Gavreto) was well-tolerated and showed durable responses in patients with RET fusion-positive non-small cell lung cancer (NSCLC), ..."

    Published: Jun 4th, 2021 at 12:00:00 PM

    Stephen V. Liu, MD, Discussed the Importance of Testing for Oncogenic Drivers in Frontline NSCLC

    "CancerNetwork sat down with Stephen V. Liu, MD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about pralsetinib for ..."

    Published: Jun 3rd, 2021 at 10:41:15 PM

    CAR T-Cell Therapy Trial in Solid Tumors Halted Following 2 Patient Deaths

    "Tmunity Therapeutics, a clinical-stage biotherapeutics company, has halted the development of its lead CAR T-cell product following the deaths of 2 ..."

    Published: Jun 3rd, 2021 at 12:45:00 PM

    Tmunity stops solid tumor CAR-T trial after 2 patients die

    "Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which ..."

    Published: Jun 2nd, 2021 at 05:37:30 PM

    Dr. Carl June's drugmaker scraps lead CAR-T program after 2 trial participants die

    "Tmunity was founded in 2015 by Oz Azam, MD, and Carl June, MD, the famed immunologist who pioneered T-cell therapies for cancer. Both physicians ..."

    Published: Jun 2nd, 2021 at 03:00:13 PM

    Exclusive: Carl June's Tmunity encounters a lethal roadblock as 2 patient deaths derail lead trial ...

    "In exclusive interviews, Tmunity founders Carl June and Oz Azam tell me that they have had to scrap their lead program for prostate cancer following ..."

    Published: Jun 2nd, 2021 at 08:22:57 AM

    Thyroid Cancer Therapeutics Market Strategies and Insight Driven Transformation 2021-2028

    "Market Segmentation: By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer (MTC), Anaplastic Thyroid Cancer, ..."

    Published: May 26th, 2021 at 04:30:00 PM

    Dr. Owonikoko on the Efficacy of Selpercatinib in Pre-Treated and Untreated RET+ Thyroid Cancer

    "... discusses the efficacy of selpercatinib (Retevmo) in pre-treated and treatment-naive patients with RET fusionpositive medullary thyroid cancer."

    Published: May 26th, 2021 at 08:16:48 AM

    All You Need to Know About Thyroid Cancer

    "Nearly 20% of the medullary thyroid cancer cases are due to the patient's inheritance of an abnormal gene from his/her parents. 2] Deficiency of Iodine ..."

    Published: May 25th, 2021 at 06:22:30 PM

    Platelet-Derived Growth Factor Receptor-alpha Subunit Targeting Suppresses Metastasis in ...

    "Thyroid cancer is the most common endocrine malignancy. ... However, poorly differentiated thyroid cancers, such as medullary, squamous and ..."

    Published: May 25th, 2021 at 06:55:53 AM

    Demi Jones' heartbreak as she reveals 'nasty' trolls claimed she LIED about her thyroid cancer ...

    "Demi said she is speaking out about her thyroid cancer battle to help others push ... The cells within the thyroid grow too quickly and create a lump. ... types which include: papillary carcinoma, follicular carcinoma, medullary thyroid ..."

    Published: May 24th, 2021 at 03:45:00 PM

    Even as many stocks tumble, Exelixis Inc. (EXEL) seems promising

    "The FDA extended the indications for Cabometyx (previously only available for treating medullary thyroid cancer) at the end of January this year."

    Published: May 24th, 2021 at 01:53:33 PM

    Love Island's Demi Jones puts on a brave face for a night out three days after revealing she's got ...

    "Thyroid cancer develops in your thyroid gland, which is located in your neck, and is ... The cells within the thyroid grow too quickly and create a lump. ... types which include: papillary carcinoma, follicular carcinoma, medullary thyroid ..."

    Published: May 21st, 2021 at 09:22:30 PM

    RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers

    "The RET inhibitor selpercatinib (Retevmo) exhibited clinical activity in almost half of patients with non-lung/non-thyroid cancers associated with RET ..."

    Published: May 20th, 2021 at 06:33:22 PM

    Blueprint Medicines, Genentech to Discuss With Regulators Gavreto's Activity in RET-Altered Tumors

    "The accelerated approval of pralsetinib in RET fusion-positive, metastatic NSCLC was based on an overall response rate of 70 percent in treatment- ..."

    Published: May 20th, 2021 at 02:40:38 PM

    Love Island's Demi Jones devastated as doctors tell her she's got thyroid cancer after operation to ...

    "The cells within the thyroid grow too quickly and create a lump. There are four types which include: papillary carcinoma, follicular carcinoma, medullary ..."

    Published: May 19th, 2021 at 09:29:01 PM

    Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

    "Regarding safety, selpercatinib can cause QT prolongation, which needs to be managed, says Niu. Other agents commonly utilized in lung cancer, such ..."

    Published: May 19th, 2021 at 09:08:59 PM

    Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 ...

    "ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected ..."

    Published: May 18th, 2021 at 01:07:30 PM

    Mutational Risk Not Associated With Distant Metastasis in Medullary Thyroid Cancer

    "The risk of distant metastasis is rare when thyroidectomy is performed before lymph node involvement occurs in patients with medullary thyroid cancer ..."

    Published: May 17th, 2021 at 06:11:15 PM

    Persistence of Elevated Procalcitonin in a Patient with Covid-19 Uncovering a Diagnosis of ...

    "... during recovery prompted the diagnosis of medullary thyroid cancer (MTC). ... calcifications and a non-homogeneous thyroid with multiple nodules."

    Published: May 17th, 2021 at 01:12:03 PM

    Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business ...

    "... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

    Published: May 14th, 2021 at 11:45:31 AM

    Kept an ocean away from its scientific advisors, Shanghai's Elpiscience keeps up the clinical ...

    "Exclusive: Carl June's Tmunity encounters a lethal roadblock as 2 patient deaths derail lead trial, raise red flag forcing a rethink of CAR-T for solid tumors ..."

    Published: May 13th, 2021 at 11:26:15 AM

    Tetanus Toxoid Vaccine Market | Analysis of Market by Product Type, Top Manufacturers, Key ...

    "Market Segmentation: By Component: By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer (MTC), Anaplastic ..."

    Published: May 7th, 2021 at 09:45:00 PM

    Patient With RET-Mutated Lung Cancer Is Eligible for Therapy With Selpercatinib or Pralsetinib

    "... [selective RET inhibitor] agents [selpercatinib (Retevmo) and pralsetinib (Gavreto)] that are approved now as a frontline therapy,1 and so that's why, ..."

    Published: May 7th, 2021 at 06:11:15 PM

    Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

    "... of medullary thyroid cancer generated $3.6 million in net product revenues. ... antitumor activity of XB002 in patients with advanced solid tumors."

    Published: May 7th, 2021 at 03:07:09 PM

    Efficacy of Selpercatinib in RET Fusion-Positive Thyroid Cancers

    "Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors ..."

    Published: May 7th, 2021 at 11:37:30 AM

    Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are ...

    "Similarly, ONC201 and CAN008 are undergoing Phase II development phase for Glioblastoma. Glioblastoma pipeline therapies in the early stage of ..."

    Published: May 7th, 2021 at 10:07:55 AM

    The Smartest Stocks to Buy With $50 Right Now

    "For context, the Cabometyx franchise, which includes sales of medullary thyroid cancer drug Cometriq, totaled almost $742 million in 2020."

    Published: May 6th, 2021 at 04:07:30 PM

    Method for Targeting RET in Thyroid Cancers and Other RET+ Advanced Cancers

    "... medullary thyroid cancer (MTC) who require systemic therapy, and those with advanced or metastatic RET fusion-positive thyroid cancer who ..."

    Published: May 5th, 2021 at 10:41:15 PM

    Tumor Agnostic RET Inhibition: The ARROW Trial

    "Jyoti Patel, MD, FASCO: Thank you for that. The ARROW trial was a registrational phase 1/2 study design in which MTC [medullary thyroid cancer] and ..."

    Published: May 5th, 2021 at 10:28:13 PM

    Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

    "Lori Wirth, MD: One thing I want to comment on is that, interestingly, the dirty kinases like vandetanib used in MTC [medullary thyroid cancer] have ..."

    Published: May 5th, 2021 at 10:07:30 AM

    Tag: United States Medullary Thyroid Cancer Market

    "Medullary Thyroid Cancer Market Size 2021 Industry Share, Strategies, Growth Analysis, Regional Demand, Revenue, Key Players and 2027 ..."

    Published: May 4th, 2021 at 09:21:50 PM

    Dr. Shafique on Selecting Between Selpercatinib and Pralsetinib in RET+ NSCLC

    "... considerations for selecting between selpercatinib (Retevmo) and pralsetinib (Gavreto) in RET fusionpositive nonsmall cell lung cancer (NSCLC)."

    Published: May 4th, 2021 at 11:21:45 AM

    UPDATED: Pfizer hits the brakes on their pivotal trial for a BCMA/CD3 bispecific on safety concerns ...

    "What started as a voluntary halt by Tmunity in the face of these deaths flipped to an FDA-enforced red light for the clinical trial, while the biotech ..."

    Published: May 3rd, 2021 at 09:22:30 PM

    Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In ...

    "Discovered by CStone's partner Blueprint Medicines, Gavreto is approved in the US and is the first approved selective RET inhibitor in China."

    Published: May 2nd, 2021 at 12:56:15 PM

    Brose Explores Treatments for a Patient With RET-Mutated Thyroid Cancer

    "Targeted OncologyTM: For a patient with medullary thyroid cancer (MTC), is there a situation where you would consider watching and waiting instead of ..."

    Published: Apr 30th, 2021 at 02:03:45 PM

    Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

    "In September 2020, the FDA approved Gavreto for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer ("NSCLC")."

    Published: Apr 29th, 2021 at 06:00:00 PM

    Researchers Weigh Benefits, Costs of Screening Newborns for Cancer Risk Mutations

    "... APC, ALK, and PHOX2B, which are associated with increased risk of childhood medullary thyroid cancer, retinoblastoma, adrenocortical carcinoma, ..."

    Published: Apr 28th, 2021 at 11:34:18 PM

    For ASU film grad, laughter really is the best medicine

    "Since 2014, Lew has been battling stage 4 medullary thyroid cancer and undergoing chemotherapy treatments. A working comedian, Lew's motto is "If ..."

    Published: Apr 28th, 2021 at 09:31:31 PM

    LIBRETTO-001 and ARROW Trials Show Positive Data in RET FusionPositive Lung Cancer

    "... multiple different malignances, the most common being papillary thyroid cancer, medullary thyroid cancer, and nonsmall cell lung cancer [NSCLC], ..."

    Published: Apr 27th, 2021 at 08:54:00 PM

    Metastatic leiomyosarcoma of the thyroid: A rare entity

    "Cancer metastasis to the thyroid gland from non-thyroid sites is a rare ... carcinoma (UTC) with a sarcomatoid pattern, medullary thyroid carcinoma ..."

    Published: Apr 27th, 2021 at 04:02:22 PM

    Post-Hoc Analysis of Pivotal Trial Demonstrates Safety of Selpercatinib in RET-Altered Advanced ...

    "Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as ..."

    Published: Apr 26th, 2021 at 07:07:30 PM

    RET Inhibition Holds Tumor-Agnostic Potential

    "... for patients with NSCLC and radioactive iodinerefractory thyroid cancer harboring RET fusions and for RET-mutant medullary thyroid cancer (MTC)."

    Published: Apr 26th, 2021 at 01:52:30 PM

    Roundtable Discussion: Treating Radioiodine-Refractory Differentiated Thyroid Cancer

    "... cancer-whether it's DTC, anaplastic thyroid cancer, or even medullary thyroid cancer-thyroid cancers harbor a high rate of actionable alterations."

    Published: Apr 26th, 2021 at 01:29:12 PM

    CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R ...

    "In March 2021, the NMPA granted approval of pralsetinib under the brand name GAVRETO for the treatment of adult patients with locally advanced ..."

    Published: Apr 26th, 2021 at 01:18:45 PM

    CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R ...

    "This may expand the labeled indications for GAVRETO in China to include advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

    Published: Apr 23rd, 2021 at 12:34:12 PM

    Clinical context crucial when treating thyroid cancer in older adults

    "For those with medullary thyroid cancer, a higher proportion died of thyroid cancer initially, but the proportion of those dying of other causes was ..."

    Published: Apr 22nd, 2021 at 02:26:15 PM

    'Desperate appeal' for 32-year-old fighting aggressive cancer who needs 10000 a month for ...

    "Tayo Bolakale Salau has been fighting medullary thyroid carcinoma, an extremely rare and aggressive form of cancer since 2015. Since his diagnosis ..."

    Published: Apr 22nd, 2021 at 10:52:30 AM

    Julie Rose, of Bridgwater, told rare cancer has spread

    ""It was explained I had a rare type of thyroid cancer called Medullary thyroid cancer. "I broke down at the shock of the news and fired a million questions ..."

    Published: Apr 20th, 2021 at 10:42:31 PM

    Lilly Presents New Data on selpercatinib in Advanced RET Fusion-Positive Gastrointestinal and ...

    "... trial showing treatment with selpercatinib demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors ..."

    Published: Apr 20th, 2021 at 10:41:15 PM

    Lilly Presents New Data on selpercatinib in Advanced RET Fusion-Positive Gastrointestinal and ...

    "i RETEVMO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021. SOURCE Eli Lilly Canada Inc. For further information: Media Contact: ..."

    Published: Apr 19th, 2021 at 08:48:45 PM

    A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an ...

    "Abstract: Anaplastic thyroid carcinoma (ATC) is a rare and highly ... For 58 patients with locally advanced or metastatic medullary thyroid cancer who ..."

    Published: Apr 19th, 2021 at 07:07:30 PM

    McIver Explores Treatment of a Patient With RET-Mutated Medullary Thyroid Cancer

    "... and deputy physician-in-chief at Moffitt Cancer Center, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer (MTC)."

    Published: Apr 19th, 2021 at 05:37:30 AM

    Global Cabozantinib Market 2021 Top Industry Trend and Segments Analysis upto 2026

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. On the basis of geographical boundaries, the market is ..."

    Published: Apr 17th, 2021 at 01:47:40 AM

    Vivek Subbiah on RET FusionPositive Cancers Efficacy of Selpercatinib - The ASCO Post

    "Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a ..."

    Published: Apr 15th, 2021 at 12:00:00 PM

    Retevmo Is Active Against Multiple Types of Advanced Cancer

    "The overall response rate was 69% for previously treated and 73% for treatment-naive people with medullary thyroid cancer with RET mutations, and ..."

    Published: Apr 13th, 2021 at 03:42:26 PM

    AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

    "NEW YORK Eli Lilly's selpercatinib (Retevmo) demonstrated anti-tumor activity in a range of RET fusion-positive tumors, according to data ..."

    Published: Apr 13th, 2021 at 11:15:00 AM

    Lilly's RET inhibitor Retevmo shows early promise in new cancer types

    ""We are excited to broaden the body of evidence for Retevmo in RET fusion-positive cancers beyond lung and thyroid tumours," said David Hyman, chief ..."

    Published: Apr 12th, 2021 at 11:37:30 PM

    Retevmo (selpercatinib) Demonstrates Activity Against Advanced RET Fusion Positive Advanced ...

    "12 Apr Retevmo (selpercatinib) Demonstrates Activity Against Advanced RET Fusion Positive Advanced Solid Tumors. Posted at 23:39h in AACR, ..."

    Published: Apr 12th, 2021 at 09:22:30 PM

    Selpercatinib plus Crizotinib May Help Target MET-Dependent Resistance in RET+ NSCLC

    ""Selpercatinib is a highly selective RET kinase inhibitor that has recently been approved by the FDA in lung and thyroid cancers with activating RET ..."

    Published: Apr 12th, 2021 at 04:30:00 PM

    Lilly's Retevmo shows encouraging antitumour activity in cancer trial

    "Eli Lilly and Company has reported that first-time data from the Phase I/II LIBRETTO-001 trial of Retevmo (selpercatinib) treatment showed promising ..."

    Published: Apr 12th, 2021 at 04:07:30 PM

    MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

    "Selpercatinib became the first treatment approved by the Food and Drug Administration (FDA) to treat RET fusion-positive lung and thyroid cancers, as ..."

    Published: Apr 12th, 2021 at 02:55:59 PM

    New Data on Selpercatinib Shows Promise for Certain Gastrointestinal Malignancies and Other ...

    "Selpercatinib (Retevmo; Eli Lilly and Company) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid ..."

    Published: Apr 12th, 2021 at 02:48:45 PM

    New Data on Selpercatinib Shows Promise for Certain Gastrointestinal Malignancies and Other ...

    "... lung cancer, in adult and pediatric patients ages 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require ..."

    Published: Apr 12th, 2021 at 12:33:45 PM

    Progress In Treating Hodgkin Lymphoma

    "Separately, retevmo, a drug from Eli Lilly already approved for lung and thyroid cancer treatments, has shown promise in beating rare tumors found ..."

    Published: Apr 11th, 2021 at 06:41:50 PM

    AACR: A 'tissue agnostic' indication for Retevmo? Lilly says it's possible with RET cancer win

    "Eli Lilly's Retevmo is already approved to treat lung and thyroid cancers driven by alterations in the RET gene. Now, the Indianapolis pharma believes it ..."

    Published: Apr 11th, 2021 at 06:22:30 PM

    MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021

    "... Administration (FDA) to treat RET fusion-positive lung and thyroid cancers, as well as RET-mutant medullary thyroid cancer (MTC), in May 2020."

    Published: Apr 11th, 2021 at 06:00:00 PM

    Lilly's Retevmo shows success in rare tumors. But can doctors identify the patients who would be ...

    "Retevmo, a drug developed by Eli Lilly's Loxo Oncology unit, shows efficacy in tumors beyond the lung and thyroid cancers where it is approved so ..."

    Published: Apr 11th, 2021 at 03:33:22 PM

    Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid Tumors

    "Selpercatinib (Retevmo) demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects (TEAEs), ..."

    Published: Apr 10th, 2021 at 02:20:54 PM

    Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

    "... the use of selpercatinib (Retevmo) in patients with RET-altered advanced medullary thyroid cancer and nonsmall cell lung cancer (NSCLC)."

    Published: Apr 10th, 2021 at 02:15:00 PM

    Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC

    "In total, 702 patients were enrolled to the trial, a majority of whom had NSCLC or medullary thyroid cancer. AEs were found to be dose dependent, with ..."

    Published: Apr 9th, 2021 at 07:52:30 PM

    Subbiah Explores Treatment of NonSmall Cell Lung Cancer With a KIF5B-RET Fusion

    "It's seen in 10% to 20% of papillary thyroid cancers. In medullary thyroid cancer [MTC], almost 100% of the patients with a hereditary form of thyroid ..."

    Published: Apr 9th, 2021 at 03:56:15 PM

    Gavreto From Blueprint Medicines Corporation

    "... metastatic RET-mutant medullary thyroid cancer (MTC) requiring systemic therapy, and advanced or metastatic RET fusionpositive thyroid cancer ..."

    Published: Apr 9th, 2021 at 03:15:30 AM

    Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and ...

    "This retrospective study was conducted to determine factors impacting postoperative recurrence in patients suffering from medullary thyroid carcinoma ..."

    Published: Apr 8th, 2021 at 08:08:22 PM

    Chimerix Announces Upcoming Presentations at the American Association for Cancer Research ...

    "ONC201: Characterization and combinatorial efficacy in brain tumors ... Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors ..."

    Published: Apr 8th, 2021 at 12:26:18 PM

    Global Cabozantinib Market 2020-2025 Business Insights and Sustainable Growth in Respective ...

    "On the basis of application, the market is segmented into: Medullary Thyroid Cancer Treatment, Second Line Treatment for Renal Cell Carcinoma,."

    Published: Apr 8th, 2021 at 11:13:35 AM

    The Four Stages of a Global Pandemic Global neuroendocrine tumors market In-Depth Analysis ...

    "Global neuroendocrine tumors market research report is sure to help ... tumors in the lungs; Pancreatic neuroendocrine tumors; Medullary thyroid ..."

    Published: Apr 7th, 2021 at 05:37:30 PM

    Global Glioblastoma Pipeline Insight 2021: Comprehensive Insights About 150+ Companies and ...

    "The drug is being studied in phase II/III for the treatment of Glioblastoma. ONC-201: Oncotherapeutics. ONC201 is a highly selective antagonist of ..."

    Published: Apr 7th, 2021 at 12:22:30 PM

    TPTX Stock Prices Decreased by -8.44%: Here's Why It Happened

    "... study including 10 with non-small cell lung cancer (NSCLC) and 11 with medullary thyroid carcinoma (MTC) who were treated from December 2019 ..."

    Published: Apr 7th, 2021 at 07:07:30 AM

    How it works: Combination therapy for type 2 diabetes

    "For example, people with medullary thyroid cancer should not take GLP-1 RAs or DPP-4 inhibitors. Moreover, people with heart failure or liver disease ..."

    Published: Apr 6th, 2021 at 08:03:45 PM

    Health Care Sector Update for 04/06/2021: TPTX,CARA,ILMN,MITO,ALXN

    "... preliminary clinical activity with tumor regression during phase I/II testing in patients with non-small cell lung cancer or medullary thyroid carcinoma."

    Published: Apr 6th, 2021 at 05:03:51 PM

    Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting

    "... presented preliminary data from the Phase I/II trial involving 21 patients, 10 with non-small cell lung cancer and 11 with medullary thyroid carcinoma."

    Published: Apr 6th, 2021 at 03:56:15 PM

    Investigational RET Inhibitor TPX-0046 Show Preliminary Clinical Activity in NSCLC, MTC

    "In a dose-finding trial, TPX-0046 elicited responses in patients with nonsmall cell lung cancer and medullary thyroid cancer who were nave to prior ..."

    Published: Apr 5th, 2021 at 07:52:30 PM

    Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of ...

    ""While we continue to evaluate TPX-0046, the initial preliminary data are encouraging, with a generally tolerable safety profile and early signals of ..."

    Published: Apr 5th, 2021 at 02:54:17 PM

    2400 people remain without rare disease drug as Takeda manufacturing woes continue

    "Since the Natpara recall in September 2019, no US revenue has been recorded and the concerns are growing. "We've been told that they plan to keep ..."

    Published: Apr 5th, 2021 at 04:18:45 AM

    'Panicked' Wilton family takes son with cancer to Vermont for COVID vaccine

    "According to the American Thyroid Association, Medullary thyroid cancer accounts for 1 to 2 percent of thyroid cancers in the United States. Receiving ..."

    Published: Apr 2nd, 2021 at 10:30:00 AM

    GSK sells royalty rights on cancer drugs for nearly $400 million

    "Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis (Nasdaq: EXEL) in the ..."

    Published: Apr 1st, 2021 at 06:56:15 PM

    How is thyroid cancer treated?

    "Medullary thyroid cancer, a type of neuroendocrine cancer that begins in the T cells of the thyroid. These are the cells that help maintain a healthy ..."

    Published: Mar 31st, 2021 at 09:22:04 PM

    Turning Point Therapeutics Announces Board Changes Nasdaq:TPTX

    "... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

    Published: Mar 31st, 2021 at 06:22:30 PM

    Multiple Trial Regimens Demonstrate Efficacy for RET-Mutated Medullary Thyroid Cancer

    "When MTCs [medullary thyroid cancers] are not highly FDG [fluorodeoxyglucose] avid, and because they are neuroendocrine tumors with somatostatin ..."

    Published: Mar 31st, 2021 at 04:30:00 PM

    Kazim Bayus

    "In March 2019, Kazim was diagnosed with medullary thyroid cancer at Yale New Haven Hospital. Soon after moving to Massachusetts, Kazim ..."

    Published: Mar 30th, 2021 at 11:48:45 AM

    Exelixis: A Look At Its Potential

    "COMETRIQ is used to treat people with medullary thyroid cancer (MTC) that has spread to other parts of the body (called metastatic MTC). COTELLIC ..."

    Published: Mar 29th, 2021 at 06:22:30 PM

    The Impact of Somatic and Germline RET Mutations in Medullary Thyroid Cancer

    "... at the University of Texas MD Anderson Cancer Center, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies."

    Published: Mar 26th, 2021 at 09:22:30 PM

    Cstone scores approval for Blueprint Medicines' Gavreto in China

    "... RET-mutant medullary thyroid cancer and other advanced solid tumors with RET ... including first-line NSCLC, thyroid cancer and other solid tumors."

    Published: Mar 25th, 2021 at 11:37:30 PM

    Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects

    "... and reorganization of healthcare services may affect thyroid disease ... "thyroid nodule", "differentiated thyroid cancer", "medullary thyroid cancer", ..."

    Published: Mar 25th, 2021 at 06:11:15 PM

    RET inhibitors for lung cancer: What to know

    "RET inhibitors target cancers that have RET gene mutations. These include non-small cell lung cancer (NSCLC), medullary thyroid cancer, and ..."

    Published: Mar 24th, 2021 at 03:00:00 PM

    Blueprint Medicines partner CStone wins Chinese approval for lung cancer therapy

    "... CStone for the development and commercialization of pralsetinib and certain other candidates in Mainland China, Hong Kong, Macau, and Taiwan."

    Published: Mar 24th, 2021 at 10:18:45 AM

    RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026

    "RET Inhibitors Drug Retevmo Gavreto Market Size Clinical Trials Insight 2026 · Global RET Inhibitors Market Opportunity: > USD 1.5 Billion · Global RET ..."

    Published: Mar 24th, 2021 at 02:54:37 AM

    CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET ...

    "... RET-mutant medullary thyroid cancer, and other advanced solid tumors ... Among all Chinese cancer patients, lung cancer is the leading cause of ..."

    Published: Mar 24th, 2021 at 02:26:13 AM

    Teen cancer patient joins list of CT residents who've turned to other states for COVID-19 vaccine

    "Schwartz was diagnosed with medullary thyroid cancer amid the pandemic and is at an all-time high for severe complications with COVID-19 - and it's ..."

    Published: Mar 23rd, 2021 at 03:20:56 PM

    La medicina de precisin llega al cncer de tiroides con fusin del gen RET positiva

    "Selpercatinib est indicado para pacientes con tumores de tiroides, bien con mutacin o fusin del gen RET, en los cuales ya hay metstasis a partir de ..."

    Published: Mar 22nd, 2021 at 11:37:30 AM

    With early phase 2 data, BridgeBio plots next steps for hypoparathyroidism drug

    "The FDA approved NPS Pharma's hormonal injection, Natpara, in 2015, after granting it orphan designation. But the medicine's new owner Takeda ..."

    Published: Mar 19th, 2021 at 02:48:45 PM

    Blueprint Medicines (BPMC) Up 2.1% Since Last Earnings Report: Can It Continue?

    "Revenues include $6 million of net product revenues from the sales of Ayvakit and $0.7 million from Gavreto. Collaboration revenues were $27.4 ..."

    Published: Mar 17th, 2021 at 03:40:13 PM

    Real-World Study Shows Vandetanib and Cabozantinib Effective for Advanced MTC

    ""Management of patients with advanced medullary thyroid cancer remains a therapeutic challenge. The multi-tyrosine kinase inhibitors (TKIs) ..."

    Published: Mar 15th, 2021 at 08:42:25 PM

    Ca19.9 Positivity Indicative of Mortality from Medullary Thyroid Cancer

    "In advanced medullary thyroid cancer (MTC), mortality may be predicted by serum carbohydrate antigen 19.9 (Ca19.9) positivity in patients as well as ..."

    Published: Mar 15th, 2021 at 01:18:45 PM

    Selpercatinib and Pralsetinib Generate Enthusiasm in RET Fusion+ NSCLC

    "The RET inhibitors selpercatinib (Retevmo) and pralsetinib (Gavreto) demonstrated high response rates in both treatment-nave and pretreated ..."

    Published: Mar 15th, 2021 at 12:11:15 PM

    Increase in Thyroid Cancer Rates Points to Overscreening

    "Rates for medullary thyroid cancer were less than one per 100,000 person-years among men and women. For the anaplastic subtype, rates were less ..."

    Published: Mar 12th, 2021 at 04:15:00 PM

    Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report?

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $4 million in net product revenues. Exelixis earned $23.3 ..."

    Published: Mar 12th, 2021 at 11:00:00 AM

    UK conditionally approves Lilly's Retsevmo

    "... advanced RET mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib."

    Published: Mar 11th, 2021 at 08:04:28 PM

    C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

    "... for the treatment of solid tumors, including relapsed or refractory NSCLC and sporadic medullary thyroid cancers that are resistant to RET inhibitors."

    Published: Mar 10th, 2021 at 08:33:09 PM

    Lilly Announces Details of Presentations at 2021 American Association for Cancer Research (AACR)

    "... will highlight safety and efficacy data of Retevmo (selpercatinib) in the treatment of RET fusion-positive cancers outside of lung and thyroid cancer."

    Published: Mar 10th, 2021 at 03:53:05 PM

    Brain Tumor Market is Projected to Propel Humbly at a CAGR of 4.19% in the 7MM for the Study ...

    "... therapies, VAL-083 and Durvalumab target unmethylated MGMT form of glioblastoma while ONC201 targets H3 K27M-mutant form of glioma."

    Published: Mar 9th, 2021 at 12:07:30 PM

    GI symptoms negatively affect quality of life in multiple endocrine neoplasia type 2

    "The MEN2B cohort had more than double the prevalence of severe to very severe abdominal cramps (35% vs. 15%) and severe bloating (50% vs. 22%) ..."

    Published: Mar 5th, 2021 at 10:15:00 PM

    Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $1.7 million of Shares

    "Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $5.56 billion; its shares were ..."

    Published: Mar 4th, 2021 at 01:15:46 PM

    Turning Point Therapeutics to Participate in Upcoming Investor Conferences

    "... being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, ..."

    Published: Mar 2nd, 2021 at 08:56:15 AM

    Guest Opinion: The FDA can help patients with rare diseases

    "The FDA approved the first parathyroid hormone therapy called Natpara as an adjunct therapy for hypoparathyroidism to be used with supplements."

    Published: Mar 1st, 2021 at 10:26:15 PM

    Thyroid cancer incidence trends by histology in 25 countries: a population-based study

    "Temporal trends for follicular and medullary thyroid cancer did not show consistent patterns across countries, but slight decreases were seen for ..."

    Published: Feb 26th, 2021 at 07:48:45 PM

    A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care

    "The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer (DTC), has ... mutations in medullary thyroid cancer and RET fusions in radioactive iodine (RAI)refractory differentiated thyroid ..."

    Published: Feb 16th, 2021 at 03:41:15 PM

    What Is a Hypoechoic Thyroid Nodule?

    "In these cases, the nodule is caused by irregular cell growth associated with the cancer. One type of thyroid cancer-medullary thyroid cancer-is ..."

    Published: Feb 15th, 2021 at 05:33:45 AM

    Chimerix: Recent Acquisition Gives This Laggard Antiviral Company A Fresh Start In Oncology

    "ONC201. This molecule has seen unprecedented single agent activity in recurrent H3 K27M mutant glioma, which currently has no effective therapy. The ..."

    Published: Feb 11th, 2021 at 06:07:30 PM

    Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss

    "... of medullary thyroid cancer generated $4 million in net product revenues. ... with Roche's RHHBY Tecentriq in patients with advanced solid tumors."

    Published: Feb 9th, 2021 at 09:30:00 PM

    Tmunity expands T-cell engineered therapies partnership with Penn.

    "February 9, 2021 -- Tmunity Therapeutics said it has expanded its T-cell engineered therapy collaboration with the University of Pennsylvania."

    Published: Feb 9th, 2021 at 06:41:15 PM

    Bob Sanders | The FDA can help patients with rare diseases

    "The FDA approved the first parathyroid hormone therapy - called Natpara - as an adjunct therapy for hypoparathyroidism to be used with ..."

    Published: Feb 8th, 2021 at 03:06:57 PM

    Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?

    "... carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC), ... capsules) is approved for the treatment of medullary thyroid cancer."

    Published: Feb 8th, 2021 at 08:00:00 AM

    How Much Do You Know About Your Thyroid?

    "As important as the thyroid gland is, it's quite clear that many of us are ... There are four different types of thyroid cancers, with medullary being the ..."

    Published: Feb 5th, 2021 at 04:05:43 PM

    Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

    "... metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy and those with RET fusion positive thyroid cancer who need ..."

    Published: Feb 5th, 2021 at 04:03:45 PM

    Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

    "The FDA granted accelerated approval to pralsetinib (Gavreto) on December 1, 2020, for patients 12 years and older with advanced or metastatic RET- ..."

    Published: Feb 4th, 2021 at 09:41:15 PM

    EGFR/RET TKI Combination Active Against EGFR+ NSCLC With Acquired RET Fusion

    "The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive nonsmall cell lung cancer with ..."

    Published: Feb 4th, 2021 at 08:11:15 PM

    Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer

    "A few rules of thumb: When medullary thyroid cancer presents as a palpable nodule-if it presents as a palpable nodule and that's when you're ..."

    Published: Feb 4th, 2021 at 03:02:51 PM

    2020 Approvals Expand Access to Care for Patients Across Tumor Types

    "... for patients harboring RET mutations and for patients with indications that include medullary thyroid cancer (MTC).1. Approvals in other rare cancers ..."

    Published: Feb 3rd, 2021 at 09:07:30 PM

    Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer ...

    "RET fusions [are found] in anaplastic thyroid cancer, papillary thyroid cancer, and other nonmedullary thyroid cancers, [as well as] in lung ..."

    Published: Feb 1st, 2021 at 02:45:00 PM

    RET Joins the Ranks of Actionable Targets in Precision Oncology

    "RET alterations occur infrequently outside of thyroid cancer. ... of medullary thyroid cancer (MTC), RET mutations subsequently have been identified in ..."

    Published: Feb 1st, 2021 at 07:25:47 AM

    Regulator designated 2 more orphan drugs

    "... metastatic non-small cell lung cancer, medullary thyroid cancer and thyroid carcinoma, and idecabtagene vicleucel that treats multiple myeloma."

    Published: Jan 28th, 2021 at 01:24:21 AM

    CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in ...

    "These results mark the first medical conference presentation of data for pralsetinib in Chinese patients with RET fusion-positive NSCLC previously ..."

    Published: Jan 28th, 2021 at 01:15:00 AM

    CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in ...

    "... RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and other advanced solid tumors with RET fusions. Data from the ARROW ..."

    Published: Jan 25th, 2021 at 02:29:41 PM

    News briefing: Jeffrey Leiden to chair Tmunity board of directors; Opdivo wins new approval in ...

    "Tmunity is currently evaluating its T-cell engineering approaches in the clinic with three programs. The first targets metastatic castrate resistant ..."

    Published: Jan 20th, 2021 at 09:18:45 PM

    Selpercatinib Safe, Effective for Medullary Thyroid Cancer With RET Mutation

    "A phase 1/2 trial found Selpercatinib to be effective, with manageable safety, in patients with RET-mutant medullary thyroid cancer, both with or without ..."

    Published: Jan 19th, 2021 at 02:45:00 PM

    Lilly, Merus Ink Up-to-$1.6B Bispecific Antibody Partnership vs. Cancer

    "... RET inhibitor indicated for forms of non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers in patients whose tumors ..."

    Published: Jan 18th, 2021 at 01:03:45 PM

    Larotrectinib Excites Landscape for TRK Fusion-Positive Thyroid Cancers

    "RET fusions are seen in papillary, poorly differentiated and anaplastic thyroid cancers and RET mutations are seen in medullary thyroid cancer."

    Published: Jan 16th, 2021 at 07:03:45 PM

    Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

    "Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive ..."

    Published: Jan 15th, 2021 at 09:30:00 PM

    Despite the challenges brought with the coronavirus disease (COVID-19) pandemic, 2020 was ...

    "New Treatments for Non-Small Cell Lung Cancer. The U.S. Food and Drug Administration (FDA) recently approved Retevmo (selpercatinib) as the first ..."

    Published: Jan 14th, 2021 at 10:48:45 PM

    Selpercatinib Effective Therapy for RET Fusion-Positive Non-Small Cell Lung Cancer

    "... in patients with RET fusion-positive solid tumors and RET-mutant medullary thyroid cancer. About half of the patients enrolled on the trial have RET ..."

    Published: Jan 13th, 2021 at 02:45:00 AM

    High risk thyroid nodule discrimination and management by modified TI-RADS

    "Thyroid papillary carcinoma was found in all patients, with the exception of one thyroid medullary carcinoma. In thyroid benign and malignant nodule ..."

    Published: Jan 11th, 2021 at 09:41:15 PM

    New Developments in Thyroid Cancer

    "This drug is approved for RET-altered thyroid cancers, namely RET-mutated medullary thyroid cancers and RET fusions in radioactive iodine ..."

    Published: Jan 8th, 2021 at 09:52:30 AM

    Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

    "ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma. Compelling Response Rates to Date; Defined Regulatory Path to Registration."

    Published: Jan 7th, 2021 at 10:48:45 AM

    Thyroid cancer: In-utero exposures can increase your risk of this disease

    "Certain genetic health conditions like familial medullary thyroid cancer, multiple endocrine neoplasia, Cowden's syndrome and familial adenomatous ..."

    Published: Jan 6th, 2021 at 05:33:12 PM

    New Drug Gives Young Thyroid Cancer Patient a Second Chance at Life

    "The FDA approved pralsetinib (Gavreto), a selective RET-inhibitor drug, for RET fusion-positive non-small cell lung cancers (NSCLC) on September 4, ..."

    Published: Jan 5th, 2021 at 08:22:30 PM

    Tmunity to Present at the 39th Annual JP Morgan Healthcare Conference

    "Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

    Published: Jan 4th, 2021 at 10:03:45 AM

    New drug approvals hit a high note in 2020 but face uncertainty in 2021

    "Along with Gavreto, Blueprint got a nod for Ayvakit in gastrointestinal stromal tumors, a rare cancer that occurs in the stomach or small intestine. Acacia ..."

    Published: Dec 30th, 2020 at 01:15:00 AM

    New Approved Treatments and Indications in Oncology

    "... nonsmall-cell lung cancer (NSCLC) and advanced thyroid cancers. ... metastatic RET-mutant medullary thyroid cancer requiring systemic therapy, ..."

    Published: Dec 28th, 2020 at 11:00:00 PM

    The Top 10 FDA Oncology Drug Approvals of 2020

    "... cell lung cancer (NSCLC), medullary thyroid cancer and other types of thyroid cancers with rearranged during transfection, or RET, alterations."

    Published: Dec 28th, 2020 at 09:52:30 PM

    7 recent drug, device approvals

    "Roche & Blueprint Medicines' Gavreto - The FDA Dec. 2 approved Gavreto, a drug developed by Roche and Blueprint Medicines, to treat patients 12 ..."

    Published: Dec 24th, 2020 at 08:11:15 AM

    EMA adopts positive opinions for breast, lung, GU cancer indications

    "... opinion for use in patients with RET fusion-positive advanced NSCLC, as well as those with medullary thyroid or thyroid cancer with RET alterations."

    Published: Dec 23rd, 2020 at 08:20:32 PM

    Bring back Natpara: FDA must help hypoparathyroidism sufferers

    "Bring back Natpara: FDA must help hypoparathyroidism sufferers. Agency must show the same urgency for these Americans that it shows for treatment of ..."

    Published: Dec 23rd, 2020 at 07:48:45 PM

    Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies

    "... and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, ..."

    Published: Dec 23rd, 2020 at 04:03:45 PM

    Types of Thyroid Cancer

    "Types of Thyroid Cancer · Differentiated · Medullary Thyroid Cancer (MTC) · Anaplastic Thyroid Cancer · Less Common Types of Thyroid Cancers · A Word ..."

    Published: Dec 21st, 2020 at 06:38:45 PM

    Blueprint Medicines (BPMC) Rises 40% in Past 3 Months: Here's Why

    "Gavreto is a once-daily oral precision therapy that selectively inhibits RET-altered cancers. In September 2020, the FDA approved Gavreto for the ..."

    Published: Dec 18th, 2020 at 10:37:30 AM

    Parathyroid Hormone Global Market Report 2020-30: COVID-19 Growth and Change

    "It also adds the rights of parathyroid hormone NATPARA. Shire Plc is a US-based pharmaceutical company focusing on innovative and rare disease ..."

    Published: Dec 17th, 2020 at 09:52:30 AM

    Oncoceutics out-licenses ONC201 for Greater China to CR Sanjiu

    ""We are thrilled to form this partnership with CR Sanjiu whose dedication to innovative therapies and make them the ideal collaborators to bring ONC201 ..."

    Published: Dec 16th, 2020 at 09:25:23 PM

    Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $595900 of Shares

    "Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $6.54 billion; its shares were ..."

    Published: Dec 14th, 2020 at 02:00:00 PM

    EMA Panel Endorses Approval of Five New Cancer Drugs

    "These cancers include RET-fusion-positive nonsmall cell lung cancer (NSCLC), RET-fusion-positive thyroid cancer, and RET-mutant medullary ..."

    Published: Dec 11th, 2020 at 03:30:00 PM

    News anchor set to have 'cancerous' tumour removed after eagle-eyed viewers spot strange ...

    "Its presence is usually indicated by a swelling in the neck. There are four main types: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid ..."

    Published: Dec 11th, 2020 at 03:18:45 PM

    Bumper crop of novel meds backed for approval by EMA's CHMP

    "... (RET) gene fusion: RET-fusion positive non-small cell lung cancer, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer."

    Published: Dec 9th, 2020 at 11:33:45 PM

    CStone's Partner Blueprint Medicines Announces US FDA Approval of GAVRETO (pralsetinib) for ...

    "Expands GAVRETO label following initial approval for RET fusion-positive non-small cell lung cancer in September 2020 --. SUZHOU, China, Dec."

    Published: Dec 9th, 2020 at 12:07:30 PM

    Tmunity to Present at the 2020 RBC Capital Markets Healthcare Private Company Conference

    "Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

    Published: Dec 7th, 2020 at 09:07:30 AM

    ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

    "If it eventually does get approved, LOXO-305 would join Lilly's RET inhibitor Retevmo (selpercatinib, formerly LOXO-292) on the market, becoming the ..."

    Published: Dec 5th, 2020 at 04:18:10 PM

    Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report?

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $9 million in net product revenues. Exelixis earned $19.9 ..."

    Published: Dec 4th, 2020 at 06:07:30 PM

    Creating central Ohio connections in the fight against cancer

    "Jane had just recovered from her own bout of cancer (medullary thyroid cancer) and while attending a cancer support forum, she and Kevin were ..."

    Published: Dec 4th, 2020 at 05:56:15 PM

    Trending News on Targeted Oncology, Week of December 4, 2020

    "... and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy."

    Published: Dec 4th, 2020 at 08:45:00 AM

    Genentech's Gavreto scores US approval for RET thyroid cancer

    "Roche's Genentech division and its partner Blueprint Medicines have scored a new approval for Gavreto in the US for the treatment of RET-altered ..."

    Published: Dec 3rd, 2020 at 11:45:00 PM

    Gavreto Approved for Treatment of RET-Altered Thyroid Cancers

    "... Genentech/Blueprint Medicines) for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who ..."

    Published: Dec 3rd, 2020 at 02:22:30 PM

    Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers

    "... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or with RET fusion-positive thyroid cancer who require systemic therapy ..."

    Published: Dec 2nd, 2020 at 08:33:45 PM

    FDA Approvals Roundup: Imcivree, Danyelza, Ga 68 PSMA-11

    "Gavreto gets expanded indications for RET-altered thyroid cancers. Blueprint Medicines' Gavreto (pralsetinib capsules) has received two new ..."

    Published: Dec 2nd, 2020 at 07:13:08 PM

    Genentech, Blueprint Medicine's Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer

    "... second precision medicine option for patients with these types of cancers, following the FDA's approval of selpercatinib (Eli Lilly's Retevmo) in May."

    Published: Dec 2nd, 2020 at 03:54:40 PM

    Roche, Blueprint catch up with Lilly as Gavreto snags FDA thyroid cancer nod

    "The FDA has approved Roche and Blueprint Medicines' Gavreto in advanced or metastatic RET-mutant medullary or RET fusion-positive thyroid ..."

    Published: Dec 2nd, 2020 at 02:19:38 PM

    Roche turns up the heat on Lilly with another Gavreto approval, elbowing its way into the thyroid ...

    "Max Gelman. Associate Editor. Roche and Blueprint Medicines are continuing to put pressure on rivals Eli Lilly and Loxo, as their Gavreto drug ..."

    Published: Dec 2nd, 2020 at 10:37:30 AM

    Roche, Blueprint raise pressure on Lilly with new Gavreto approval

    "Retevmo (selpercatinib) was simultaneously approved by the agency for the lung and thyroid cancer in May, so has enjoyed an all-too brief period as ..."

    Published: Dec 1st, 2020 at 09:52:30 PM

    FDA Approves Pralsetinib for Thyroid Cancers Harboring RET Alterations

    "On December 1, 2020, the FDA granted approval to pralsetinib (Gavreto, Blueprint Medicines Corporation) for patients with advanced or metastatic ..."

    Published: Dec 1st, 2020 at 08:22:30 PM

    FDA approves Gavreto for RET-altered thyroid cancers

    "Source: Adobe Stock. Pralsetinib (Gavreto, Blueprint Medicines) is a once-daily oral therapy designed to target oncogenic RET alterations. The FDA ..."

    Published: Dec 1st, 2020 at 07:48:30 PM

    Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or ...

    "Tumor Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary thyroid carcinoma receiving Gavreto. Patients may be at risk ..."

    Published: Dec 1st, 2020 at 07:26:15 PM

    FDA OKs Blueprint Medicines and Roche's Gavreto for type of medullary thyroid cancer

    "Blueprint Medicines (BPMC -2.5%) and collaboration partner Roche (OTCQX:RHHBY +2.1%) announce the FDA nod for Gavreto (pralsetinib) for the ..."

    Published: Dec 1st, 2020 at 05:20:17 PM

    November UKG Workforce Activity Report: Smaller Businesses Lose Shifts

    "Approximately 10-20% of people with papillary thyroid cancer (the most ... RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid ..."

    Published: Nov 30th, 2020 at 09:30:00 PM

    Cabozantinib for Prostate Cancer - A Renewed Hope

    "... hepatocellular carcinoma,5 and medullary thyroid cancer,6 enthusiasm for single-agent use in prostate cancer was lost after the above experience."

    Published: Nov 30th, 2020 at 09:50:44 AM

    Adrenocortical Carcinoma Pipeline, Emerging Therapies and Key Players by DelveInsight

    "Cabozantinib is already approved by the US FDA for the treatment of metastatic medullary thyroid cancer, advanced renal cell carcinoma with history ..."

    Published: Nov 25th, 2020 at 03:30:00 PM

    Multikinase Inhibitor Options Abound for Patients With RET-Mutant Medullary Thyroid Cancer

    "RET aberrations in medullary [thyroid cancer are] mostly point mutations. In papillary thyroid cancer, you can still have point mutations, but it's mostly ..."

    Published: Nov 23rd, 2020 at 01:48:45 PM

    Catalent, Blueprint Enter GAVRETO Commercial Supply Pact

    "GAVRETO is a new therapy developed by Blueprint Medicines for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as ..."

    Published: Nov 23rd, 2020 at 01:02:52 PM

    Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval ...

    "Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO (pralsetinib) ..."

    Published: Nov 20th, 2020 at 01:01:18 PM

    'What you see here now, this is my wife. It feels like we've got her back': Middlesbrough coach ...

    "Gemma, 40, was given 12 months to live last year but her brain tumour is now 'stable' after use of a trial drug from Germany; ONC201 costs 5,000 per ..."

    Published: Nov 19th, 2020 at 06:18:45 PM

    Real-World Date Confirm Vandetanib and Cabozantinib Are Effective 1L/2L Treatments for ...

    "For the majority of patients with medullary thyroid cancer (MTC), vandetanib (Caprelsa) and cabozantinib (Cabometyx) are both effective treatment ..."

    Published: Nov 19th, 2020 at 03:36:02 PM

    Interesting WRB Put And Call Options For July 2021

    "Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. The approval is for the ..."

    Published: Nov 12th, 2020 at 04:48:45 PM

    Cabozantinib Plus Pembrolizumab May Improve Melanoma Outcomes

    "... such as renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. c-MET activation promotes PD-L1 expression, noted Jain."

    Published: Nov 12th, 2020 at 03:52:30 PM

    Objective Responses Observed in Rare Thyroid Tumors With Dual Checkpoint Blockade

    "The most common thyroid cancer subtype was papillary in 47% of patients, while other subtypes in the cohort included medullary thyroid cancer (MTC; ..."

    Published: Nov 6th, 2020 at 03:18:45 PM

    Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $9 million in net product revenues. Exelixis earned $19.9 ..."

    Published: Nov 5th, 2020 at 08:00:00 PM

    Tmunity to Present at Upcoming Investor Conferences

    "Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

    Published: Nov 5th, 2020 at 06:30:00 PM

    Roles of the RET Proto-oncogene in Cancer and Development

    "Moreover, point mutations in RET are responsible for multiple endocrine neoplasia types 2A and 2B, which can develop into medullary thyroid cancer ..."

    Published: Oct 30th, 2020 at 07:07:30 PM

    NIH Starts Clinical Trial with ONC206, a Next-Generation Imipridone

    "While DRD2 is also targeted by ONC201, ONC206 exhibits distinct biological effects and chemical properties that position its clinical development in ..."

    Published: Oct 29th, 2020 at 03:56:15 PM

    Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

    "... with various types of RET-altered thyroid cancers and other solid tumors. ... medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

    Published: Oct 27th, 2020 at 02:03:45 PM

    Pralsetinib and Selpercatinib Expand the RET+ NSCLC Paradigm

    "Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non ..."

    Published: Oct 27th, 2020 at 10:49:28 AM

    Lilly Reports Third-Quarter Financial Results, Updates Guidance

    "... Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth ..."

    Published: Oct 26th, 2020 at 03:56:15 PM

    Triple meeting the point of turning to TPX-0022

    "However, TPX-0022 hits two additional kinases involved in tumour ... assets Turning Point is now highlighting include TPX-0046, a Ret inhibitor to rival ..."

    Published: Oct 24th, 2020 at 02:15:00 PM

    Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock

    "... a Phase 1 study called SHIELD-1 in patients with advanced or metastatic solid tumors harboring genetic alterations in MET; RET inhibitor TPX-0046, ..."

    Published: Oct 24th, 2020 at 09:00:00 AM

    Thyroid cancer: Cushing syndrome is a lesser-known warning sign what is it?

    ""Medullary carcinoma of the thyroid is also probably related to this group of tumours. It is suggested that the great majority of the tumours associated with ..."

    Published: Oct 22nd, 2020 at 08:25:40 PM

    Pralsetinib

    "Pralsetinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive non- ..."

    Published: Oct 19th, 2020 at 12:11:15 PM

    Orphan Drugs Market to Witness Massive Growth by 2027 | Top Players Hoffmann-La Roche Ltd ...

    "... Gaucher disease type 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or gastro-esophageal junction adenocarcinoma, ..."

    Published: Oct 18th, 2020 at 08:03:45 PM

    VIDEO: Surgeon shares pearls for new drug delivery options

    "Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients. Precision Oncology News, 2020. Single-Cell ..."

    Published: Oct 18th, 2020 at 07:30:00 PM

    Hunting Resistance Mechanisms in RET-Fusion Lung Cancer

    "Pralsetinib is a potent and selective TKI that targets RET alterations, which drive roughly 1%-2% of NSCLC cases, and was designed to have limited ..."

    Published: Oct 15th, 2020 at 06:45:00 PM

    TRK Fusions Help to Fulfill Unmet Need in Thyroid Cancer Treatment Landscape

    "TRK fusions have not been observed in medullary thyroid cancer, however, limiting use of larotrectinib (Vitrakvi), a TRK inhibitor, to patients with DTC ..."

    Published: Oct 15th, 2020 at 04:07:30 PM

    A Phase II Study of Cabozantinib, Nivolumab, and Ipilimumab Immunotherapy in Patients with ...

    "Cabozantinib inhibits an enzyme called tyrosine kinase which can fuel cancer growth; it is already used to treat medullary thyroid cancer. Nivolumab ..."

    Published: Oct 15th, 2020 at 01:18:45 PM

    Endocrine Update 2021 - LIVESTREAM

    "... medullary thyroid cancer; current and recently approved systemic treatment ... of bone loss after bariatric surgery to prevent metabolic bone disease."

    Published: Oct 14th, 2020 at 02:48:45 PM

    RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

    "Selpercatinib (Retevmo) joins the ranks of therapies approved for several tumor types, with indications for patients with nonsmall cell lung cancer ..."

    Published: Oct 14th, 2020 at 12:56:15 PM

    ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients

    "The key takeaway from these data were that testing for NTRK gene fusions should be routine for patients with non-medullary, advanced thyroid cancer ..."

    Published: Oct 13th, 2020 at 04:07:30 PM

    Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung Cancer

    "The LIBRETTO-001 study demonstrated promising activity with selpercatinib, the selective RET inhibitor, as treatment of patients with RET-mutant ..."

    Published: Oct 13th, 2020 at 12:17:42 PM

    Hainan's Lecheng begins to sell top-notch US cancer drug

    "According to the news outlet, the drug is called pralsetinib and it is extremely effective in the treatment of non-small cell lung cancer. The Food and ..."

    Published: Oct 12th, 2020 at 11:37:30 PM

    YOUR HEALTH: One young man saved from a rare cancer

    "Tanner had stage four medullary thyroid cancer. Doctors tried every treatment available but nothing worked. "It was going to be hospice," said Cleveland ..."

    Published: Oct 12th, 2020 at 09:33:45 PM

    Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer

    "... with RET-altered medullary thyroid cancer (MTC) or advanced thyroid cancer. These findings ultimately led to the FDA approval of this RET inhibitor, ..."

    Published: Oct 9th, 2020 at 05:41:37 PM

    Teacher who was diagnosed with thyroid cancer at age 21 and had 100 tumors in her lungs - but ...

    "An ultrasound led to a diagnosis of medullary thyroid cancer. Doctors then performed surgery to remove her thyroid and 42 lymph nodes. Ashley Wyss ..."

    Published: Oct 9th, 2020 at 08:26:47 AM

    Teacher with 100 cancerous tumours in her lungs who refused to live in fear dies

    ""She will be remembered for her positivity, kindness, and strength during her nine-year battle with medullary thyroid cancer. A tumour resulted in Ashley ..."

    Published: Oct 7th, 2020 at 08:26:15 PM

    Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3 and TIGIT in medullary thyroid ...

    "Researchers analyzed a large cohort of medullary thyroid carcinomas ... coexpression were identified as promising biomarkers for tumor recurrence, ..."

    Published: Oct 7th, 2020 at 12:33:26 PM

    Cancer is Still the Real Global Health Crisis Four Stocks with Answers (EXEL, BMY, NBIO, MRK)

    "... the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, ..."

    Published: Oct 6th, 2020 at 01:07:30 PM

    Selpercatinib Induces Infrequent Hypersensitivity in RET Fusion-Positive NSCLC, Analysis Shows

    "Selpercatinib (LOXO-292)-related hypersensitivity reactions occurred infrequently in patients with RET fusion-positive nonsmall cell lung cancer ..."

    Published: Oct 2nd, 2020 at 09:24:59 PM

    Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years ...

    "CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreatic cancer at least 16.5 months pre-diagnosis. ERBB2 ..."

    Published: Oct 2nd, 2020 at 06:56:15 PM

    A Look Back at the FDA News from September 2020

    "... of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusionpositive thyroid cancer."

    Published: Oct 2nd, 2020 at 01:30:00 PM

    US FDA approval tracker: September

    "Roche will co-commercialise Gavreto with Blueprint in the US after paying $650m up front for rights. Elsewhere, Glaxosnithkline's Nucala became the ..."

    Published: Oct 1st, 2020 at 03:33:45 PM

    Fast Five Quiz: Thyroid Cancer Practice Essentials

    "Most thyroid cancers are papillary carcinomas, with follicular carcinomas, medullary thyroid carcinomas, and anaplastic carcinomas accounting for far ..."

    Published: Oct 1st, 2020 at 03:00:00 PM

    NSCLC Treatment Portfolio Gains RET-Targeted Therapy

    "Results showed that pralsetinib elicited durable responses, with 57% and 70% of patients with previously treated and treatment-nave disease ..."

    Published: Sep 30th, 2020 at 01:07:41 PM

    Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

    "... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in ..."

    Published: Sep 29th, 2020 at 05:37:30 PM

    10 recent exec moves affecting the pharma industry

    "Philadelphia-based drugmaker Tmunity named Johnson & Johnson and GlaxoSmithKline veteran Vijay Reddy, MD, its new chief research and ..."

    Published: Sep 29th, 2020 at 04:28:29 PM

    Blueprint Medicines Rises YTD on Robust Ayvakit Progress

    "Both companies will co-commercialize Gavreto in the United States while Roche alone will commercialize the drug outside the United States. Story ..."

    Published: Sep 29th, 2020 at 04:18:45 PM

    Blueprint Medicines Rises YTD on Robust Ayvakit Progress

    "Further, the FDA granted a Priority Review to Gavreto for the treatment of advanced/metastatic RET-mutant medullary thyroid cancer (MTC) and RET ..."

    Published: Sep 29th, 2020 at 02:48:45 PM

    The window of opportunity opens wider for Ascendis

    "This aims to overcome Natpara's problem variable PTH levels; Natpara was also associated with calcium imbalances, and carried a black box ..."

    Published: Sep 28th, 2020 at 02:55:36 PM

    Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

    "... medullary thyroid cancer who require systemic therapy, and c) patients 12 and older with advanced or metastatic RET-fusion positive thyroid cancer ..."

    Published: Sep 28th, 2020 at 02:15:00 PM

    Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer

    "Singapore, 28 September 2020 - An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

    Published: Sep 28th, 2020 at 12:33:45 PM

    Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

    "... lung cancer, b) adults and children 12 and older, with advanced or metastatic RET-mutated medullary thyroid cancer who require systemic therapy, ..."

    Published: Sep 28th, 2020 at 12:02:33 PM

    Clinical Trial of Selpercatinib Shows Strong Response for Patients with Non-Small Cell Lung Cancer

    "Singapore, 28 September 2020 An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by ..."

    Published: Sep 26th, 2020 at 07:41:15 PM

    Tmunity to Present at Upcoming Investor Conferences

    "Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

    Published: Sep 25th, 2020 at 09:11:15 PM

    Healthy Living: Retevmo for Thyroid Cancer

    "... in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including medullary thyroid cancer."

    Published: Sep 24th, 2020 at 02:15:00 PM

    Study: Pralsentinib May Be an Effective Treatment for RET Mutation-Positive Medullary Thyroid ...

    "Pralsetinib (BLU-667) shows promise as an effective treatment for patients with advanced RET mutation-positive medullary thyroid cancer (MTC), ..."

    Published: Sep 23rd, 2020 at 02:48:45 PM

    Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

    "Gavreto (pralsetinib) is a targeted therapy indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small ..."

    Published: Sep 22nd, 2020 at 11:48:45 PM

    Positive top-line data drive Blueprint toward an sNDA

    "This rare disease is often undiagnosed or misdiagnosed, according to ... in RETm medullary thyroid cancer and RET fusion-positive thyroid cancer by ..."

    Published: Sep 21st, 2020 at 06:11:15 PM

    Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer

    "These findings indicate that routine testing for NTRK gene fusions should be considered in patients with non-medullary advanced thyroid cancer as this ..."

    Published: Sep 21st, 2020 at 03:22:30 PM

    Blueprint Medicines says durable clinical benefits observed for Gavreto in thyroid cancer

    "GAVRETO was well-tolerated, and overall, treatment-related adverse events were primarily mild to moderate. Investigator-reported serious/servere ..."

    Published: Sep 21st, 2020 at 12:00:00 PM

    Thyroid Cancer: Small Gland, Big Impact

    "There are four main types of thyroid cancer (papillary, follicular, medullary and anaplastic). Luckily, most types of thyroid cancer are very treatable and ..."

    Published: Sep 20th, 2020 at 09:22:30 PM

    Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC

    "Patients with medullary thyroid cancer (MTC) harboring abberations in RET who were treated with pralsetinib (Gavreto) across therapy lines exhibited ..."

    Published: Sep 20th, 2020 at 07:41:15 PM

    Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

    "Potent and durable clinical activity was shown with pralsetinib (Gavreto) as treatment of patients with RET-mutant advanced medullary thyroid cancer ..."

    Published: Sep 20th, 2020 at 09:00:00 AM

    Progress in treating medullary thyroid cancer

    "Recently, there has been tremendous progress made in treating this disease with targeted therapy. We recently spoke with Mimi Hu, M.D., to learn more..."

    Published: Sep 18th, 2020 at 05:37:30 PM

    Turning Point Therapeutics to Participate in HC Wainwright Precision Oncology Investor Conference

    "... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

    Published: Sep 16th, 2020 at 01:18:45 PM

    Best Life: New drug controls rare cancers with gene mutation

    "But for those with medullary thyroid cancer, a rare form of the disease, there have been few effective options. Now, introducing the first young man in ..."

    Published: Sep 15th, 2020 at 09:14:29 PM

    Selpercatinib

    "Reduce selpercatinib dose in patients with severe hepatic impairment. Consult manufacturer's labeling for recommended dosage modifications for ..."

    Published: Sep 14th, 2020 at 09:56:15 PM

    From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell ...

    "This month, Tmunity Therapeutics expects to finish enrolling an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic ..."

    Published: Sep 14th, 2020 at 09:00:00 PM

    Benefits and limitations of TKIs in patients with medullary thyroid cancer: A systematic review and ...

    "... meta-analysis, researchers documented clinical response and toxicities of tyrosine kinase inhibitors (TKIs) in advanced medullary thyroid carcinoma ..."

    Published: Sep 13th, 2020 at 11:47:34 AM

    Data Shows That Workers Are Waiting Much Too Long to Start Saving for Retirement

    "... of proteins known to drive aggressive tumor growth for around 1% to 2% of all cases of NSCLC, and around 60% of all medullary thyroid cancers."

    Published: Sep 13th, 2020 at 11:37:30 AM

    Is Blueprint Medicines a Good Biotech Stock to Buy Now?

    "... and around 60% of all medullary thyroid cancers. In a clinical trial leading to its approval, Gavreto shrank tumors for 70% of treatment-naive NSCLC ..."

    Published: Sep 13th, 2020 at 10:18:45 AM

    Look back at pharma news in the week to September 11, 2020

    "In conjunction of the Gavreto approval in NSCLC, Blueprint also announced that the FDA has accepted pralsetinib new drug application (NDA) in RET- ..."

    Published: Sep 11th, 2020 at 06:11:15 PM

    Pralsetinib receives FDA approval for lung cancer with RET gene fusions

    "... cancer types, including NSCLC and medullary thyroid cancer, and treatment options that selectively target these genetic alterations are limited."

    Published: Sep 11th, 2020 at 04:07:30 PM

    FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

    "Specifically, pralsetinib elicited an overall response rate (ORR) of 57% (95% CI, 46%-68%) and a complete response (CR) rate of 5.7% in 87 ..."

    Published: Sep 11th, 2020 at 01:39:10 PM

    GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for ...

    "Tmunity also added to their leadership team by selecting Simona King as their CFO. A nearly 20-year vet of Bristol Myers Squibb in various financial ..."

    Published: Sep 10th, 2020 at 09:51:32 PM

    Health Beat: RETEVMO for thyroid cancer saves man's life

    "Ninety percent of all patients are cured if it's caught early, but for those with medullary thyroid cancer, a rare form of the disease, there have been few ..."

    Published: Sep 10th, 2020 at 08:48:45 PM

    FDA Approves Gavreto for Treatment of RET-Positive, Metastatic NSCLC

    "The FDA granted accelerated approval to pralsetinib (Gavreto, Blueprint Medicines) for adults with metastatic RET fusionpositive non-small cell lung ..."

    Published: Sep 10th, 2020 at 07:28:38 PM

    Health Beat: RETEVMO for thyroid cancer saves man's life

    "Andersen used RETEVMO on Tanner, who was 17. Within a few treatments, Tanner's tumors began to shrink. "My goal was to finish high school and at ..."

    Published: Sep 10th, 2020 at 12:11:15 PM

    Retevmo for thyroid cancer

    "RETEVMO was approved in May for people with non-small cell lung cancer, and two types of thyroid cancer with specific gene mutations, including ..."

    Published: Sep 10th, 2020 at 06:12:29 AM

    Gavreto (pralsetinib)

    "Medscape - Non-small cell lung cancer dosing for Gavreto (pralsetinib), frequency-based adverse effects, comprehensive interactions, ..."

    Published: Sep 9th, 2020 at 09:33:45 PM

    Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying

    "Although the onset of hereditary medullary thyroid cancer (MTC) depends on mutational risk, researchers sought to analyze the impact of this risk on ..."

    Published: Sep 9th, 2020 at 04:30:00 PM

    FDA Approvals Roundup: Gavreto and Trulicity

    "Gavreto approved for metastatic lung cancer with RET gene fusions ... medullary thyroid cancer and RET fusion-positive thyroid cancer, which are also ..."

    Published: Sep 9th, 2020 at 03:56:15 PM

    FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC

    "Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received ..."

    Published: Sep 8th, 2020 at 02:26:15 PM

    Pralsetinib: Second Drug for RET+ NSCLC Approved in US

    "Selpercatinib is also indicated for use in RET+ NSCLC and was approved for use RET+ medullary thyroid cancer and RET+ thyroid cancer."

    Published: Sep 8th, 2020 at 11:40:23 AM

    UPDATED: Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly

    "Four months after Eli Lilly's Retevmo got the first FDA OK to treat RET-altered tumors, Roche and Blueprint Medicines are stepping into the ring with ..."

    Published: Sep 8th, 2020 at 06:50:15 AM

    Roche joins competition in new targeted therapy for NSCLC

    "The Retevmo trial also showed that 10 out of 11 previously treated NSCLCL patients with brain metastases had intracranial responses (CNS ORR), and ..."

    Published: Sep 7th, 2020 at 11:48:45 PM

    FDA Approves Gavreto for RET Fusion Lung Cancer

    "Gavreto (formerly known as BLU-667), developed by Blueprint Medicine in collaboration with Genentech, inhibits a receptor tyrosine kinase known as ..."

    Published: Sep 7th, 2020 at 04:52:30 PM

    II-VI Sell-Off is an Overreaction, Says Five-Star Analyst

    "... chemotherapy and for RET mutation-positive medullary thyroid cancer (MTC) that requires systemic treatment and for which there are no acceptable ..."

    Published: Sep 7th, 2020 at 03:45:00 PM

    FDA OKs Blueprint/Roche's Gavreto As Rival To Lilly's Retevmo

    "... transfection (RET) fusion-positive non-small cell lung cancer, setting the stage for a head-to-head battle for market share with Eli Lilly's Retevmo."

    Published: Sep 7th, 2020 at 11:15:00 AM

    Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drug

    "Approval sets up a rivalry with Eli Lilly's RET inhibitor Retevmo (selpercatinib), and the verdict from experts at this year's American Society of Clinical ..."

    Published: Sep 7th, 2020 at 10:40:38 AM

    Illuminating Hrthle cell carcinoma

    "The selective RET kinase inhibitor, selpercatinib (Retevmo; Eli Lilly [NYSE: LLY]), also known as LOXO-292, has been shown to have robust ..."

    Published: Sep 7th, 2020 at 08:48:45 AM

    FDA approves Roche's Gavreto to treat metastatic RET fusion-positive NSCLC

    "... (RET) fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer and other RET-altered solid tumours."

    Published: Sep 7th, 2020 at 04:10:13 AM

    Fundraiser for University of Reading law student with cancer to get ONC201 drug

    "Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford Trainee Reporter. (4). Skip to next photo. 1/4."

    Published: Sep 7th, 2020 at 04:07:30 AM

    Fundraiser for University of Reading law student with cancer to get ONC201 drug

    "Fundraiser for University of Reading law student with cancer to get ONC201 drug. By Celine Byford. (3). Skip to next photo. 1/3. Show caption. 1/3."

    Published: Sep 5th, 2020 at 04:18:45 PM

    Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

    Published: Sep 5th, 2020 at 02:37:30 AM

    FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers

    "The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as ..."

    Published: Sep 5th, 2020 at 01:30:00 AM

    Blueprint, Roche take on Lilly with FDA approval for RET cancer drug Gavreto

    "It was only May when Eli Lilly's Retevmo became the first FDA-approved drug for RET-altered tumors. Now, a rival therapy has arrived with a better ..."

    Published: Sep 5th, 2020 at 01:07:30 AM

    FDA Approves Pralsetinib in RET Fusion-Positive NonSmall Cell Lung Cancer

    "The FDA has approved pralsetinib (formerly BLU-667, Gavreto) for the treatment of adult patients with metastatic RET fusionpositive nonsmall cell ..."

    Published: Sep 4th, 2020 at 10:52:30 PM

    Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With ...

    "RET-activating fusions and mutations are key disease drivers in many cancer types, including NSCLC and medullary thyroid cancer (MTC), and ..."

    Published: Sep 2nd, 2020 at 06:56:15 PM

    Selpercatinib Demonstrates Durable Efficacy and Intracranial Activity in RET+ NSCLC

    "The RET inhibitor selpercatinib (LOXO-292; Retevmo) was shown to have durable efficacy with mostly low-grade adverse effects (AEs) in patients with ..."

    Published: Sep 2nd, 2020 at 06:33:45 PM

    Expert Highlights Major Advancements in Honor of Thyroid Cancer Awareness Month

    "In addition, another RET inhibitor, pralsetinib (BLU-667), is also appearing promising for the treatment of RET-mutant MTC and papillary thyroid cancer ( ..."

    Published: Sep 2nd, 2020 at 04:07:30 PM

    RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer

    "RET alterations are present among 70% of patients with in medullary thyroid cancers (MTC) and 10% of other thyroid cancers, but RET-specific ..."

    Published: Sep 2nd, 2020 at 01:52:30 PM

    BMS oncology chief Namouni lands at Blueprint Medicines to lead R&D

    "Fouad Namouni, M.D., arrives after Roche forked over $775 million in cash and equity for the rights to pralsetinib outside the U.S. and China."

    Published: Sep 2nd, 2020 at 11:25:10 AM

    Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech

    "Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprint's RET rival to Eli Lilly's Retevmo, which got out in ..."

    Published: Aug 29th, 2020 at 06:00:00 PM

    New Lung, Thyroid Cancer Tx; COVID Risk in Cancer: It's TTHealthWatch!

    "In the thyroid cancers, they had 55 patients with the medullary thyroid cancer previously treated. Sixty-nine percent had a response to the agent with 82 ..."

    Published: Aug 28th, 2020 at 05:37:30 PM

    Adults With Rare Blood Cancers Can Now Receive Treatment From Home

    "... as mutation or fusion, in the RET gene, and it is able to treat non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancers."

    Published: Aug 28th, 2020 at 03:56:15 PM

    LIBRETTO-001 Trial Shows Promise for Selpercatinib in NSCLC Marked by RET Gene Fusions

    "Results from this trial observed in patients with RET-altered lung and thyroid cancers also led to the approval of selpercatinib by the FDA in May for ..."

    Published: Aug 28th, 2020 at 02:48:45 PM

    Trending News on Targeted Oncology, Week of August 28, 2020

    "Selpercatinib demonstrated durable efficacy as treatment of patients with medullary thyroid cancer harboring the RET mutation whether or not they ..."

    Published: Aug 27th, 2020 at 02:26:15 PM

    Selpercatinib may provide an effective response against RET-mutated thyroid cancer

    "Selpercatinib, a highly selective RET kinase inhibitor, was effective in antitumor activity against medullary thyroid cancer. 2. Selpercatinib caused ..."

    Published: Aug 27th, 2020 at 12:56:15 PM

    Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC

    "... which evaluated selpercatinib (formerly known as LOXO-292; Retevmo) as treatment of patients with RET fusion-positive nonsmall cell lung cancer ..."

    Published: Aug 27th, 2020 at 09:59:44 AM

    Selpercatinib Shows Durable Efficacy in RET Fusionpositive NSCLC

    "Selpercatinib is a novel, ATP-competitive, highly selective small-molecule inhibitor of RET kinase. Selpercatinib was designed to penetrate the central ..."

    Published: Aug 26th, 2020 at 09:11:15 PM

    Selpercatinib May Be New Standard of Care for RET-Altered Thyroid Cancers, Study Shows

    "Researchers suggest that the void could potentially be filled with selpercatinib (formerly known as LOXO-292; Retevmo). Selpercatinib is the first ..."

    Published: Aug 26th, 2020 at 09:00:00 PM

    New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

    "RET+ lung cancers are aggressive and have a poor prognosis, but new targeted drug selpercatinib (Retevmo) benefits more than 90% of patients who ..."

    Published: Aug 26th, 2020 at 08:48:45 PM

    Efficacy of Selpercatinib in RET FusionPositive NonSmall-Cell Lung Cancer

    "Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusionpositive NSCLC who ..."

    Published: Aug 24th, 2020 at 12:01:40 PM

    Tri-Cities hockey league, gamers join forces for 5th-grader fighting rare cancer

    "When he came in for imaging tests, they discovered medullary thyroid cancer. That form of cancer accounts for just 1 to 2 percent of the already ..."

    Published: Aug 19th, 2020 at 09:00:00 PM

    Selpercatinib Aimed at RET-Altered Cancers

    "Selpercatinib Aimed at RET-Altered Cancers. List of authors. Razelle Kurzrock, M.D.. August 27, 2020. N Engl J Med 2020; 383:868-869"

    Published: Aug 18th, 2020 at 02:26:15 PM

    Vandetanib confers clinical benefit for certain patients with medullary thyroid cancer

    ""Medullary thyroid cancer is a rare neuroendocrine malignancy that derives from parafollicular cells of the thyroid gland that secrete the polypeptide ..."

    Published: Aug 14th, 2020 at 07:41:15 PM

    What Are the Warning Signs of Thyroid Cancer?

    "Medullary thyroid cancer: Medullary thyroid cancer arises in the C cells in the thyroid gland. C cells produce a hormone called calcitonin. Elevated levels ..."

    Published: Aug 11th, 2020 at 06:50:11 AM

    Thyroid cancer cells signs and symptoms: What are the signs of thyroid cancer?

    "Medullary thyroid carcinoma cn run in fmilies, nd npestic thyroid crcinom is extremely rre nd normlly found in people over 60."

    Published: Aug 7th, 2020 at 03:13:10 PM

    Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

    "Cometriq (cabozantinib capsules) for the treatment of medullary thyroid cancer generated $5.1 million in net product revenues. Exelixis earned $16.3 ..."

    Published: Aug 6th, 2020 at 03:20:48 PM

    Neuroendocrine Tumors Market 2020-2026 Emerging Trends | Major Giants Ipsen Pharma ...

    "Carcinoid tumors in the lungs; Pancreatic neuroendocrine tumors; Medullary thyroid carcinoma; Merkel cell carcinoma; Pheochromocytoma of the ..."

    Published: Aug 3rd, 2020 at 12:00:00 PM

    A 67-Year-Old Woman With Differentiated Thyroid Cancer

    "Those 2 diagnoses are anaplastic, or undifferentiated thyroid cancer. Then the other diagnosis is medullary thyroid cancer. Transcript edited for clarity."

    Published: Jul 31st, 2020 at 03:22:30 PM

    Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat

    "Blueprint Medicines and Roche will co-develop pralsetinib globally in RET-altered solid tumors, including non-small cell lung cancer (NSCLC), ..."

    Published: Jul 30th, 2020 at 07:41:15 PM

    Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review

    "Abstract: Medullary thyroid cancer (MTC) is typically associated with multiple endocrine neoplasia type 2 syndrome (MEN 2), but not with multiple ..."

    Published: Jul 28th, 2020 at 08:37:30 PM

    Phosphoprotein biomarkers to guide cancer therapy are identified

    "To find biomarkers, the researchers first used a unique mouse model of medullary thyroid carcinoma, or MTC, whose growth of the tumor can be ..."

    Published: Jul 28th, 2020 at 06:56:15 PM

    License to Pill: Biotech and pharma deals from July 11-July 24

    "... for treating RET-altered non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancer, as well as other solid tumors."

    Published: Jul 28th, 2020 at 09:45:00 AM

    Aviation Active Noise and Vibration Control System Market Trend Shows A Rapid Growth By 2026 ...

    "Medullary Thyroid Cancer Treatment Market 2020 Global Future Growth| Size, Share, Demand, Regional Trends, Segmentation and Forecasts to ..."

    Published: Jul 25th, 2020 at 08:15:00 AM

    Dil Bechara: What Ailed Kizzie Basu? Here's All You Need To Know About Thyroid Cancer

    "Types of Thyroid cancer include Papillary thyroid cancer, Follicular thyroid cancer, Anaplastic thyroid cancer, and Medullary thyroid cancer. These types ..."

    Published: Jul 23rd, 2020 at 07:07:30 PM

    SEngine Organoid Testing Leads to Treatment Change for Two Metastatic Colorectal Cancer ...

    "... to the multi-tyrosine kinase inhibitor vandetanib (Sanofi/Genzyme's Caprelsa), currently approved for medullary thyroid cancer, but noted no disease ..."

    Published: Jul 23rd, 2020 at 01:52:30 PM

    Lilly's Patient Centric Approach Speeds Treatments To Patients

    "Retevmo entered clinical testing in May of 2017 and received FDA approval less than three years later. Jacob Van Naarden, COO for Loxo Oncology at ..."

    Published: Jul 22nd, 2020 at 08:03:45 AM

    Pulmonary function in patients with multiple endocrine neoplasia 2B

    "... characterize pulmonary function among patients encountering multiple endocrine neoplasia type 2B (MEN2B). Experts analyzed pulmonary function ..."

    Published: Jul 21st, 2020 at 10:52:30 PM

    Industry News: Roche collaborates with Blueprint Medicines to bring a new treatment to people ...

    "... RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors."

    Published: Jul 21st, 2020 at 08:37:30 PM

    The Oncologist's Role With Savvy Patients

    "It's long been associated with thyroid cancer, particularly medullary thyroid cancer, but now it's been found through deeper and deeper genomics in a ..."

    Published: Jul 20th, 2020 at 08:14:38 PM

    FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

    "... treatment of patients with RET alterationpositive nonsmall cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers."

    Published: Jul 20th, 2020 at 06:33:45 PM

    Cabozantinib Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and ...

    "Medullary Thyroid Cancer Treatment; Second Line Treatment for Renal Cell Carcinoma. Details specified in the document: Consumption graphs of all ..."

    Published: Jul 19th, 2020 at 12:45:00 PM

    Look back at pharma news in the week to July 17, 2020

    "Roche was also in the news for its collaboration with Blueprint Medicines on the development of the US biotech's targeted cancer candidate pralsetinib."

    Published: Jul 17th, 2020 at 04:52:30 PM

    Trending News on Targeted Oncology, Week of July 17, 2020

    "... in progression-free survival in patients with symptomatic and progressive medullary thyroid cancer in a post-hoc analysis of the phase III ZETA trial."

    Published: Jul 16th, 2020 at 09:33:45 PM

    Targeted oncogene therapy before surgery in pediatric patients with advanced invasive thyroid ...

    "Mostly pediatric patients with thyroid cancer initially present with operable disease, however, there are some ... the response to therapy and long-term tolerance in patients with widely invasive medullary thyroid cancer, in whom the ..."

    Published: Jul 16th, 2020 at 08:15:00 AM

    Father Admits 'Helping' With Son's Prizewinning Cancer Project

    "A high schooler from the southwestern municipality of Chongqing won first prize in the 34th CASTIC for her research on medullary thyroid cancer, ..."

    Published: Jul 15th, 2020 at 12:45:00 PM

    Blueprint Medicines Corporation Collaborates Roche as (BPMC) soars 3.60% in a week

    "Pralsetinib is an investigational once-daily oral precision therapy that is used to treat cancer patients driven by oncogenic RET alterations. Under the ..."

    Published: Jul 15th, 2020 at 11:37:30 AM

    Roche pays $775m upfront to access Blueprint's RET programme

    "... fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

    Published: Jul 15th, 2020 at 11:15:00 AM

    Roche-Blueprint ink licensing and collaboration deal for pralsetinib

    "Pralsetinib is a once-daily, investigational oral precision therapy offered by Blueprint, which has been used for the treatment of patients with RET-altered ..."

    Published: Jul 15th, 2020 at 06:56:15 AM

    AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On ...

    "In addition, a safety trial in dry eye disease patients is expected to be ... cancer, medullary thyroid cancer, other thyroid cancers, and other solid tumors."

    Published: Jul 14th, 2020 at 09:33:45 PM

    Roche Invests in Blueprint Medicines, Maker of RET Inhibitor Pralsetinib

    "... medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers. ... "Beyond lung cancer, pralsetinib's tumour-agnostic potential further ..."

    Published: Jul 14th, 2020 at 07:52:30 PM

    Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

    "... cell lung cancer, medullary thyroid cancer, as well as other solid tumors. ... for pralsetinib in RET-mutant and RET fusion-positive thyroid cancers."

    Published: Jul 14th, 2020 at 07:48:21 PM

    Noteworthy Tuesday Option Activity: INTU, CTXS, HON

    "Pralsetinib, proposed for the treatment of RET fusion-positive NSCLC, RET mutation-positive MTC, and RET fusion-positive thyroid cancer, is under FDA ..."

    Published: Jul 14th, 2020 at 04:18:45 PM

    Should Value Investors Buy Asbury Automotive Group (ABG) Stock?

    "Separately, 60% of previously treated and 74% of treatment naive RET-mutant medullary thyroid cancer patients responded to pralsetinib. Roche's ..."

    Published: Jul 14th, 2020 at 03:26:43 PM

    Elmont continues to face high cancer rates

    "In one case, Mimi Pierre-Johnson said, a man who had lived in Elmont for more than 40 years was diagnosed with medullary thyroid cancer, despite ..."

    Published: Jul 14th, 2020 at 03:00:00 PM

    Roche pits its targeted cancer Blueprint against Lilly

    "Lilly's own Ret inhibitor Retevmo (selpercatinib) was recently approved in Ret-mutated non-small cell lung and thyroid cancers, giving it a few months' ..."

    Published: Jul 14th, 2020 at 02:01:40 PM

    Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

    "Retevmo was the first cancer treatment to target RET and gain FDA approval. Blueprint and Roche hope to follow. The biotech company has already ..."

    Published: Jul 14th, 2020 at 12:06:24 PM

    Roche collaborates with Blueprint Medicines for new treatment of RET-altered cancers

    "Blueprint Medicines has submitted a new drug application (NDA) for pralsetinib to the US Food and Drug Administration (FDA) and a marketing ..."

    Published: Jul 14th, 2020 at 10:52:30 AM

    Roche to pay Blueprint $775M for pralsetinib rights, setting up showdown with Lilly

    "Lilly won FDA approval for Retevmo in the treatment of NSCLC and two types of thyroid cancer in May. Blueprint is targeting the same indications and ..."

    Published: Jul 14th, 2020 at 10:09:32 AM

    Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to ...

    "Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game."

    Published: Jul 14th, 2020 at 07:52:30 AM

    Roche gene testing key to $1.7 billion deal for Blueprint cancer drug

    "The Swiss drugmaker will pay $675 million in cash and make a $100 million equity investment in Blueprint for rights to pralsetinib, which could gain ..."

    Published: Jul 14th, 2020 at 06:50:12 AM

    Vienna Airport June passenger numbers down 95%

    "Earlier this month, Blueprint also submitted pralsetinib to the FDA for treating advanced RET mutant and RET fusion-positive thyroid cancers. "In bringing ..."

    Published: Jul 12th, 2020 at 12:00:00 PM

    Vandetanib Remains Safe and Effective in Medullary Thyroid Cancer

    "A post-hoc analysis of the phase III ZETA trial shows that vandetanib improved PFS in medullary thyroid cancer. The tyrosine kinase inhibitor vandetanib ..."

    Published: Jul 10th, 2020 at 04:52:30 PM

    Coronavirus: Kiwi diagnosed with rare cancer in Romania struggling to get home

    "It revealed he had stage four medullary thyroid cancer. Nick Daniels has stage four thyroid cancer. He is trying to come home to Auckland. Nick Daniels/ ..."

    Published: Jul 6th, 2020 at 06:20:05 AM

    Parents of boy, 4, with rare cancer pin hopes on experimental drug

    "... ONC201 trials had "shown minimal to no efficacy". However, "if the mother needs to feel that she has done everything, we will help her in her efforts."

    Published: Jul 2nd, 2020 at 07:29:17 PM

    NCI Trials for July 2020

    "NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET ..."

    Published: Jul 2nd, 2020 at 12:56:15 PM

    FDA Approval Sought for Pralsetinib to Treat Advanced RET+ Thyroid Cancers

    "... treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancers, according to ..."

    Published: Jul 2nd, 2020 at 05:22:17 AM

    LMNL Joins COVID-19 Battle, PFE/BNTX Vaccine Data Promising, EVLO On Watch

    "Pralsetinib is an investigational, once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, including ..."

    Published: Jul 1st, 2020 at 10:17:42 PM

    FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid Cancer

    ""Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted ..."

    Published: Jul 1st, 2020 at 07:41:15 PM

    Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers

    "The FDA granted accelerated approval to selpercatinib in May for patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and ..."

    Published: Jul 1st, 2020 at 01:18:45 PM

    Estrogen Receptor Agent Approved

    "Retevmo Approved in Lung and Thyroid Cancers. On May 8, the U.S. Food and Drug Administration (FDA) announced the approval of Retevmo ( ..."

    Published: Jun 30th, 2020 at 09:56:15 PM

    Progress in Targeted Therapy for Lung Cancer: New Data From ASCO 2020

    "Please note that in the selpercatinib approval, it is available for any line of therapy and should be considered as a first therapy. Looking for RET is ..."

    Published: Jun 29th, 2020 at 01:41:15 PM

    Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

    "Pralsetinib is an investigational treatment for the detection of RET alterations in cancer patients. Burning Rock Chief Medical Officer Hao Liu said in a ..."

    Published: Jun 29th, 2020 at 01:09:35 AM

    BRIEF-Burning Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co ...

    "... Rock And CStone Pharmaceuticals Reached Strategic Collaboration On Co-Development Of Companion Diagnostics For Pralsetinib In China."

    Published: Jun 26th, 2020 at 02:07:48 PM

    Pulmonary abnormalities, lung cysts seen in children, young adults with MEN2B

    ""This study evaluated lung function and anatomy in patients with MEN2B using pulmonary function tests and available CT images," Jaydira Del Rivero, ..."

    Published: Jun 24th, 2020 at 05:15:00 AM

    Dr. Halmos on Recent Advancements in NonSmall Cell Lung Cancer

    "Another advance is the development and the awaited approval of pralsetinib (BLU-667). These agents are exceptional treatment options for patients ..."

    Published: Jun 22nd, 2020 at 01:05:48 PM

    NCCN Updates Clinical Practice Guideline for Thyroid Carcinomas

    "After FNA results yield a medullary thyroid carcinoma diagnosis, a new bullet is listed under diagnostic procedures for additional cross-sectional ..."

    Published: Jun 19th, 2020 at 07:52:30 PM

    VIDEO: Advantages of aggressive therapy for metastatic EGFR-mutated NSCLC

    "Rotow also mentioned the recent FDA approval of selpercatinib for the treatment of RET fusion-positive NSCLC. She highlighted findings from a ..."

    Published: Jun 19th, 2020 at 06:45:00 PM

    Non-small-cell lung cancer therapies lead FDA approvals in May

    "In addition to Tabrecta and Retevmo were Qinlock (ripretinib, Deciphera Pharmaceuticals Inc.), a kinase inhibitor, for advanced gastrointestinal ..."

    Published: Jun 18th, 2020 at 01:30:00 PM

    $400000 SBIR grant fast-tracks new approach to treating lung, thyroid cancers

    "KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, and medullary thyroid cancer, among others. About Purdue ..."

    Published: Jun 15th, 2020 at 03:56:15 PM

    Selpercatinib shows durable response in RET-fusion positive NSCLC

    ""LOXO-292, or selpercatinib, is a highly potent selective RET-inhibitor," Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson ..."

    Published: Jun 15th, 2020 at 12:00:00 PM

    Increasing incidence of cancer and stage migration towards advanced disease in children and ...

    "... whereas stage migration towards advanced disease was seen for Hodgkin lymphomas, soft tissue sarcomas and medullary thyroid carcinomas."

    Published: Jun 12th, 2020 at 12:55:40 PM

    Nurses Unlock Role in Cancer Genetics

    "People found to have a genetic mutation for medullary thyroid cancer can encourage family members to undergo screening, as there is a nearly 100% ..."

    Published: Jun 11th, 2020 at 02:03:45 PM

    Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

    "Pralsetinib, an oral selective RETkinase inhibitor, targets both RET fusions and alterations. For the ARROW study (ClinicalTrials.gov identifier: ..."

    Published: Jun 10th, 2020 at 10:18:45 PM

    Genetic Testing Becomes Vital in Sequencing Treatments for Patients With Thyroid Cancer

    "The highly selective RET inhibitor pralsetinib (BLU-667), for example, is under investigation now and has shown encouraging findings in thyroid ..."

    Published: Jun 9th, 2020 at 04:18:45 PM

    NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program

    "... for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients."

    Published: Jun 8th, 2020 at 06:56:15 PM

    Real Housewife Alum Jill Zarin on Finding Love After Cancer Loss: Says Husband Would Approve ...

    "Medullary thyroid cancer accounts for approximately 2% of all thyroid cancers. Approximately 25% of all medullary thyroid cancer is inherited, and a test ..."

    Published: Jun 7th, 2020 at 01:07:30 PM

    Fundraising vital as family of Eva Williams wait to see if she will be accepted on to one of four ...

    "... all essentially means is that the trials aren't readily accessible and we feel as though time is probably running out on us accessing the ONC201 trial."

    Published: Jun 7th, 2020 at 08:48:45 AM

    Selpercatinib Prompts Dramatic Response in RET Fusion-Positive Ansplastic Thyroid Carcinoma

    "... RET-mutant medullary thyroid cancer and those with other RET fusion-positive thyroid cancers in the phase I/II LIBRETTO-001 trial (NCT03157128), ..."

    Published: Jun 5th, 2020 at 11:03:45 PM

    "Mommy, my brain hurts," a kindergartner tells her mother. The girl is then diagnosed with a brain ...

    "ONC201, an experimental drug, is part of a Phase I testing study at the hospital, Raegen Sieck said. "We are going to put all of our hope and faith into ..."

    Published: Jun 5th, 2020 at 03:22:30 PM

    Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?

    "Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

    Published: Jun 5th, 2020 at 01:18:45 PM

    RET Inhibition Shows Significant Intracranial Responses in RET-Altered NSCLC

    ""Selpercatinib had marked intracranial anti-tumor activity in RET fusionpositive patients with [NSCLC and] CNS metastases. Tumor responses were ..."

    Published: Jun 4th, 2020 at 04:18:45 AM

    Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

    "... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

    Published: Jun 3rd, 2020 at 03:00:00 PM

    Asco 2020 movers cell therapy companies dominate the risers

    "Supportive sellside analysts duly described TPX-0046 as potentially best-in-class, no doubt mindful of the $325m offering that Turning Point had ..."

    Published: Jun 3rd, 2020 at 03:56:15 AM

    $2 million SBIR grant fast-tracks cancer drug platform technology

    "KinaRx portfolio includes therapeutic candidates for acute myeloid leukemia, lung cancer, medullary thyroid cancer, among others. About Purdue ..."

    Published: Jun 2nd, 2020 at 06:56:15 PM

    Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients

    "... medullary thyroid cancer, and RET fusion-positive thyroid cancer. ... In this 27-patient cohort, 13 patients had RET fusion-positive thyroid cancer, and ..."

    Published: Jun 2nd, 2020 at 02:38:41 PM

    US FDA approval tracker: several early decisions in May

    "Retevmo, which Lilly gained through its Loxo acquisition, was approved in ... Retevmo (selpercatinib), Eli Lilly, 1,172, Approved (early ~2 months)."

    Published: Jun 1st, 2020 at 09:22:30 PM

    A Look Back at the FDA News from May 2020

    "Pralsetinib (BLU-667) was granted a priority review on May 29, 2020, for the treatment of patients with advanced solid tumors harboring RET ..."

    Published: Jun 1st, 2020 at 03:00:00 PM

    Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

    "RET inhibitor pralsetinib (BLU-667) induced responses in a number of patients with rare and difficult to treat RET fusionpositive solid tumors."

    Published: Jun 1st, 2020 at 12:56:15 PM

    Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare ...

    "... TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic ..."

    Published: Jun 1st, 2020 at 12:45:00 AM

    Pralsetinib Demonstrates Significant Findings in RET+ Solid Tumors as FDA Grants Priority Review

    "In thyroid cancers specifically, RET fusions can be found in about 10% to 20% of papillary thyroid cancers (PTCs), mutations are found in about 50% of ..."

    Published: May 31st, 2020 at 03:00:00 PM

    Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drug

    "... medullary thyroid cancer. Blueprint said it plans to file for FDA approval of pralsetinib in RET mutant- and fusion-positive thyroid cancers next month."

    Published: May 31st, 2020 at 05:15:00 AM

    Jefferson, Chad

    "... son of Charles and Connie Jefferson, passed away from complications of a brain injury during his battle with Medullary Thyroid Cancer, while being ..."

    Published: May 31st, 2020 at 12:18:43 AM

    ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with ...

    "The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumours harbouring RET ..."

    Published: May 30th, 2020 at 09:45:00 PM

    ASCO 2020: Oncoceutics' ONC201 Demonstrates Clinical Benefit

    "To date, tumors with an H3 K27M mutation have no effective treatments. They are also associated with poor overall survival. ONC201, a "founding ..."

    Published: May 29th, 2020 at 10:51:10 PM

    Other news to note for May 29, 2020

    "TPX-0046 also demonstrated antitumor activity in RET-driven cell-derived and patient-derived xenograft tumor models, including those that harbor a ..."

    Published: May 29th, 2020 at 02:15:00 PM

    Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene ...

    "RET alterations are most common in medullary thyroid cancers (approximately 90% of advanced cases), papillary thyroid cancers (approximately ..."

    Published: May 29th, 2020 at 12:33:45 PM

    BRIEF-Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate

    "TURNING POINT THERAPEUTICS INC - A PHASE 1/2 TRIAL OF TPX-0046 IN RET TKI-NAVE AND -PRETREATED PATIENTS IS ONGOING Source ..."

    Published: May 29th, 2020 at 12:00:00 PM

    BRIEF-Blueprint Medicines Highlights Durable Clinical Activity And Well-Tolerated Safety Profile Of ...

    "* BLUEPRINT MEDICINES CORP - NDA ACCEPTED BY FDA AND MAA VALIDATED BY EMA FOR PRALSETINIB IN RET FUSION-POSITIVE NSCLC ..."

    Published: May 27th, 2020 at 09:37:41 PM

    Pulmonary function in patients with multiple endocrine neoplasia 2B (MEN2B)

    "They included 36 patients with MEN2B (18 males, 18 females) based on the availability of PFTs; 27 patients had undergone at least two PFTs and ..."

    Published: May 27th, 2020 at 12:56:15 PM

    Pulmonary and thyroid carcinoma: FDA approves the treatment with Retevmo

    "The Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for three types of cancer treatment that present alteration (changing) in the ..."

    Published: May 19th, 2020 at 09:00:51 PM

    8 recent drug approvals

    "The FDA approved Retevmo, Eli Lilly's drug designed to treat three types of tumors non-small cell lung cancer, medullary thyroid cancer and other ..."

    Published: May 19th, 2020 at 02:37:30 PM

    Multiple Treatment Guideline Updates Released for Lung Cancer

    "Selpercatinib was added as a "preferred" first-line and subsequent treatment option (category 2A), cabozantinib and vandetanib were added as ..."

    Published: May 19th, 2020 at 12:45:00 AM

    Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

    "... trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently ..."

    Published: May 15th, 2020 at 07:52:30 PM

    Onc Daily: Olaparib in Ovarian Cancer, Smoking and Lung Cancer Survival

    "Update on Medullary Thyroid Carcinoma. The Medscape reference team has updated the detailed information on medullary thyroid carcinoma to include ..."

    Published: May 15th, 2020 at 03:33:45 PM

    Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder

    "In a phase 2 trial, pralsetinib triggered a response in 65% of patients with RET fusion-positive NSCLC, according to updated data set for presentation ..."

    Published: May 15th, 2020 at 02:03:45 PM

    Selpercatinib receives FDA nod

    "The presence of RET alterations must be confirmed via laboratory testing before initiating treatment with selpercatinib. Advertisement. The approval is ..."

    Published: May 14th, 2020 at 09:45:00 PM

    Retevmo Approved for RET-Driven NSCLC and Thyroid Cancers

    "adults and children at least 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; ..."

    Published: May 14th, 2020 at 08:37:30 PM

    With new lung cancer data at ASCO, Blueprint Medicines nips at Eli Lilly's heels

    "The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, ..."

    Published: May 14th, 2020 at 01:41:15 PM

    FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations

    "FDA has approved Retevmo (selpercatinib) capsules to treat non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in ..."

    Published: May 14th, 2020 at 12:56:15 PM

    Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing ...

    "Oral Presentation. Presentation Title: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Session Title: ..."

    Published: May 14th, 2020 at 10:07:30 AM

    FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer

    "Medullary thyroid cancer, which involves a specific type of cell, is uncommon-accounting for only 4% of all thyroid cancers-but it frequently has RET ..."

    Published: May 13th, 2020 at 10:07:30 PM

    Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

    "... cell lung cancer, medullary thyroid cancer and other types of thyroid cancers in patients whose tumors have an alteration (mutation or fusion) in a ..."

    Published: May 13th, 2020 at 09:33:45 PM

    Lilly Cancer Treatment Lands FDA Approval

    "... cancer, as well as the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid ..."

    Published: May 13th, 2020 at 09:05:48 PM

    Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO

    "Lilly got an edge with an FDA approval for its drug, called selpercatinib or Retevmo, last week - months ahead of the agency deadline - but ..."

    Published: May 13th, 2020 at 09:03:22 PM

    ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

    "Pralsetinib, also called BLU-667, shrank tumors in 100% of those patients. Nearly three-quarters of them had enough shrinkage to be responders."

    Published: May 13th, 2020 at 09:00:00 PM

    ASCO: Blueprint's RET inhibitor pads its case ahead of FDA lung cancer decision

    "Blueprint submitted pralsetinib for FDA approval as a treatment for RET fusion-positive NSCLC in the first quarter this year, and with a priority review ..."

    Published: May 13th, 2020 at 06:11:15 PM

    The Role of Multikinase TKIs for NSCLC

    "Shirish M. Gadgeel, MD, MBBS: The efficacy results with multikinase tyrosine kinase inhibitors are better in patients with medullary thyroid carcinoma ..."

    Published: May 12th, 2020 at 10:07:30 AM

    Lilly's Retevmo wins US nod for specific lung, thyroid cancers

    "US regulators have approved Eli Lilly's Retevmo (selpercatinib) as the first therapeutic specifically designed for patients with advanced RET-driven ..."

    Published: May 11th, 2020 at 10:11:42 PM

    Retevmo (selpercatinib) FDA Approval History

    "Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), ..."

    Published: May 11th, 2020 at 08:15:00 PM

    Under Armour, Marriott fall; Cardinal Health, AMC rise

    "The pharmaceutical company's cancer drug Retevmo was approved by the Food and Drug Administration. Quidel Corp., up $50.35 to $208.95."

    Published: May 11th, 2020 at 07:18:45 PM

    Blueprint Medicines up 11% on prospects of RET inhibitor pralsetinib

    "Blueprint Medicines (BPMC +10.7%) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib ..."

    Published: May 11th, 2020 at 06:56:15 PM

    Onc Daily: Selpercatinib Approved, ASCO Goes Virtual

    "... of RET-positive tumors in adults with nonsmall cell lung cancer that has spread; the treatment of advanced medullary thyroid cancer (MTC) or MTC ..."

    Published: May 11th, 2020 at 04:41:15 PM

    Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug ...

    "Recon: FDA approves Lilly's Retevmo for thyroid, lung cancers; China approves Novartis' MS drug Mayzent. Posted 11 May 2020 | By Michael Mezher."

    Published: May 11th, 2020 at 03:56:15 PM

    FDA Approves Selpercatinib for Certain NonSmall Cell Lung, Thyroid Cancers

    "Selpercatinib is a kinase inhibitor which helps to prevent cancer cells from growing. Prior to beginning treatment, an RET gene mutation must be ..."

    Published: May 11th, 2020 at 03:33:45 PM

    Opdivo-Yervoy Combination Continues to Show Superior Long-Term Outcomes in Renal Cell ...

    ""The ORRs in patients with intermediate- and poor-risk disease who received ... NSCLC that has spread in adults; Advanced medullary thyroid cancer ..."

    Published: May 11th, 2020 at 03:22:30 PM

    Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug Retevmo

    "Blueprint's RET inhibitor pralsetinib, also known as BLU-667, hit a 61% response rate in RET fusion-positive NSCLC patients. The company recently ..."

    Published: May 11th, 2020 at 12:11:15 PM

    FDA approves Retevmo for lung cancer, thyroid cancer subsets

    "... RET fusion-positive non-small cell lung cancer that has spread; advanced RET fusion-positive medullary thyroid cancer or medullary thyroid cancer ..."

    Published: May 11th, 2020 at 11:06:11 AM

    Drugmakers Overhaul the Sales Pitch Amid Coronavirus Lockdowns

    "The new Lilly drug, Retevmo, treats lung and thyroid cancers that have certain genetic traits. After many employees began working from home in ..."

    Published: May 11th, 2020 at 09:56:15 AM

    FDA clears Lilly's Retevmo for RET-positive lung, thyroid cancers

    "Retevmo reaches the market after Loxo's Vitrakvi (larotrectinib), which was approved by the FDA to treat any solid tumour that has a neurotrophic ..."

    Published: May 10th, 2020 at 05:00:15 PM

    UPDATED: A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival ...

    "Regulators stamped their OK on selpercatinib, which can now be marketed as Retevmo to patients suffering from 3 different types of cancers all driven ..."

    Published: May 10th, 2020 at 04:52:30 PM

    A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close ...

    "The FDA action covers RET fusion-positive non-small cell lung cancer and thyroid cancer, along with RET-mutant medullary thyroid cancer."

    Published: May 10th, 2020 at 11:37:30 AM

    Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

    ""The approval of selpercatinib marks an important milestone in the treatment of NSCLC, making RET-driven cancers now specifically targetable in the ..."

    Published: May 9th, 2020 at 07:19:44 PM

    Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo

    "Retevmo is the eighth cancer drug approved by the FDA this year, following new medicines for breast, lung, liver and gastrointestinal cancers. Later this ..."

    Published: May 9th, 2020 at 07:30:42 AM

    Retevmo (selpercatinib) FDA Approval History

    "FDA approval history for Retevmo (selpercatinib) used to treat Non-Small Cell Lung Cancer, Thyroid Cancer. Supplied by Eli Lilly and Company."

    Published: May 9th, 2020 at 02:08:20 AM

    BRIEF-Eli Lilly Receives US FDA Approval For Retevmo

    "* RETEVMO IS EXPECTED TO BE AVAILABLE FROM SPECIALTY PHARMACIES WITHIN ONE WEEK. Source text for Eikon: Further company ..."

    Published: May 9th, 2020 at 12:22:30 AM

    Lilly Receives US FDA Approval for Retevmo (selpercatinib), the First Therapy Specifically for ...

    "... for Patients with Advanced RET-Driven Lung and Thyroid Cancers ... RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."

    Published: May 8th, 2020 at 11:15:00 PM

    Lilly Moves Ahead With Retevmo Launch In A Challenging Environment

    "The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology ..."

    Published: May 8th, 2020 at 10:52:30 PM

    FDA Approves Selpercatinib for RET-Mutant NSCLC, Thyroid Cancers

    "Advanced or metastatic medullary thyroid cancer in patients aged 12 or older who require systemic therapy; Advanced RET fusion-positive thyroid ..."

    Published: May 8th, 2020 at 09:45:00 PM

    FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic ...

    "Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations. "Innovations in gene-specific therapies continue to ..."

    Published: May 8th, 2020 at 12:45:00 PM

    'Consistent increase' observed in larger, more aggressive thyroid tumors in California

    ""Papillary, medullary and anaplastic histological subtypes showed increasing incidence rates, while the incidence of follicular carcinoma remained ..."

    Published: May 8th, 2020 at 07:18:45 AM

    Hopes high that Eva Williams will start lifeline treatment in eight weeks as she approaches 10th ...

    ""We spoke today with our oncologist at Alder Hey and he again re-enforced that the ONC201 trial is something to pursue, however we also discussed ..."

    Published: May 7th, 2020 at 05:38:57 PM

    Blueprint Medicines (BPMC) Q1 Earnings Top, Revenues Soar Y/Y

    "Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an ..."

    Published: May 6th, 2020 at 03:56:15 PM

    Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates

    "... of medullary thyroid cancer generated $4.7 million in net product revenues. ... Tecentriq in patients with locally advanced or metastatic solid tumors."

    Published: May 5th, 2020 at 02:48:45 PM

    First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and ...

    "Likewise, primary hyperparathyroidism with such non-medullary thyroid carcinoma is rare. The specific molecular profile of hobnail PTC (HPTC) is ..."

    Published: May 4th, 2020 at 03:22:30 PM

    Consensus on Thyroid Fine Needle Aspiration Biopsies During the COVID-19 Pandemic

    "Conversely, as delays in diagnosis and treatment for medullary thyroid cancer can adversely affect the prognosis, it is recommended to assess ..."

    Published: May 4th, 2020 at 01:03:48 PM

    Turning Point Therapeutics to Host First Quarter Conference Call

    "... patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is currently being ..."

    Published: May 2nd, 2020 at 06:22:30 PM

    Martha Bowen

    "... away peacefully in her home, surrounded by her beloved family on April 30, 2020, after a 10-year courageous battle with medullary thyroid cancer."

    Published: May 2nd, 2020 at 08:59:34 AM

    Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in ...

    "Selpercatinib and pralsetinib are potent and selective tyrosine kinase inhibitors targeting the rearranged during transfection (RET) receptor in various ..."

    Published: Apr 30th, 2020 at 09:56:15 AM

    Medicare rebate for rare cancer diagnosis test

    ""I was diagnosed 29 years ago with medullary thyroid cancer and there was no treatment for me for 28 years and my cancer progressed," she said. Last ..."

    Published: Apr 30th, 2020 at 07:30:00 AM

    Familial aggregation and heritability of non-medullary thyroid cancer in an Asia population: A ...

    "In this nationwide cohort study, researchers evaluated the extent of familial aggregation of non-medullary thyroid cancer (NMTC) and the relative risks ..."

    Published: Apr 27th, 2020 at 03:33:45 PM

    COVID-19: Defer 'Bread and Butter' Procedure for Thyroid Nodules

    "Exceptions for considering FNA include more urgent thyroid disease ... "Regarding medullary thyroid cancer (MTC), early diagnosis and surgery do ..."

    Published: Apr 24th, 2020 at 06:33:45 AM

    Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated ...

    "In this retrospective cohort study involving 1,060 medullary thyroid carcinoma (MTC) patients, researchers described the prevalence of bone ..."

    Published: Apr 21st, 2020 at 03:00:00 PM

    The Role of RET Rearrangements in Lung Cancer

    "... which is formerly known as BLU-667, and selpercatinib, formerly known as LOXO-292. We entered with it being investigated in patients specifically ..."

    Published: Apr 17th, 2020 at 12:56:15 PM

    Most fine-needle aspiration thyroid biopsies can be 'safely delayed' during COVID-19

    "Patients with suspected medullary thyroid cancer (MTC), which is relatively rare, should undergo measurement of serum calcitonin and be referred ..."

    Published: Apr 10th, 2020 at 03:45:00 PM

    Study Describes First Mechanism of Resistance to RET Inhibitor Selpercatinib

    "... against tumors, such as non-small cell lung cancer (NSCLC) or medullary thyroid cancer (MTC), that are positive for RET fusions or mutations."

    Published: Apr 10th, 2020 at 12:22:30 PM

    Cancer biotech Oncoceutics loses CEO, chair and co-founder

    "The first lead compound to emerge from this program is ONC201, an orally active small-molecule DRD2 antagonist. The company is supported by ..."

    Published: Apr 3rd, 2020 at 09:56:15 PM

    Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

    "For RET fusions, selpercatinib (LOXO-292) has shown an objective response rate (ORR) upward of 85%, adds Levy. Additionally, AMG 510 is an oral ..."

    Published: Apr 2nd, 2020 at 03:00:00 PM

    Rolling NDA Submitted for Pralsetinib in RET+ NSCLC Based on Topline ARROW Data

    "Topline data were reported for patients with RET-mutant medullary thyroid cancer (MTC), both untreated patients and those who had previously ..."

    Published: Apr 1st, 2020 at 03:33:45 PM

    Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

    "... RET-based oncology drug programs, including top-line data from the pralsetinib trial for patients with RET-mutant medullary thyroid cancer (MTC)."

    Published: Apr 1st, 2020 at 12:45:00 PM

    Blueprint Medicines' pralsetinib shows positive action in RET-altered thyroid cancer

    "... announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors."

    Published: Apr 1st, 2020 at 12:03:19 PM

    Blueprint Medicines Announces the Achievement of Key Portfolio Milestones

    "74% overall response rate in treatment-naive RET-mutant medullary thyroid cancer and 89% overall response rate in RET fusion-positive thyroid ..."

    Published: Mar 30th, 2020 at 03:22:30 PM

    Trends in Thyroid Cancer Incidence and Incidence-Based Mortality in California

    "The most common histologic type was papillary thyroid carcinoma (87.8%) followed by follicular thyroid carcinoma (7.2%) and medullary thyroid ..."

    Published: Mar 30th, 2020 at 01:00:28 PM

    2020 Market Spotlight: Thyroid Cancer - ResearchAndMarkets.com

    "Selpercatinib for Thyroid Cancer (September 29, 2019); Pralsetinib for ... Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): Phase I/II - ARROW ..."

    Published: Mar 27th, 2020 at 08:37:30 PM

    UCLA, UT Southwestern join NCCN

    "... he was vice president of Research and Development at Loxo Oncology, where he led the overall clinical development of selpercatinib (LOXO-292, ..."

    Published: Mar 27th, 2020 at 12:00:29 PM

    Thyroid Cancer Market Study, 2014-2026 - Novartis Leads Industry Sponsors With the Highest ...

    "Figure 6: Selpercatinib for Thyroid Cancer (September 29, 2019): Phase I/II - LIBRETTO-001. Figure 7: Pralsetinib for Thyroid Cancer (June 3, 2019): ..."

    Published: Mar 26th, 2020 at 04:14:08 PM

    Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report?

    "... of medullary thyroid cancer, generated $13.8 million in net product revenues. ... inhibitor, in patients with locally advanced or metastatic solid tumors."

    Published: Mar 24th, 2020 at 02:57:55 PM

    Meet 'Gentle George' the boy from Bishop's Stortford asking for help to get back to school

    "MEN2B is a condition which creates tumours in three areas of the body, due to overactive endocrine glands. George's diagnosis came too late to ..."

    Published: Mar 22nd, 2020 at 11:37:30 AM

    Amazon Boosts Overtime Pay For US Warehouse Workers

    "Cometriq treats medullary thyroid cancer. Are cancer ... Vertex essentially owns the market for treating rare genetic disease cystic fibrosis (CF)."

    Published: Mar 21st, 2020 at 04:07:30 AM

    Four regimens receive priority review for lung cancer indications

    "The agent also received priority review for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer. The FDA granted priority ..."

    Published: Mar 20th, 2020 at 07:07:30 PM

    Blueprint Medicines Corporation: An Undervalued Company With Attractive Prospects

    "... cell lung cancer) and RET-mutation-positive MTC (medullary thyroid cancer). ... Currently, there are no effective approved therapies for this disease."

    Published: Mar 17th, 2020 at 03:00:00 PM

    Resources In Medicine Are Continually Targeted at Controlling COVID-19 Spread

    "... Eli Lilly and Company to assist in identifying patients with non-small cell lung cancer and medullary thyroid cancer harboring RET variants who may ..."

    Published: Mar 12th, 2020 at 03:00:00 PM

    Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials

    "... also known as LOXO-292. In that case, the test is being developed to look for RET fusions, which are the molecular target of selpercatinib, including ..."

    Published: Mar 10th, 2020 at 10:30:00 PM

    Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference ...

    "And then we have a capsule formulation called COMETRIQ that is indicated for a rare form of thyroid cancer called medullary thyroid cancer. So, we're ..."

    Published: Mar 10th, 2020 at 11:03:45 AM

    Prediction of biochemical cure in patients with medullary thyroid cancer

    "... biochemical cure in medullary thyroid cancer (MTC). Using multivariable logistic regression analysis, they determined clinical and histopathological ..."

    Published: Mar 6th, 2020 at 05:45:00 PM

    NCI Trials for March 2020

    "A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)."

    Published: Mar 6th, 2020 at 03:30:00 PM

    American Association of Endocrine Surgeons Publishes Guidelines for Thyroid Disease Surgery

    "All patients diagnosed with medullary thyroid carcinoma should undergo genetic testing for a germline RET mutation, and those with multiple ..."

    Published: Mar 6th, 2020 at 11:00:00 AM

    Morphology of bone metastases should guide treatment in medullary thyroid cancer

    ""The impact of bone metastases in metastatic medullary thyroid carcinoma (MTC) on patient morbidity and prognosis has not been studied in detail ..."

    Published: Mar 4th, 2020 at 04:03:45 PM

    Prognostic Effect of Bone Metastases in Medullary Thyroid Cancer

    "Bone metastases are present in more than a quarter of patients with metastatic medullary thyroid carcinoma (MTC), most often with an osteolytic ..."

    Published: Mar 4th, 2020 at 10:48:45 AM

    Thyroid Cancer Drugs Market Forecasts, 2020-2030 - Increasing Use of Combination Drugs Spurs ...

    "For example, Vandetanib (Caprelsa) and Cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC)."

    Published: Feb 29th, 2020 at 11:56:15 AM

    Boy with a fatal form of brain cancer to pursue trial in USA

    "In a desperate bid to find options, Ms Hatzl has also considered a drug called ONC201, which has been shown to kill tumour cells in studies overseas, ..."

    Published: Feb 28th, 2020 at 08:33:57 PM

    George Labonte is running to show other survivors that cancer can't stop them

    "In early 2016, I was diagnosed with a rare and incurable cancer called Medullary Thyroid Carcinoma. At the time, I wasn't sure if I would live out the ..."

    Published: Feb 27th, 2020 at 05:11:15 PM

    Exelixis: Potential Catalysts Ahead For This Mid-Cap Oncology Company

    "Another drug, Cometriq capsules, has been approved by the FDA in progressive and metastatic medullary thyroid cancer indication. The active ..."

    Published: Feb 26th, 2020 at 02:41:58 PM

    Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

    "Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $13.8 million in net product revenues. Exelixis also earned ..."

    Published: Feb 25th, 2020 at 08:00:00 PM

    Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of ...

    ""Given the encouraging clinical activity observed for cabozantinib in phase 1 and 2 trials in differentiated thyroid cancer, and the poor prognosis for ..."

    Published: Feb 24th, 2020 at 02:56:15 PM

    Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer

    "Blueprint Medicines is studying a combination of Tagrisso with its RET inhibitor BLU-667 in patients with advanced EGFR-mutant NSCLC who also ..."

    Published: Feb 24th, 2020 at 01:03:45 PM

    Predictive Markers for mCRC

    "We know there is the BLU-667 compound and there's a LOXO-292 compound that's currently out there being used for thyroid and lung cancer. And the ..."

    Published: Feb 20th, 2020 at 01:07:33 PM

    Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief ...

    "The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

    Published: Feb 14th, 2020 at 03:25:51 PM

    Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark

    "Blueprint Medicines initiated the rolling submission of NDA to the FDA for its precision therapy pralsetinib to address the RET fusion-positive ..."

    Published: Feb 13th, 2020 at 07:03:45 PM

    Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q4 2019 Results - Earnings Call ...

    "This morning in addition to financial results for 2019, we will highlight key value drivers for Blueprint Medicines in 2020, discuss topline pralsetinib in ..."

    Published: Feb 13th, 2020 at 01:15:00 PM

    EU Speedy Review Success For Kite But Not For Lilly

    "... therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib ..."

    Published: Feb 12th, 2020 at 02:56:15 PM

    Stock To Watch: Blueprint Medicines (BPMC)

    "A New Drug Application for Pralsetinib for previously treated RET-mutant medullary thyroid cancer is expected to be filed with the FDA in the second ..."

    Published: Feb 11th, 2020 at 10:48:45 AM

    Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

    "... the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier."

    Published: Feb 11th, 2020 at 10:03:45 AM

    Exelixis bounces back with new prostate cancer data

    "Exelixis bounces back with new prostate cancer data ... as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe."

    Published: Feb 10th, 2020 at 07:48:45 PM

    Testing for RET Fusions in NSCLC Remains Critical as Targeted Therapy BLU-667 Evolves

    "The selective RET inhibitor BLU-667 has demonstrated durable responses in patients with RET fusion-positive lung cancer in the phase I ARROW ..."

    Published: Feb 8th, 2020 at 01:03:45 PM

    A Look Back at FDA News from January 2020

    "... Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer ... non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET ..."

    Published: Feb 4th, 2020 at 07:48:45 PM

    Jennifer Jeske, 47

    "The family appreciates memorials to ThyCa Donation, Attn: Medullary Thyroid Cancer Research Fund, P.O. Box 1102, Olney, Maryland, 20830-1102."

    Published: Feb 4th, 2020 at 02:00:00 PM

    Investigators Seek New Standard in RET Fusion-Positive NSCLC

    "Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care (SOC) for patients ..."

    Published: Feb 4th, 2020 at 01:48:45 PM

    Takeda unveils profit surprise on Shire integration-and no US Natpara supply till 2021

    "Takeda doesn't expect any Natpara sales in the U.S. into fiscal 2020 ending in March 2021, as discussions with FDA to resume supply after a recent ..."

    Published: Jan 31st, 2020 at 05:00:00 PM

    FDA Grants Priority Review to Selpercatinib for Lung and Thyroid Cancer Subsets

    "The application is based on findings from the phase I/II LIBRETTO-001 trial, which evaluated selpercatinib in RET-altered NSCLC and thyroid cancers."

    Published: Jan 30th, 2020 at 03:50:01 PM

    Lilly's NDA for Selpercatinib Gets FDA's Priority Review

    "... non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer ... Many industry players are adopting this method to bring new cancer ..."

    Published: Jan 30th, 2020 at 03:41:15 PM

    Lilly's NDA for Selpercatinib Gets FDA's Priority Review

    "The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is ..."

    Published: Jan 30th, 2020 at 11:33:45 AM

    Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib

    "... review for selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer ..."

    Published: Jan 30th, 2020 at 06:18:45 AM

    Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers

    "Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers ... fusion-positive thyroid cancer, and RET-mutant medullary thyroid cancer ..."

    Published: Jan 30th, 2020 at 01:54:51 AM

    CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST

    "... RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer has been granted priority review by the FDA - with a decision expected ..."

    Published: Jan 29th, 2020 at 04:37:30 PM

    FDA grants priority review to selpercatinib for RET-altered NSCLC, thyroid cancer

    "The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary ..."

    Published: Jan 29th, 2020 at 04:03:45 PM

    FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer

    "The New Drug Application (NDA) for selpercatinib (LOXO-292) was granted FDA Priority Review for the treatment of patients with advanced RET ..."

    Published: Jan 29th, 2020 at 12:24:49 PM

    Bay Street Likely To Open Higher

    "Eli Lilly has applied for approval of the treatment in three different types of tumors with altered RET: non-small-cell lung cancer, medullary thyroid ..."

    Published: Jan 29th, 2020 at 12:18:45 PM

    Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning Sign

    "Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning ... At its initial stages, thyroid cancer might not exhibit any symptoms. ... syndromes including Cowden's syndrome, familial medullary thyroid cancer, ..."

    Published: Jan 29th, 2020 at 10:48:45 AM

    Lilly's selpercatinib application nabs accelerated review in US

    "... advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer."

    Published: Jan 29th, 2020 at 10:37:30 AM

    Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application

    "... RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."

    Published: Jan 27th, 2020 at 07:15:00 PM

    National Brain Tumor Society Backs Oncoceutics' Phase II Trial for Subset of High-Grade Gliomas

    "ONC201 is the first imipridone dopamine receptor D2 antagonist (DRD2) that treats high-grade glioma by selectively targeting G protein-coupled ..."

    Published: Jan 24th, 2020 at 05:33:45 PM

    Patients with Hypoparathyroidism Warned of Extended NATPARA Recall

    "NATPARA was voluntarily pulled off the market by the manufacturer (Takeda) after small particles of rubber were found in some samples of the ..."

    Published: Jan 24th, 2020 at 03:52:30 AM

    Trial drug ONC201 hopes for wife of Boro coach Graeme Lee

    "FOOTBALL fans in the North-East are being urged to show their support for the wife of a former player. Graeme Lee started his career with Hartlepool ..."

    Published: Jan 23rd, 2020 at 11:00:00 PM

    CStone successfully hosted the first US R&D Day in New York

    "A total of five NDA submissions in Mainland China and Taiwan for CS1001, an anti-PD-L1 monoclonal antibody; pralsetinib, a RET inhibitor; and ..."

    Published: Jan 23rd, 2020 at 01:02:23 PM

    Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

    "The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."

    Published: Jan 21st, 2020 at 08:00:00 PM

    Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

    "... to fund clinical trials for pralsetinib in RET-driven cancers, including its Phase 3 AcceleRET Lung clinical trial for pralsetinib in first-line RET-altered ..."

    Published: Jan 20th, 2020 at 05:00:00 PM

    Pralsetinib effective, safe for RET fusion-positive NSCLC

    "Approximately 90% of patients with advanced medullary thyroid cancer have RET mutations. The ongoing phase 1/phase 2 ARROW trial evaluated ..."

    Published: Jan 20th, 2020 at 10:03:45 AM

    Lilly will aim for one $1bn-$5bn deal per quarter in 2020

    "Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in a phase 1/2 trial for non-small cell ..."

    Published: Jan 16th, 2020 at 10:15:00 PM

    FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...

    "It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.Do not use ..."

    Published: Jan 16th, 2020 at 06:07:30 PM

    A venture firm warms to funding neuroscience

    "But only three - the cell therapy companies Kyverna, Tmunity, and Arsenal Biosciences - are publicly known. Any hints? Unlock this article by ..."

    Published: Jan 15th, 2020 at 11:00:00 AM

    Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

    "Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."

    Published: Jan 13th, 2020 at 12:52:30 PM

    Turning Point Therapeutics Announces Program Updates and Milestones for 2020

    "Multiple RET-Positive Patients with Solvent-Front Mutations Previously Treated with Other Investigational RET Inhibitors Dosed with TPX-0046"

    Published: Jan 11th, 2020 at 08:00:00 PM

    Thyroid cancer is somewhat mysterious

    "Thyroid cancer is one of the rarer cancers and not in the list of the top 10 ... The medullary thyroid cancer (MTC) comes from a different cell in the ..."

    Published: Jan 10th, 2020 at 10:26:15 PM

    GIST kissed ahead of V-Day PDUFA, Blueprint design plan for Ayvakit goes 'fourth'

    "Blueprint also plans to submit, in the second quarter, an NDA to the FDA for pralsetinib for medullary thyroid cancer previously treated with an ..."

    Published: Jan 10th, 2020 at 06:52:30 PM

    Pralsetinib Achieves Durable Responses in Patients With RET+ NSCLC

    "Pralsetinib (BLU-667), a highly-selected RET inhibitor, achieved a favorable overall response rate (ORR) with prolonged durability in patients with ..."

    Published: Jan 10th, 2020 at 04:05:18 PM

    Top-Line Data Reported for Pralsetinib in Patients with RET Fusion-Positive NSCLC

    "... to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously treated with an approved multikinase inhibitor."

    Published: Jan 9th, 2020 at 08:56:15 PM

    Turning Point Therapeutics Announces Management Transition

    "The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

    Published: Jan 9th, 2020 at 01:37:30 PM

    Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

    "Notably, pralsetinib is also being studied for RET-mutant medullary thyroid carcinoma (MTC). The company plans to complete the NDA submission for ..."

    Published: Jan 9th, 2020 at 01:36:51 PM

    Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

    "The ARROW study evaluated once-daily oral, pralsetinib in 80 patients with RET fusion-positive NSCLC who received prior treatment with ..."

    Published: Jan 9th, 2020 at 10:15:00 AM

    Thyroid Cancer Drug Market Had A Booming Decade || Celgene Corporation, AstraZeneca ...

    "Global thyroid cancer drug market is rise gradually to an estimated value of ... thyroid cancer, Follicular thyroid cancer, Hurthle cell cancer, Medullary ..."

    Published: Jan 9th, 2020 at 08:22:30 AM

    Turning Point (TPTX) Marches Ahead, Awaits TRIDENT-1 Data Update In 2020

    "Next up in the pipeline TPX-0046 is under phase I/II study for the treatment of advanced solid tumors with abnormal RET genes. Another clinical drug ..."

    Published: Jan 8th, 2020 at 10:15:00 PM

    Blueprint Reports High Response Rates From Lung Cancer Patients in Early Pralsetinib Trials

    "In the second quarter, the company plans to file an NDA for the medullary thyroid cancer indication. RET fusions appear in approximately 1 to 2 ..."

    Published: Jan 8th, 2020 at 04:15:00 PM

    Lilly looms over Blueprint as the biotech files targeted cancer drug

    "The biotech also intends to ask regulators to approve pralsetinib as a treatment for medullary thyroid cancer, with an application planned for the ..."

    Published: Jan 8th, 2020 at 02:36:21 PM

    Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

    "Its most advanced competitor is Indianapolis-based Eli Lilly's Loxo Oncology division, whose RET inhibitor LOXO-292 (selpercatinib) has also shown ..."

    Published: Jan 8th, 2020 at 02:33:45 PM

    Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission

    "... Medicines said Wednesday that it had started a rolling submission to the Food and Drug Administration for the drug BLU-667 (pralsetinib), based on ..."

    Published: Jan 7th, 2020 at 06:37:54 PM

    Orphan Drugs Market Growth Strategies by 2027 with Leading Key Players Takeda ...

    "Based on disease the market is segmented into Hodgkin lymphoma, ... 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or ..."

    Published: Jan 7th, 2020 at 01:03:45 PM

    Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment

    "We focus on the concept of risk assessment for thyroid cancer at different stages of the diagnostic pathway for ...... MTC-medullary thyroid cancer."

    Published: Jan 4th, 2020 at 11:00:00 AM

    Plea for access to new drug for girl diagnosed with brain cancer

    "The new drug, ONC201, is being trialled in the USA and Germany but not ... ONC201 has been shown to kill tumour cells in studies overseas but the ..."

    Published: Jan 2nd, 2020 at 02:00:00 PM

    New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    "She joins from Tmunity Therapeutics, where she also served as chief medical ... At Tmunity, she was responsible for the development of the company's ..."

    Published: Jan 1st, 2020 at 02:00:00 PM

    Video Series Offers Support to Cancer Caregivers

    "The American Cancer Society (ACS) created a video series for caregiver support to address their most-asked ... RET-Mutant Medullary Thyroid Cancer"

    Published: Dec 31st, 2019 at 05:56:15 PM

    CURE's Clinical Trial Corner: December 2019

    "The trial will enroll 400 patients with advanced or metastatic RET-mutant medullary thyroid cancer who have received no prior systemic therapy for ..."

    Published: Dec 30th, 2019 at 08:00:00 PM

    Lilly opens Phase III trial of highly targeted Loxo drug in thyroid cancer

    ""This Phase III trial of selpercatinib in patients advanced or metastatic ... The thyroid cancer trial is randomizing patients to receive selpercatinib or ..."

    Published: Dec 30th, 2019 at 03:41:15 PM

    Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

    "Selpercatinib is an orally administered drug in clinical development for cancers with abnormalities in the rearranged during transfection (RET) kinase."

    Published: Dec 30th, 2019 at 11:56:14 AM

    Lilly launches late-stage study of LOXO-292 in medullary thyroid cancer

    "Eli Lilly (NYSE:LLY) initiates a Phase 3 clinical trial, LIBRETTO-531, evaluating selpercatinib (LOXO-292) in previously untreated patients with ..."

    Published: Dec 27th, 2019 at 05:56:15 PM

    First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC

    "Breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and RETfusion-positive thyroid cancers have ..."

    Published: Dec 25th, 2019 at 12:19:20 PM

    Thyroid Cancer Treatment Market Will Generate New Growth Opportunities in the Next Upcoming ...

    "Follicular cancer, medullary cancer, and Anaplastic cancer are different types of thyroid cancers. The treatments which is available for thyroid cancer ..."

    Published: Dec 23rd, 2019 at 12:30:00 PM

    New medical chief at Rubius Therapeutics

    "Dr. Coughlin joins Rubius from Tmunity Therapeutics, where she served as CMO and was responsible for the development of Tmunity's CAR-T and ..."

    Published: Dec 23rd, 2019 at 12:02:47 PM

    Rubius Therapeutics Appoints Christina Coughlin, MD, Ph.D., as Chief Medical Officer

    "A trained oncologist and immunologist, Dr. Coughlin joins Rubius from Tmunity Therapeutics, Inc., where she served as chief medical officer and was ..."

    Published: Dec 18th, 2019 at 02:56:15 PM

    Natpar(a): A Case in Point for Rare Disease Drugs?

    "While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the ..."

    Published: Dec 17th, 2019 at 08:56:15 PM

    Eli Lilly Shines With BTK Inhibitor Drug In Treating B-Cell Leukemias And Lymphomas

    "It used its drug LOXO-305 to treat B-Cell Leukemias and Lymphomas. ... Eli Lilly's other product from the acquisition of LOXO, known as LOXO-292, ..."

    Published: Dec 17th, 2019 at 04:15:00 PM

    RET Inhibitor Trial Updates at ASCO and ESMO

    "... the BLU-667 agent in medullary thyroid cancer predominantly. That, again, showed extremely good response rate, with a total response rate, overall ..."

    Published: Dec 17th, 2019 at 04:03:45 PM

    ESMO 2019 LIBRETTO-001 Trial Updates

    "... an update of the LIBRETTO-001 study for differentiated thyroid cancer and medullary thyroid cancer was presented, and the partial response was in ..."

    Published: Dec 17th, 2019 at 03:52:30 PM

    LOXO-292 in Patients With RET-Fusion Lung Cancer

    "LOXO-292 in Patients With RET-Fusion Lung Cancer. Insights From: Jacob Sands, MD, Dana-Farber Cancer Institute; Benjamin Besse, MD, PhD, ..."

    Published: Dec 17th, 2019 at 01:05:47 PM

    Turning Point Therapeutics to Participate in 38th Annual JP Morgan Healthcare Conference

    "The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."

    Published: Dec 16th, 2019 at 04:03:45 PM

    Top M&A Deals in 2019

    "LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial ..."

    Published: Dec 13th, 2019 at 02:14:20 PM

    Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

    "Pralsetinib (formerly BLU-667) in being studied in the phase I/II ARROW study evaluating previously-treated patients with receptor tyrosine RET-fusion ..."

    Published: Dec 13th, 2019 at 01:37:30 PM

    Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why

    "... is being evaluated in several late-stage studies for cancer indications. ... lung cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC)."

    Published: Dec 13th, 2019 at 11:00:00 AM

    Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

    "Lilly Initiates Lung Cancer Study on Selpercatinib: Lilly began a phase III study to evaluate its oral RET inhibitor, selpercatinib/LOXO-292in previously ..."

    Published: Dec 12th, 2019 at 02:33:45 PM

    Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

    "Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

    Published: Dec 12th, 2019 at 01:03:45 PM

    Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

    "Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."

    Published: Dec 12th, 2019 at 08:33:45 AM

    Lilly launches first of its kind trial for RET fusion-positive NSCLC

    "The LIBRETTO-431 clinical trial is assessing selpercatinib, also known as LOXO-292, for treatment-naiive RET fusion-positive non-small cell lung ..."

    Published: Dec 11th, 2019 at 08:11:15 PM

    Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

    "The trial will examine the effects of selpercatinib (LOXO-292) in cancer patients who have had no prior treatment for their condition. Participants will be ..."

    Published: Dec 11th, 2019 at 04:48:45 PM

    Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...

    "Selpercatinib has received breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET ..."

    Published: Dec 11th, 2019 at 10:48:45 AM

    Lilly opens late-stage RET fusion-positive NSCLC study

    "Eli Lilly (NYSE:LLY) launches the Phase 3 LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naiive RET ..."

    Published: Dec 11th, 2019 at 01:39:59 AM

    A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based ...